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3ABSTRACT
The high incidence of obstructive coronary artery disease in the West of 
Scotland has resulted in a clinical problem of increasing magnitude, 
namely ischaemic ventricular dysfunction and its clinical correlate "heart 
failure". In this thesis, the history of the identification of heart failure is 
traced, reflecting the still present confusion as to what constitutes "heart 
failure" and how this should be managed.
This thesis documents the use and limitations of the accepted clinical and 
haemodynamic measures for the identification of these patients with heart 
failure and the prediction of their subsequent mortality. Various non- 
invasive and invasive measurements were made and the overall 
conclusions from this work are that the appropriate differing tests require 
to be performed to address specific aspects, namely
a) The identification of the patient with heart failure requires a 
combination of symptoms and the demonstration of impaired 
ventricular function (radionuclide angiography in this thesis).
b) The assessment of the patients' clinical status, as reflected by the 
impact of the disease on his capacity to work is optimally assessed 
by measurement of gas exchange on exercise.
c) The prediction of subsequent death cannot be made on the basis 
of clinical or haemodynamic indices, but is dependent on the 
extent of myocardial "loss", measured in this thesis acutely by 
perfusion imaging and in the chronic state by the impact on 
systolic function (left ventricular ejection fraction).
4d) Right ventricular dysfunction plays an important role for
subsequent mortality, where there is associated left ventricular 
dysfunction.
In the patient with left ventricular dysfunction as a consequence of 
coronary artery disease, treatment should encompass an appreciation of 
the absolute requirement of the myocardium for perfusion and of the 
factors that determine myocardial flow. These factors are often 
disregarded, resulting in further jeopardy of the already ischaemic 
myocardium. In this thesis, it is these aspects that in general have been 
examined with the commonly applied therapy, such as diuretics. From 
the work presented, it is evident that diuretics, smooth muscle relaxants, 
such as calcium channel blockers and inotropic agonists, exert an overall 
beneficial effect by maintaining myocardial perfusion whereas, for 
example, nitrates need to be prescribed with care as they may reduce 
myocardial perfusion (by reducing the blood pressure).
Heart failure is easy to recognise but difficult to define. Hopefully this 
thesis has cast some light on the complexities of definition and 
management of heart failure.
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PARTI
HISTORICAL INTRODUCTION
Our concepts of heart disease and heart failure have evolved gradually 
over centuries. Treatment did not wait upon knowledge of anatomy, 
physiology and pathophysiology.
The earliest herbals, the pharmacopoeia o f our forebears, date from 3000 
B.D. - the tablet from Summner and the Pien T'Seo Ching composed by 
Emperor Shan Nung in China around 2700 B.C. and the Papyrus Ebers 
dated 1550 B.C., but containing material from the previous 5-20 
centuries (1). Much of the skill and knowledge of the ancients has 
undoubtedly been lost to us. Atherosclerosis, for example, has been 
found in mummies of the 21st dynasty (circa 1000 B.C.) and was 
certainly known to the Egyptians. Angina was described in the 
Babylonian Talmund. The Chinese were well versed in the importance 
of examining the pulse.
The concept of "pneuma", which was important to Greek medicine 
appeared at about 600 B.C. with Anaximenes (2). The whole period of 
Greek medicine is marked by a wealth of both information and dis­
information. As early as 500 B.C. (circa) Alcamaeon, a pupil of 
Pythagoras in Croton in southern Italy, was dissecting animals (Exerctato 
Anatomica de Mortu Cordis et Sanguinis in Animalibur). He talked of 
"vessels” but it was Herophilus in about 300 B.C. who understood that 
vessels contained blood and studied the rhythm and rate of arterial 
pulsation with the assistance of a clepsydra (3). This knowledge was not 
appreciated and in the 18th century, interest in the arterial pulse was re­
awakened with the pulse watch.
[
i
19
Erasistratus understood that the heart’s ventricles act as a pump 
(particularly the left ventricle), and described the valves. He was cited 
by Galen as having "invented" capillaries, "arteries and veins, the vessels 
carrying respectively pneuma and blood are each successively divided up 
into a great number of smaller and smaller branches, and are spread to 
all parts of the body so that there is no part in which their terminations 
are not present" (4). It was not until 1661 that the existence of 
capillaries was demonstrated by Malpighi - and that blood flowed 
through these, by Leeuwenhoek. The experimental proof of blood flow 
from arteries to veins was provided by Walaeus de Wale at Leiden (5).
The dexographer, Caelius Aurelianus (5th century A.D.) (6) recorded 
Herophilus had earlier attributed sudden death for which no cause could 
be found, to paralysis of the heart - "repentintam mortem nulla ex 
manifesta causa venientum, fieri inquit paralysis cordis". He seems 
personally to have observed cases of shock accompanying the onset of 
atrial fibrillation and to have had a clear idea of the signs and symptoms 
of acute myocardial infarction - praecordial heaviness, pain (especially in 
the "left side near the mamilla"), the choking sensation, the collapse with 
clear mind and the poor prognosis. This pre-dates by several centuries 
the careful clinical observations of Heberden in 1768 and the subsequent 
controversy of the pathophysiological implications of calcification of the 
coronary arteries finally established by Jenner (18th Century).
Aretaeus, a contemporary of Galen (circa 150-200 A.D.), described 
death due to "cardiac passion" clearly identifying the heart rather than 
the stomach as was originally believed as the cause. Symptoms were 
described as including a small and weak pulse, a noisy heart beat where 
the heart is leaping powerfully, fainting, blackouts, numbness and
20
paralysis of the limbs, profuse ungovernable sweating, coldness of the 
whole body, and loss of sensation and speech (7). However, it was 
undoubtedly the teaching of Galen which dominated thinking over the 
following centuries, particularly in the matter of circulation of blood 
which was thought to ebb and flow by the power of pulsation generated 
as the heart acting as a bellows (8). This was disputed by Praxagoras, 
who distinguished arteries from veins and asserted that the power of 
pulsation possessed by the arteries was quite independent of the heart, a 
view that was rejected not only by Galen but also Herophilus. Galenic 
doctrine is apparent throughout the Middle Ages and well into the 
Renaissance. Medicine was dominated by dogma, supposedly based on a 
theoretic approach. The disciplines of personal observation and 
experimentation had yet to have their day.
Anatomy and Physiology
In Avicenna's Cannon (9) he notes in his chapter on "Suffocation and 
Angina" that "cyanche" sometimes goes to the heart and kills. The Latin 
commentators Andrea Alpago (died 1521) and Joannes Costaeus (died 
1603), in their discussions of this confusing chapter (10), cite the Galenic 
statement that a variety of "cyanche" exists in which there are no signs of 
inflammation in the mouth or upper structures but the patient feels 
suffocation of his throat - a reference perhaps to congestive heart failure 
(11). In his next chapter, Avicenna describes "pernicious suffocation" in 
which "respiration is difficult when the body is erect and is worse in 
recumbency. In contriving to breathe, the restless patient keeps 
extending his neck. When foam appears, the case is usually hopeless, 
especially if the colour of the face is unfavourable". Although Avicenna, 
in his chapters on the heart discusses diseases that affect the pericardium, 
the causes of syncope and palpitation and indeed how the heart may be
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affected by other structures such as the transfer of matter from quinsy or 
pneumonia, the discussion on dyspnoea is confined to the section on 
pulmonary disease in accordance with Greek tradition (12). The entirely 
humoralistic approach of Avicenna is faithfully reproduced by Jean 
Femel (1507-1558) with his ancient and mediaeval concept of "down 
dropping catarrh" [destillabo, called katarrhous by the Greeks] that was 
formed in the large cerebral sinuses or ventricles and discharged in large 
volumes causing numerous symptoms and diseases, including obstruction 
of the lung with dyspnoea and suffocation (13). From Capivaccius's 
text book (14), with the notes made by Dodonaeus (1581) (15) and 
Schenckius (1665) (16), it is clear that in the 16th and 17th centuries the 
suffocative catarrh theory of Femel applied both to pulmonary oedema 
and to severe inflammation of the respiratory tract. The heart was 
considered to be an organ of respiration. The understanding of its 
physiology was that of Hippocrates and Galen and owed little to direct 
observation. Dropsy (hydrops), an abnormal swelling of the abdomen, 
was defined as a hepatic disorder, due chiefly but not solely, to "cold 
dyscrasia". The difference between hepatic concavity and convexity was 
stressed - "the abdomen is weakly resistant to palpitation and pressure on 
the diaphragm causes dyspnoea ..., the patient can not readily climb 
stairs and is dyspnoeic on the slightest exertion". Ludovicus Mercatus 
(? 1520-71606) clearly distinguished between dropsy of the thorax 
(hydrops thoracus) and dropsy of the lung (hydrops pulmonis) and 
suggested that fluid might reach the chest by precipitation from the head 
or by upward migration from an ascitic abdomen, fluid being attracted 
back to the chest by suction passed through branches of the pulmonary 
artery into the pleural cavity (17,18). The anatomy might be correct, at 
least in part, but the physiology was entirely mythical. Even the writings 
at the end of the 16th century, including that of Mercatus, recorded little
22
of the 'new anatomy1, gleaned from pathological dissection. For 
example, Annafis who died in 1288 had described a "lesser circulation" 
(19), that is the coronary circulation, and challenged the Galenic theory 
that blood passed through pores from the right to the left ventricle - but 
the Galenic theory held sway until Harvey, centuries later, described the 
third circulation.
With Carolus Piso (1563-1633) who described paroxysmal nocturnal 
dyspnoea and its anatomical counterpart, hydrothorax, we can see the 
beginnings of clinical and anatomical empiricism (20). The clinical 
syndrome began to be correlated with observation, albeit based on 
Galenic concepts of physiology. With Fabrizio Bartoletti (1576-1633) 
(21) we see an attempt to arrange old and new knowledge in an 
intelligible order, although his book was published some 90 years after 
that of Vesalius ("De Humani Corporis Fabrica", 1543) (22) which 
marked the beginnings of anatomy as a modem science. Bartoletti 
comments on dropsy of the chest (hydrothorax), he felt doubtful if Galen 
knew of hydrothorax; contrary to Mercatus he believed that the disease 
was one of the thoracic cavity rather than the lung, that fluid migrates in 
diseased lungs and is squeezed out into the pleural cavity, and that 
"unless there has been a passage of water from the lung into the cavity of 
the thorax it does not assume the form of dropsy". He noted from 
personal observation that the fluid was the same as that of ascites, and by 
asserting that it was produced in the lung he discounted Mercatus's 
theory that it resulted from suction of stagnant urine by the lungs. 
Melchior Sebezius (1578-1674) published a beginner's handbook in 1661 
(23). He described respiratory difficulty in three grades of severity - 
dyspnoea, asthma and orthopnoea - but for explanation returned to the 
old Galenic theory of obstruction, caused mainly by "precipitation of
23
fluid from the brain": the feet became swollen by "overflow of fluid 
from the chest" and weakness was caused by "sympathy with the heart, 
which became damaged by its immersions in harmful fluids".
The 16th century was the age of anatomy. Vesalius refuted the Galenic 
theory of pores in the right ventricle (22). Canano described valves in 
veins (24) in 1541. Michael Servetus (1546) (25) and Recaldo Colombo 
(1558) (26) each independently described the pulmonary circulation.
With William Harvey, and later Richard Lower, came the concept of 
circulation and the advent of cardiovascular physiology. Harvey explains 
"that the source and store-house of blood and the place for its perfections 
is in the lungs and heart". By accurately describing in "De Motu 
Cordis" that in the dying heart (27) the atria survive the ventricles and 
the right atrium survives the left, he laid the foundation for much of the 
present knowledge on cardiac impulse conduction. The clinical 
implications of Harvey's experiments are often not stated, but they can 
be divined. In his second letter to Riolen (28) he suggested that "many 
dangerous kinds of illness and surprising symptoms" ensue "if the 
circulation is hindered, perverted or overstimulated", including 
descriptions of suffocation, asthma and "suffocative catarrh" suggesting 
perhaps congestive heart failure. He also noted that if the ventricles 
became distended to the limit of their capacity the heart ceases to beat 
and death by suffocation ensues. Lower's work, essentially a 
continuation of Harvey's, relied similarly on direct observation and 
experiment. In 1669 he published Tractus de Corde Item de Motu et 
Colore Sanguinis and Chyli in Eum Transitu (29), describing how the 
colour of blood changes as it passes through the lungs and obtains "a 
nitrous spirit" from the air. In the second chapter, he maintains that the 
two sides of the heart should have "like strength in order to maintain a
24
constant circulation", noting that inequality occurred rarely but the 
"cardiac parenchyma is subject to various illness:.., which interfere with 
its pulsation. Hence it gives out blood feebly and slowly". Although 
Lower did not develop the idea further for the left ventricle, he 
speculated on the underlying pathophysiology of the right ventricle when 
discussing the arrangement of the ventricular muscle and the action of the 
"moderator band". This can be translated as "But it (the right ventricle) 
might be spread apart so far beyond its proper stretch that its fibres could 
no longer contract and return to normal. This could be brought about by 
the onrushing torrent of blood (since the wall is thin) or by suppression 
of the heart's movement (if the quantity of blood is excessive)" (30).
Marcello Malpighi (1628-1694), who never published, but whose 
"consultations" have been preserved, had demonstrated as early as the 
1660's the implication of the pulmonary circulation in dyspnoea. His 
ideas were based on earlier experiments, conducted with Fracassati and 
which included ligation of pulmonary vessels together with minute 
anatomical studies using a microscope (31). The first demonstration of 
circulating erythrocytes within the capillaries belongs, however, to 
Antony van Leeuwenhoek (32). Giorgio Baglivi, a pupil of Malpighi, 
provides the clinical picture of "stagnation and sudden coagulation of 
blood in the lungs and praecordium", with "foaming" as a symptom for 
which blood letting is an "instant remedy" though it must sometimes be 
done repeatedly (33). Further, in his writings on asthma, he describes a 
sleeping patient who "is suddenly aroused by severe asthma or is taken 
with suffocation and opens the windows and wants fresh air". Baglivi 
indicates that this is dropsy of the chest and is best treated by phlebotomy 
and diuretics (34). A similar clinical picture of paroxysmal nocturnal 
dyspnoea, recognised as a "maldistribution of intrathoracic fluid" that
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could be treated with diuretics and purges, was described by Carolus 
Piso in 1618 (35).
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THE HISTORY OF TREATMENT
This recognition that the underlying pathophysiology of breathlessness 
may be treated pharmacologically with specific agents leads directly on 
to the modem management of heart failure.
Cardiovascular Drugs
1. Cardiac Glycosides
In 1775 William Withering's opinion was sought as to the merits 
of a herbal tea, commonly used in Shropshire for the relief of dropsy. 
Withering, a talented botanist, recognised foxglove from over 20 or so 
ingredients as being the cause of the violent vomiting and purging that 
accompanies its use (36). This plant had a long history of folk use 
having been listed in many of the herbals of Edward Ill's  reign (1327- 
1377) (37). Originally known as "foxglove” it was named Digitalis 
Purpurea in 1542 by the German botanist Leonard Fuchs and described 
as "a violent medicine" (38,39).
In 1785 Withering published "An Account of the Foxglove and Some of 
Its Medical Uses: With Practical Remarks on Dropsy and Other 
Diseases" (36). In this he described in detail how to determine the 
correct dosage (highly relevant as it was known to be a deadly poison - 
"dead men's bells" in Scotland). Withering was of the opinion that 
digitalis acted directly against dropsy since it did not increase urinary 
flow in people who did not have fluid retention. He did not realise that 
it was a cardiac stimulant, although he recognised that it had "power 
over the motion of the heart, to a degree yet unobserved in other 
medicine, and that this power may be converted to salutory ends". In 
1799 a Manchester physician, John Ferrier, felt that the production of
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urine was of secondary importance in comparison to the reduction of 
pulse rates. Thomas Beddoes noted that digitalis increased the contractile 
action of cardiac muscle fibres (38).
Richard Bright in reports of medical cases (1827) was the first to 
distinguish between dropsy of cardiac origin and that due to renal 
disease, where the "urine was albuminous" (38). Despite this the misuse 
of digoxin continued and as late as 1911 Potter's Materia Medica and 
Pharmacopoeia recommended digitalis as an aphrodisiac.
In the early 1900s the effects of digitalis on the heart began to be 
elucidated with the introduction of the polygraph in 1902 by James 
McKenzie (40) and the electrocardiograph by William Einthoven in 1903 
at Leiden University (41). Work carried out by Cushing and McKenzie 
in London and by Karl Wenckebach in Holland suggested the correct 
indications for the use of digitalis were atrial fibrillation and for heart 
failure in sinus rhythm.
Attempts to isolate the active principle in digitalis met with no success 
and in 1820 the Societe de Pharmacie in Paris offered a prize of 500 
francs, which doubled after five years. This was not awarded until 1841 
when Homolle and Quevenne, pharmacists at the Hopital de la Charite in 
Paris, isolated the impure but active crystalline material, probably mainly 
digitoxin, which they called digitaline. Digitaline crystallised was 
isolated in 1869 by Claude Alphonse Nativelle. In the late 1920s the 
powdered leaves of digitalis lanata were found to have a greater 
pharmacological activity than digitalis purpurea, and Sidney Smith of 
Burroughs Wellcome isolated and separated the glycosides and thus 
identified a new glycoside which he called digoxin (42).
28
In 1888 Ouabain was isolated by Amaud from the bark and roots of the 
ouabaio tree (Acocanthera sp.) from which the Somalis of East Africa 
prepared their arrow poison. It was also present in the infusions of the 
barks and seeds of Strophanthus gratis used by the Pahouins. Thomas 
Fraser, working in Edinburgh, investigated a variety of arrow poisons 
from different varieties of Strophanthus, thus renewing interest in the 
isolation of cardiac stimulants. In 1933 Arthur Stoll and co-workers 
isolated a crystalline cardiotonic glycoside from squill (’’the bulb of the 
sea onion"- Urginea maritime) which technically was similar to that of 
digitalis and was used by the ancient Egyptians and Greeks (43).
2. Nitrates
Amyl nitrate had originally been synthesised at the Sorbonne 
in 1844 by Balard who noted that its vapour gave him a severe headache. 
In 1865 Sir Bernard Ward Richardson showed that the facial flushing 
was due to dilatation of the capillaries. Gamgee showed that nitrate 
induced dilatation of blood vessels led to a drop in blood pressure.
In 1867, Thomas Brunton, working as a newly qualified physician at 
Edinburgh Royal Infirmary and faced with a patient with paroxysmal 
nocturnal angina, found that cupping and venesection proved consistently 
helpful. His friend, Arthur Gamgee, who had been using amyl nitrate to 
lower blood pressure in animals suggested that this might be tried and 
Brunton found this to be immediately effective in relieving chest pain 
(44). In the following years Brunton examined other nitrates, including 
the readily available nitroglycerin whose explosive properties had been 
discovered by Alfred Nobel, but found that it caused such severe 
headaches that he pursued it no further (St. Bartholomew's Reports 
1876). Nitroglycerin itself was discovered in 1847 by the French 
chemist Ascagne Sobrero and to avoid the intense headache, which he
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attributed to overdosage, William Murrell developed a tablet containing
0.5 - 1.0 mg. of nitroglycerin to be dissolved slowly in the mouth (with 
larger doses for oral or topical preparations) and published in the Lancet 
in 1879 (45).
Analogues and nitroglycerin have been synthesised and the first of these, 
pentaerythritol tetranitrate, was introduced in 1896. More recently, 
isosorbide dinitrate and isosorbide mononitrate have been manufactured.
It was some time before it became appreciated that nitrates induce 
relaxation of smooth muscle throughout the body.
3. Alternative Vasodilators
In attempts to find alternatives to nitrates, and in the context of 
growing understanding of several of the underlying mechanisms, drugs 
which block calcium ion influx into ventricular smooth muscle have been 
developed. In 1942 Max Bochnuhl and Gustav Erhardt of Hoechst 
synthesised fenpiparane, an anologue of methodone, which could be used 
as a papaverine substitute. In 1958, Erhardt synthesised prenylamine 
(Synadrin) and in 1965 Janssen synthesised nidaflazine which 
incorporated a lignocaine residue, in an attempt to confer anti-arrhythmic 
activity. The Richardson Merrell company developed perhexilene 
(Pexid), a fenpiparane analogue, with a reduced diphenylhydryl ring. In 
1962 Knoll and company developed an open chain papaverine analogue - 
verapamil (46). In 1965 Bernard Loev for Smith Kline and French 
synthesised a series of dihydropyridines and published the discovery of a 
relatively long lasting compound that dropped the blood pressure in 
animals but in 1967, before Loev's work was protected by patent, Vosser 
and Wagner working for Bayer patented nifedipine (47).
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4. Diuretics
The removal of oedema relied on the removal of blood, sweat or 
urine: blood - by cupping or leeches; sweat - by herbal diaphoresis; and 
diuresis - again by herbs. Diuretic herbs were known to the ancients, 
particularly Rhu and Figwort, and the last herbal diuretic appeared in the 
British Pharmacopoeia in 1932 (Infusum Bachu). Xanthine alkaloids, 
present in tea, coffee and cocoa, all had diuretic properties and Bronne in 
his doctoral dissertation at the University of Strasbourg in 1886, 
investigated the diuretic action of caffeine. His supervisor, von 
Schroeder, looked at a chemically similar alkaloid in cocoa 
(theobromine). Shortly afterwards, theophylline was isolated from tea 
extract though not properly characterised until it was synthesised by 
Wilhelm Traube in 1902 (39). Minkowsky established that it was three 
times more potent than caffeine. It is however very insoluble so that it 
was not until it was bound to ethylene-diamine that it become universally 
available as aminophylline.
The first of the more modem diuretics was discovered accidentally when 
Arthur Vogl, a medical student at the Wenckebach Clinic in Vienna 
University, was instructed to give a syphilitic patient mercury salicylate. 
Not realising how insoluble this was in water, he ordered a solution to be 
prepared but a colleague, to save his embarrassment, offered a soluble 
mercurial antisyphilitic - merbaphen - and this he gratefully accepted.
On the carefully charted recording of urinary output he noted that the 
patient had a diuresis. He therefore gave merbaphen to another syphilitic 
patient with aortic valve disease and gross congestive failure in whom 
conventional diuretics had failed. This produced a 10 litre diuresis. It 
soon became evident, however, that merbaphen could produce fatal 
colitis or nephrotoxicity (48,49). In 1924 mersalyl was introduced. This
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was often life saving although it was known to be toxic and had to be 
given parenterally. In 1941 Walker, Bott and Oliver, using micro- 
analytical techniques, showed that the reabsorption of water from the 
glomerular filtrate depended largely on the efflux of sodium ions across 
the tubule wall and that mercurial diuretics probably acted on inhibiting 
dehydrogenase enzymes, thus diminishing the movement of sodium and 
chloride ions. They then set out to synthesise a mercury-free 
dehydrogenase inhibitor and eventually in 1962 ethacrynic acid emerged. 
This however was five years after the discovery of thiazide diuretics. In 
1940 Mann and Keilin, working in Cambridge on antibacterial 
sulphonamides, noted that sulphonamides which retained both hydrogen 
ions were carbonic anhydrase inhibitors. These included sulphanilamide 
which produced an alkaline diuresis when given in massive doses (50).
In 1945 Pitt and Alexander established that inhibition of carbonic 
anhydrase in the kidney blocked reabsorption of sodium in the distal 
tubule. This property of naturesis subsequently shown to be secondary to 
blocking of the bicarbonate excretion was exploited by Schwarz who 
induced diuresis in patients with congestive heart failure with large oral 
doses of sulphanilamide. Roblin and Clapp synthesised hetero-cyclic 
sulphonamides in the belief that being more acidic than conventional 
sulphonamides they would better compete with carbon dioxide for the 
active site of the enzyme: acetazolamide was one such. Karl Bayer, 
working for Sharp and Dohme, thought a carbonic anhydrase inhibitor 
that acted in the proximal portion of the tubule might increase chloride 
excretion and thus promote loss of sodium chloride which would be 
useful in the treatment of hypertension which was currently being treated 
by reduced dietary salt intake. Sprague and Novello synthesised several 
aromatic sulphonamides for Bayer and his colleagues to test, eventually 
producing dichlorphenamide. The attachment of an amino group to the
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benzene ring of compounds similar to dichlorphenamide together with 
various other substitutions led to the development of benzothiadiazine 
which was marketed as chlorothiazide in 1957. Thiazide diuretics 
herewith replaced the toxic mercurial diuretics. In attempts to enhance 
diuretic potency other analogues of dichlorphenamine were synthesised, 
such as the open chain substituted derivative where the second acidic 
group was replaced by a carboxyl group. This led to the introduction of 
frusemide by Hoechst in 1962 and its structual analogue, bumetanide, in
1972. These drugs act on the loop of Henle to induce a brisk intense 
diuresis. They are powerful drugs which remain the mainstay of diuretic 
therapy for heart failure today though thiazides retain an important role 
for milder diuresis in patients in the "diuretic” treatment of high blood 
pressure.
5. Angiotensin Converting Enzyme Inhibitors
In 1934 Goldblatt published his work on renal ischaemia 
producing persistent elevation of systolic blood pressure and, three years 
later, Juan Fasciolo showed that transplantation of a kidney from a 
hypertensive animal into one with hypertension induced by bilateral 
nephrectomy that the ischaemic kidney was a potent source of renin 
(51,52). In 1939 Clifford Wilson and Frank Byron (53) demonstrated 
renal arteriolar degeneration associated with hypertension, laying the 
foundation for two further papers in 1940 - Eduardo Braun-Menendez, 
Juan Fasciolo et al "The Substance Causing Renal Hypertension" (54) 
and Irving Page and O.M. Helmer "A Crystalline Substance 
(Angiotensin) Resulting from the Reaction Between Renin and Renin- 
Activator" (55).
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In 1956 Skeggs et al (56) discovered the enzyme that converts 
angiotensin I to angiotensin II, but it was not until 1967 that the key role 
of angiotensin conversion was described in the lungs (Ng and Vane,
1967, 1968) (57,58).
In 1965 Ferreira described a bradykinin potentiating factor present in the 
venom of the Brazilian arrowhead viper (Bothrops jararaca) and in 1968 
Bakhle showed that this venom also inhibited the conversion of 
angiotensin I to angiotensin II, but it was not until 1972 until Engel et al 
appreciated that both actions of the venom were caused by the same 
components. Subsequently Ferreira et al isolated nine peptides, one of 
which was a nonapeptide called teprotide which was tested in vivo and 
was synthesised by Ondetti et al. In 1977 David Cushman, Hong Son 
Cheung and Emily Sabo and Miguel Ondetti of the Squibb unit 
developed captopril, which supplanted teprotide and is a nonapeptide 
possessing at least ten times the activity.
In 1978 two groups (Curtis et al and Gavras et al) (59,60) simultaneously 
reported on the use of intravenous teprotide for chronic congestive heart 
failure, both papers demonstrating improved cardiac function with 
reduced systemic vascular resistance. The following year two papers 
appeared on the use of captopril in congestive heart failure (Davis et al, 
Turini et al) (61,62) showing increased cardiac output, reduced 
pulmonary wedge pressure and systemic vascular resistance. Although 
captopril is undoubtedly effective it does have side effects, which may be 
associated with the presence of a sulfhydryl group.
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6. Other Inotropic Drugs
The theory of competitive drug antagonism was first formulated 
by Sir John Henry Gaddum (1900-1965), working at the Wellcome 
Physiological Research Laboratories, with his paper "The Action of 
Adrenaline and Ergotamine on the Uterus of the Rabbit" (1926) (63). 
This work showed that when the response to a drug was plotted against 
the logarithm of drug concentration, an S-shaped curve was obtained. A 
later paper "The Quantitative Effect of Antagonistic Drugs" (1937) 
showed that the effects of competitive drug antagonism could be 
expressed mathematically. Sune Bergstrom, working with US von Enler 
and U Hamberg, reported the "isolation of noradrenaline from the 
adrenal gland" (1949) (64). Noradrenaline was also independently 
isolated by BF Tullar (1950). Noradrenaline is an alpha agonist which 
causes vasoconstriction.
Earlier James Gunn (1822-1958) (65) wrote on the pharmacological 
actions and therapeutic uses of some compounds related to adrenaline -13 
phenylamine, tyramine, benzedrine and ephedrine - and concluded that 
one action which is retained by compounds based on phenyl-ethylamine, 
even with a modified structure, are its action on smooth muscle with 
pressor hypertensive effects. In 1946 Ulf von Enler showed that 
noradrenaline is the predominant transmitter of the post-ganglionic 
sympathetic nerve fibres (66). It had been known for some time that the 
peripheral vasoconstrictive effects of adrenaline could be prevented by 
using antagonists (ergot alkaloids, phenoxybenzamines) whereas 
peripheral vasodilation could not. In 1948 RP Ahlquist introduced a 
hypothesis which accounted for these differing effects by postulating the 
existence of two different types of receptors - alpha and beta (67).
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For something like ten years, only alpha antagonistic effects were known
then in 1958 dichloroisoprenaline was discovered, which was the first
substance to selectively and competitively prevent beta receptor effects.
In 1962 Sir James Whyte Black and JB Stephenson reported the
development of pronethalol, a specific adrenergic beta receptor
antagonist. A large number of compounds were made and tested and in
1949 the paper "A New Adrenergic Beta-Receptor Antagonist” -
propranolol was published. Propranolol has now been augmented by an
extensive range of adrenergic beta blocking drugs with differing degrees
of cardioselective action (68). In 1967 AM Lands and co-workers
discovered that variations in sensitivity of the beta receptors to stimulant
and blocking drugs (depending on their chemical composition) allowed 
the differentiation of two types of receptors - Bj in the heart and small
intestine and B2 in the bronchi, vascular beds and uterus (69). Levy and
Wilkenfield (1969) showed that there are drugs available able to 
selectively block either B \  or B2 receptors without affecting the other
type of B receptors (70). Similarly, as shown by Choon-Kang et al 
(1970), salbutamol selectively activates B2 receptors and relaxes
bronchial smooth muscle, without producing unwanted cardiac
stimulation (71). This led to the development of selective beta
antagonists in the form of prenalterol (l-[4-hydroxyphenoxy]-3- 
isopropyl-amino-2 propranol) which is essentially a B \  agonist and
pirbuterol which has a greater effect on B2 receptors than on Bj
receptors (2-hydoxy-methyl-3-hydroxy-6-[ 1 -hydroxy-2-test-butylamino- 
ethyl=pyridine 2HC1]). These drugs can be expected to produce 
different degrees of vasodilatation and inotropic stimulation of the 
myocardium.
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HISTORY OF CLINICAL RECOGNITION OF HEART FAILURE
On the sound basis of new anatomical knowledge - a process begun in 
the 16th Century, came the "clinicians" of the following centuries. 
Raymond Vieussens (1641-1716) was according to Senec "an earnest 
student of anatomy". He wrote "the smallness, weakness and 
irregularity of the pulse can be ascribed to the small amount of blood that 
flowed from the left ventricle into the aorta as well as to the lessened 
force with which that ventricle pushed the blood into the artery, and to 
the irregularity of its contraction. As to the leaden colour of the lips, the 
dimmed lustre of the eyes, the dropsical swelling of the legs and thighs, 
and their lowered temperature, I would say that these symptoms can be 
viewed as the result of the disturbed circulation" (72). Lancisi of Rome 
(1654-1720) had a wider view than Vieussens and in the second part of 
De Motu Cordis et Aneurysmatibus (73) there was an attempt at 
classification of "aneurysm" or dilatation of the heart - citing causes as 
heredity, mechanical obstruction from inside the heart as from calcified 
or leaking valves or calcified arteries, or from outside the heart as from 
chronic catarrh, asthma, palpitation, nervous and psychic conditions.
His contemporary who also and independently studied heart disease - 
Hippolito Francesco Albertini was a pupil of Malpighi, a colleague of 
Valsalva and a teacher of Morgagni. In 1726, five years after its 
presentation, a paper was published in the transactions of the Bologna 
Scientific Society (74) which commented on the respiratory difficulties 
that depended on damage to the heart and praecordium. Albertini 
systematically employed palpation as an aid to diagnosis, recognising the 
quality of the heart's impulse, its extent, the presence of thrills and the 
location of the heart, particularly if it was enlarged and whether it was 
thin walled or thick walled (hypertrophied). He also discussed "remoter"
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symptoms of heart disease such as pains in the shoulders and arms, and 
recognised difficulties in breathing as being accumulation of fluid due to 
obstruction to the circulation through the heart (clearly differentiating 
this from "hydrops" of the pleura).
Giovanni Battista Morgagni (1681-1771) in his monumental work De 
Sedibus et Causis Moriborum et Anatomes Indignatis - Libri Quinque 
(Venice 1761), in which he freely admits he borrows from many sources 
Albertini, Valsalva and Senec, laid the foundation for the anatomic 
concept. This was not discovered by Morgagni but he communicated it 
in a uniquely clear way - the value of careful case histories, various 
aetio-logical and therapeutic features, and the clinical symptoms in the 
light of revelation after death - that is a method of diagnosing and 
explaining disease in terms of pathological anatomy (75). These methods 
became more general, especially after their adoption by Corvisart and 
Laennec. In the latter part of the 18th Century in England, interest in 
heart disease was kindled by William Heberden (1710-1801) the 
consummate physician of the Hippocratic type, whose bedside 
observations were keen and discriminating. In 1768 he described with 
remarkable clarity the clinical picture of what we now recognise as 
angina pectoris, of which he reported 20 cases (76). Indeed his 
description has not been surpassed to date "but there is a disorder of the 
breath marked with strong and peculiar symptoms, considerable for the 
kind of danger belonging to it, and not extremely rare, which deserves to 
be mentioned more at length. The seat of it, and the sense of strangling, 
and anxiety with which it is attended, may make it not improperly be 
called angina pectoris.
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Those who are afflicted with it, are seized while they are walking (more 
especially if it be uphill and soon after eating) with a painful and most 
disagreeable sensation in the breast which seems as it would extinguish 
life, if it were to increase or to continue; but the moment they stand still, 
all this uneasiness vanishes. In all other respects, the patients are, at the 
beginning of this disorder, perfectly well, and in particular have no 
shortness of breath from which it is totally different. The pain is 
sometimes situated in the upper part, sometimes in the middle, 
sometimes at the bottom of the os stemi, and often more inclined to the 
left than to the right side. It likewise very frequently extends from the 
breast to the middle of the left arm. The pulse is, at least sometimes, not 
disturbed by this pain, as I have had opportunities of observing by 
feeling the pulse during the paroxysm. Males are more liable to this 
disease, especially such as have passed their fiftieth year". Heberden 
had little idea that his description of pain had any connection with the 
heart far less the coronary arteries but others in Britain had. A patient of 
John Fothergill's (1712-1780) with typical angina was sent to John 
Hunter for autopsy after his sudden death at the age of 63 because it was 
suspected by Fothergill that the heart was at fault (77). The heart was of 
"ligamentous consistence and in many parts of the left ventricle almost 
white and hard". "The two coronary arteries from their origin to many 
of their ramifications upon the heart were become one piece of bone".
In fact when Hunter himself died (1793) he was found to have 
extensively ossified coronary arteries and had been known to suffer from 
angina. His friends Edward Jenner and Caleb Hillier Parry refrained 
from discussing or publishing their thoughts on the association of angina 
with ischaemia of the heart muscle until after his death (Parry's Syncope 
Angiosa 1799) (78). Following Parry's statements Alan Bums (1781- 
1813), working in Glasgow as an anatomy demonstrator, attempted to
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demonstrate what he believed was the central mechanism of angina i.e. 
relative ischaemia of the muscle. The heart "has peculiar vessels set 
apart for its nourishment. In health, when we excite the muscular system 
to more energetic action than usual, we increase the circulation in every 
part, so that to support this increased action, the heart and every other 
part has its power augmented. If, however, we call in to vigorous 
action, a limb, round which we have with a moderate degree of 
tightness, applied a ligature, we find that the member can only support 
its action for a very short time; for now its supply of energy and its 
expenditure, do not balance each other; consequently, it soon from a 
deficiency of nervous influence and arterial blood, fails and sinks into a 
state of quiescence. A heart, the coronary vessels of which are 
cartilaginous or ossified, is in nearly a similar condition; it can, like the
lim b , with a moderately tight ligature, discharge its function so
long as its action is moderate and equal. Increase, however, the action 
of the whole body, and along with the rest, that of the heart, and you
will soon see i t  the truth of what has been said; with this
difference, but as there is no interruption in action of the cardiac nerves, 
the heart will be able to hold out a little longer than the limb. If a person 
walks fast, ascends a steep or mounts a pair of stairs, the circulation in 
their state of health is hurried, and the heart is felt beating more 
frequently against the ribs than usual. If, however, a person with the 
nutrient arteries of the heart diseased in such a way as to impede the 
progress of the blood along them, attempts to do the same, he finds, that 
the heart is sooner fatigued than the other parts are, which remain 
healthy. When, therefore, the coronary arteries are ossified, every agent 
capable of increasing the action of the heart, such as exercise, passion 
and ardent spirits, must be a source of danger" (79).
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The next notable advance came from France. Jean-Nicolas Corvisart 
(1755-1821), a clinician but an ardent advocate of autopsy control of 
diagnosis, was mainly interested in "aneurysm" which in the terminal 
stages resulted in "heart failure" (80). He was able to distinguish 
between failure of the right and left heart. In addition he occasionally 
refers to the sounds of the heart being audible by listening "close by" in 
cases of "active aneurysm". In 1808 he translated and republished the 
"Investum Novum", published by Auenbrugger in 1761 adding his own 
comments (81). Auscultation as a diagnostic method began to be 
accepted. Corvisart was also clearly conversant with the back pressure 
theory of the failing heart although his written explanations were not as 
clear as those of Vieussens almost 100 years earlier or of Hope some few 
years later.
In 1819 Laennec (1781-1826) published "De L f Auscultation Mediate" 
(82). With the invention of the stethoscope the medical world awoke to 
the immense value to diagnosis of auscultation in addition to percussion, 
palpation and inspection. Laennec's main interest was in respiratory 
disease and he often misinterpreted sounds from the heart (eg of the two 
heart sounds he assigned the first to ventricular contraction and the 
second to auricular contraction). In Vienna Joseph Skoda (1805-1881) 
checked Laennec's work by experiment at the bedside and with autopsy, 
together with the clinician Carl Rokitansky (1804-1878). With these two 
clinicians, Vienna became renowned as the centre for clinical teaching 
and the teaching of the art of diagnosis (83).
Ludwig Traube (1818-1876) twice visited Vienna to study under Skoda 
(1841 and 1843). In 1871 he published an article noting that the failing 
heart caused reciprocal changes in the kidney with congestion of that
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organ (84). He also discussed embolic infarction and primary 
contraction of the kidney which he believed was either causative or 
associated with hypertrophy of the heart.
Now was the age of physical diagnosis epitomised by the Irish clinicians, 
Graves, Corrigan, Cheyne and Adams, and above all William Stokes 
(1807-1878). Stokes, educated in Dublin, Glasgow and Edinburgh, was 
familiar with the work of Laennec and Skoda. In his major work 
"Diseases of the Heart and Aorta" (1854) (85) he sets forth the 
importance of judging the gravity of heart disease not only in the 
presence of a murmur but "it is in the vital and anatomical conditions of 
the muscular fibres that we find the key to cardiac pathology: for, no 
matter what the affection may be its symptoms mainly depend on the 
strength or the weakness, the irritability or the paralysis, the anatomical 
health or disease of the cardiac muscle. It was long ago observed by 
Laennec that valvular disease had but little influence on health when the 
muscular condition of the heart remained sound, and every day's 
experience confirms this observation”. He advocated, only in passing, 
the use of digoxin but used mercury to strengthen "the weak 
myocardium” with favourable results - increasing urine output, 
decreasing the size of the liver and lessening dyspnoea.
Contemporary with Stokes, Peter Mere Latham (1789-1875) is of interest 
for his hypothesis of "pseudohypertrophy", which he named the 
temporary "distension" of the overfilled ventricle which returned to 
normal when the overload was removed (86). When the muscular 
structure was damaged by disease and the elastic properties lost, he 
termed this dilatation and clearly described the secondary effects of 
congestion of the lungs, the venous system and oedema, which he
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regarded as the body's way of attempting to drain the extra fluid and thus 
lessening the work of the heart. He also discussed five cases of angina 
which differed from the usual in that the pain was of sudden onset, lasted 
an inordinate time, recurred with the slightest provocation (status 
angiosus) and resulted in death. At autopsy in some of these patients not 
only were their coronaries found to be ossified but the heart muscle was 
"softened" (87). James Hope (1801-1841), whose medical education 
started as a resident physician in Edinburgh, then a year in Paris and 
later hospitals in Italy, Bavaria and Holland, first published his Principles 
and Illustrations of Morbid Anatomy in 1834 (88). In this he was the 
first to provide a clear exposition of the back pressure theory of heart 
failure (89).
The term "chronic myocarditis" was appearing in the literature - often 
applied to processes that were not inflammatory - and indeed earlier 
Morgagni seems to have recognised this confusion - he thought that the 
process might often be degenerative rather than inflammatory (90). 
Virchow taught that inflammation might start in the interstitial tissue 
which by contraction or exudation, by causing pressure, might damage 
muscle fibres (91). This hypothesis was reversed by Carl Weigert (1847- 
1904) (92). While investigating the effects of smallpox he noticed a 
fibrin-like change in the parenchymal cells with loss of nucleii, which he 
regarded as the first step in a process later termed "coagulation necrosis" 
by Cohnheim (90,93). Subsequently there was proliferation and fibrous 
tissue formation as part of a reparative process. Weigert believed that 
initial damage in the case of the heart would affect the muscle cells.
This damage may be caused by chemical or bacterial toxins, but also 
from excessive strain on muscle fibres that are overstretched, 
overworked and poorly nourished, as in aortic regurgitation or "lessened
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circulation through the coronary arteries” (Dock's translation) "In 
atheromatous changes of the coronary arteries not infrequently 
thrombotic or embolic obstructions form in the branches of the arteries.
If the obstruction forms slowly, or at least in such wise that the collateral 
channels exist, but not enough to keep up nutrition, a slow atrophy 
occurs with destruction of the muscle fibres without injury to the 
connective tissue. The muscle fibres that disappear are replaced by 
fibrinous connective tissue, and the so-called chronic myocarditis is 
nothing else than such a process" (92).
In 1881 Cohnheim and von Schulthess-Rechberg published the results of 
experiments occluding coronary arteries in dogs and transferring these 
results to man concluded that ligation of larger branches was rapidly fatal 
(93). They argued that in the extensive area of myocardium involved, 
the circulation became stagnant and with the accumulation of noxious 
chemical products this tended to paralyse the muscle.
There followed then a very exciting time in medicine - Pasteur's 
preventative vaccination (1880), Koch's discovery of the tubercle 
bacillus (1882), Lavereau's description of the parasite of malaria (1881), 
Lister's aseptic principles for surgery (1886), Fitz's operation for 
appendicitis and in 1896 Roentgen described the x-ray. Heart disease 
and its problems faded from the forefront until the early 20th Century 
when interest was reawakened with His, Keith and Flack, Gaitskell and 
Tawara, McKenzie's polygraph and Einthoven's electrocardiograph and 
Thomas Lewis's "The mechanisms of the Heart Beat" (1911).
This might be termed the era of the physiologists. Adolf Fick (1829- 
1901) developed the Fick principle for the measurement of cardiac output
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- the principle of measurement of blood flow by dilution, being that the 
faster the blood flow the less oxygen is taken up per unit of flowing 
blood. In 1897 George Neil Stewart (94) published a series of 
experiments measuring circulation time using changes in conductivity 
and the principles of indicator dilution measurements. The control of 
cardiac output had been seen as an intriguing problem since the mid 19th 
century. Control of heart function involves both heart rate and stroke 
volume. The relationship between the length of the muscle fibre and its 
strength of contraction in skeletal muscle was known to Fick and was 
investigated by one of his former students - M. Blix (1891). Otto Frank 
(1865-1944) (95) formulated some of the fundamental principles of 
cardiac contraction. He says of isometric contraction "the peaks 
(maxima) of the isometric curve rise with increasing initial tension 
(filling). (I call this part of the family of curves the first part). Beyond 
a certain level of filling, the peaks decline (second part of the family of 
curves)". In 1914 Straub and Wiggers both published on the factors 
controlling pressure curves, but as with Frank they had difficulty 
demonstrating a quantitative relationship (96,97). In 1912 Starling, 
Evans, Patterson and Piper began to work together which culminated in 
"the law of the heart" (98,99).
"The law of the heart" is therefore the same as that of skeletal muscle 
namely that the mechanical energy set free on passage from the resting to 
the contracted state, depends on the area of "chemically active surfaces",
i.e. the length of the muscle fibres. This formula serves to "explain" the 
whole behaviour of "the isolated mammalian heart". Starling's work 
emphasised the effects of venous flow - that increased cardiac output was 
determined by the increased venous inflow, until atrial pressure was 
considerably elevated and that there was a relationship between the
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diastolic volume of the ventricle and the work developed in the following 
systole. But in the intact animal the law did not describe phenomena 
observed, such as a higher cardiac output in resting animals than in the 
heart lung preparation and the mechanisms by which cardiac output could 
increase above resting levels (100,101). In 1878, A Waller (102) had 
the idea that increased output was accomplished by blood entering the 
heart from distended pulmonary veins at a higher pressure. Stanley 
Samoff and Erik Berglund confirmed that there is a consistent 
relationship between atrial pressure and ventricular stroke work and 
demonstrated series or families of ventricular function curves, by which 
concept changes in ventricular function could be understood. With 
regard to myocardial failure they state "The shape of the normal 
ventricular function curve does not confirm the interpretation that cardiac 
failure may result merely from stretching the muscle fibre beyond the 
point where an increased filling pressure causes a decrease in cardiac 
work. We consider myocardial failure to be an alteration of the 
contractility of the myocardial fibres resulting in a shift of the ventricle 
from a normal function curve to a depressed one. The increased filling 
pressures are not the cause of failure but a consequence of decreased 
myocardial contractility" (103).
Historically the clinical manifestations of heart failure have been 
regarded as arising as a consequence of either inadequate cardiac output 
(backward failure hypothesis first proposed by Hope in 1832) (104) or 
the damming up of blood behind one or both ventricles (forward heart 
failure hypothesis proposed by McKenzie) (105).
Backward failure - the overworked ventricle first hypertrophies and then 
dilates. As it dilates the blood gets dammed up behind it and an
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increased venous pressure is transmitted ultimately to the capillaries 
where oedema is formed.
Forward failure, based on Starling's findings, that as the pressure in the 
great veins rose the pressure in the capillaries fell, thus Starling was 
forced to propose that the only explanation could be the loss of fluid with 
an increased capillary permeability ("The dropsy is entirely conditioned 
by the state of the capillary wall"). McKenzie championed this theory. 
"The blood passes through the capillaries at a slow rate, impairs their 
nutrition, and allows transudation to take place, which we call dropsy" 
(105). It was several years before Landis' technique eventually 
demonstrated that capillary pressure was increased in heart failure (106). 
It was not until after the introduction of cardiac catheterisation by 
Coumand and Richards, which allowed sampling of arterial and venous 
blood, that there was demonstrated there was a group of conditions in 
which there was undoubted cardiac failure, but the cardiac output was 
increased - the "high output failure" of anaemia, thyrotoxicosis, A-V 
fistula, cor pulmonale, beri-beri and Paget's disease.
This resulted in a small change in the definition which is now widely 
reproduced "a state in which the heart fails to maintain an adequate 
circulation for the needs of the body" (Paul Wood) (107). What it leaves 
undefined are "the needs of the body". Peter Harris' St. Cyrus lecture of 
1986 succinctly and logically deals with the various possibilities - 
glucose, fatty acids, oxygen, but there is no evidence for reduced uptake 
of any of these substances (108). Peter Harris also discusses the control 
exerted by the autonomic nervous system, the central nervous system and 
endocrine mechanism and finally comes to the conclusion that evolution 
in warm blooded animals has produced a system to provide a high
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cardiac output to support physical exercise, with the delivery of oxygen 
to exercising muscles together with a high resting arterial pressure which 
allows for this increase in cardiac output with a relatively unchanged left 
ventricular emptying pressure. "A damaged heart becomes progressively 
unable to maintain arterial pressure at first during exercise and ultimately 
at rest. When this happens the body responds in the stereo-typed manner 
for which it has been programmed by natural selection to maintain the 
arterial pressure during exercise or trauma".
The identification or diagnosis of heart failure is still problematical. 
Clinically the mechanisms of "forward and backward" heart failure 
operate to a greater or lesser degree in most patients with heart failure. 
Blood pressure measurement per se is not particularly helpful in 
identifying the patient with chronic heart failure, since by definition, 
blood pressure is maintained by a variety of compensatory mechanisms. 
Perhaps little has changed since Sir Thomas Lewis wrote "It is 
impossible thoughtfully to survey, in the light of early experience, the 
field of medical work covering diseases of the heart without realising the 
central problem to be failure of the heart to accomplish its work to a 
lesser or greater degree. The very essence of cardiovascular practice is 
recognition of early heart failure and discrimination between different
grades of failure When a patient seeks advice and heart disease is
suspected, or is known to be present, two questions are of chief 
importance. Firstly, has the heart the capacity to do the work demanded 
of it when the body is at rest? Secondly, what is the condition of the 
heart's reserve? These questions can be correctly answered in almost all 
cases by simple interrogations and by bedside signs" (109).
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PART 2 
WHAT IS HEART FAILURE?
Introduction
Paul Wood in 1956 stated that "heart failure may be defined as a state in 
which the heart fails to maintain an adequate circulation for the needs of 
the body despite a satisfactory filling pressure" (1). The limitations of 
such a definition are now recognised, particularly in respect to defining 
and measuring "adequacy", "needs" and "satisfactoriness". In patients, 
if the circulation is inadequate to supply the needs of the body, oxygen 
uptake should be diminished. Yet in early studies, using the Fick 
principle (2), this was clearly not the case and in the face of evidence 
that resting cardiac output may be normal in untreated patients with 
undoubted features of clinical heart failure.
The clinical features which comprise the syndrome of congestive heart 
failure are well recognised. It is now appreciated that they reflect an 
altered setting of cardiovascular control mechanisms that may be 
regarded as "compensatory" (3) responses to a chronic (cardiac) 
reduction in cardiac output, and that they are manifest predominantly as 
the consequences of salt and water retention. The changes may affect 
every aspect of the cardiovascular system, fluid balance and their 
interactive neurohumoral control mechanisms. "Cardiac reserve" is 
encroached upon and reduced, with clinical implications in respect of 
exercise. Therapy readjusts one or more of these mechanisms, thus the 
overall cardiovascular status to net symptomatic benefit (with also some 
improvement in life expectancy).
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The scope of this thesis is restricted to those patients with "heart failure" 
secondary to coronary artery disease, thus the impairment of cardiac 
performance is the consequence of (a) ischaemic necrosis with loss of 
myocardium - either as a major event as in myocardial infarction where a 
large mass of myocardium is lost, or as the cumulative loss of small 
regions of myocardium from recurrent ischaemic episodes; (b) acute 
ischaemia which is a potent reversible negative inotropic influence, or (c) 
myocardial "stunning" which represents the delay in full contractile 
recovery, which may take some days following an episode of severe 
ischaemia. Acute reduction of ventricular function causes an acute 
reduction in cardiac output, a rise in end diastolic pressure and 
pulmonary venous pressure, incipient or actual pulmonary oedema, and 
the acute neurohumoral responses, predominantly of the adrenergic or 
the sympathetic system that are responsible for the clinical features of 
shock where the perturbation (and associated pain and anxiety) are 
sufficiently severe. Chronic, or repeated and prolonged (eg "stunning") 
acute reduction of overall ventricular function leads to the chronic 
"compensatory" changes of heart failure involving (a) the heart, (b) the 
rest of the body.
Most of the experimental work on heart failure has been carried out on 
animal models of either mechanical overload, rapid pacing, or myo­
cardial poisoning. In overload models; "ventricular failure" is produced 
either by abnormal volume or pressure loads. These lead to differing 
cardiac compensatory responses. Chronic volume or "diastolic" overload 
(A-V shunting or mitral regurgitation) leads to chronic dilatation with 
slippage of fibres, such that sarcomere lengths remain normal and 
diastolic chamber compliance is increased. Increased systolic wall 
tension, associated by the Laplace relationship with volume, leads to
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secondary hypertrophy, explaining how wall thickness is unaltered while 
the total mass of the left ventricle increases. Chronic pressure "systolic 
overload" (eg by aortic banding or high blood pressure) leads to 
hypertrophy, with thickening of the ventricular wall; diastolic volume 
tends not to change. Much is known about the changes that occur in 
cardiac chamber geometry, myocytes, collagen matrix and vasculature in 
hypertrophy, and in overt congestive heart failure where the simplest 
interpretation of the voluminous literature is that these changes become 
more severe. Experimental coronary artery occlusion and infarction has 
also been used as a model of heart failure and compensatory hypertrophy 
where remodelling of the residual myocardium is observed. This is 
particularly relevant when it comes to interpreting the effects of exercise 
which are an integral part both of the symptoms and the evaluation of 
heart failure, given also that clinical ischaemia may be "silent". This 
thesis describes only clinical studies - in all their uncontrolled complexity 
but relevant uniquely to the clinical problem, its evaluation and its 
treatment.
"Heart failure" is becoming the major cardiovascular problem of this 
decade, its prevalence is increasing. Milton Packer (4) estimates that 
there are nearly 12 million people in the world with symptoms of heart 
failure, an "additional 40 million with important degrees of left 
ventricular dysfunction", and that "the numbers of persons hospitalised 
for heart failure has risen nearly four-fold during the past 15 years".
The reason for the increase is partly due to the more effective 
management of acute events - with increased numbers of patients 
surviving acute myocardial infarction, albeit with impaired ventricular 
function. It may be due partly to the increased longevity of the general 
population: most patients with heart failure are older than 65 years and
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heart failure is a common reason for hospital admission in this age 
group. Heart failure is a huge, expensive and growing problem.
In any evaluation of heart failure, it is important to distinguish subgroups 
with differing prognosis, differing characteristics and potentially 
different responses to treatment - if such subgroups exist and can be 
practically identified. This is likely to be particularly important when 
heart failure is secondary to coronary disease because of the potential 
contribution to impaired contractile function of stress induced ischaemia 
(which may be " silent”) and also the potential contribution to overall 
cardiac performance of right ventricular ischaemia/infarction (which may 
be unrecognised), as well as differences in the neurohumoral and cardiac 
compensatory responses in relation to the severity of the condition.
This thesis describes a number of studies of heart failure from coronary 
disease, that are directed to these ends and whether there is a component 
that can be identified which may be influenced by therapy. There is 
therefore a need to classify patients accurately so that differing 
populations may be correlated and the effects of pharmacological 
intervention assessed. As all patients have significant coronary 
atherosclerotic disease, pharmacological interventions have been 
restricted to those drugs which might be expected to influence 
"ischaemia". Alterations of neurohumoral mechanisms have not been 
studied.
Conventionally, as cardiac failure is a disease of "symptoms", these are 
classified clinically using a variety of schemes, of which the most widely 
employed is the New York Heart Association. There is a great deal of 
doubt as to whether this is the most effective method of classifying
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patients, either with respect to the degree of impairment or to risk of 
mortality.
Published studies have required differing inclusion criteria for the 
diagnosis of 'heart failure1. The simplest require the presence of 
cardiomegaly on chest x-ray, while others require the demonstration of 
raised left ventricular end diastolic pressure or reduced cardiac index. 
There is no universal agreement as to what constitutes 'heart failure' and 
how this may be best identified in the clinical setting. In the following 
chapter, conventional methods of classifying patients with heart failure 
are examined and compared. Since conventional clinical assessments are 
clearly not optimal in identifying the patient with 'heart failure', other 
non-invasive techniques, such as perfusion imaging, have been employed 
to assess other factors which may be important in this group of patients, 
where heart failure is secondary to coronary artery disease.
The experimental work of this thesis comprises of two parts - the first 
examining various methods by which the patient with heart failure may 
be identified, and the second in which the effects of pharmacological 
interventions are examined in small groups of these patients.
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CLINICAL CLASSIFICATION
Introduction
The opening paragraph of Sir Thomas Lewis' Diseases of the Heart (1) 
identifies the diagnosis and assessment of heart failure as the cardinal 
problem in clinical cardiology. The principal complication of almost all 
forms of heart disease is heart failure. Thomas Lewis states that two 
questions are of importance "Firstly, has the heart the capacity to do the 
work demanded of it when the body is at rest? Secondly, what is the 
condition of the heart's reserve?''.
Lewis also wrote "These questions can be correctly answered in almost 
all cases by simple interrogations and by bedside signs".
Symptoms and Signs and Attempts at Classification 
Braunwald's text book identifies the following (a) symptoms, 
breathlessness, effort intolerance; (b) signs, raised jugular venous pulse, 
peripheral oedema, tachycardia, third heart sound, cardiomegaly and 
basal crepitations, as being associated with "heart failure" (2). There are 
various ways in which symptoms and signs may be classified but the 
most widely accepted is that of the New York Heart Association (Table 
1) (3). The importance of attempting to classify patients lies in 
identifying those characteristics that might identify the patient more 
likely to die, so that interventions may be judged to be more or less 
successful.
A small series of studies are presented in which the New York Heart 
Association grading is examined in detail, for the prediction of 
subsequent mortality and the degree of ventricular impairment. Clinical
Table 1
New York Heart Association (3)
Grade Symptoms
I No limitation
II Breathless on normal exertion
III Breathless on minimal exertion
IV Breathless at rest
Table 2
NEW YORK HEART ASSOCIATION GRADING
GRADE % TOTAL POPULATION %  MORTALITY
II 27% 26%
III 51% 38%
IV 22% 43%
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signs and symptoms, usually employed for the diagnosis of heart failure, 
are then examined in a similar manner.
a) Introduction
The efficacy of the New York Heart Association Grading System, 
for the prediction of subsequent mortality, was assessed in patients with 
heart failure secondary to coronary artery disease.
Methods
Patient Population
Sixty four patients who were clinically judged to have congestive heart 
failure by at least two experienced cardiologists were included. 
Congestive heart failure was thought to be secondary to significant 
coronary artery disease, based either on coronary arteriography or past 
history of myocardial infarction. Patients were followed for a mean of 
19 +  4 months and all deaths recorded. Deaths were classified as (a) 
cardiac, if the symptoms and signs preceding death suggested myocardial 
infarction, progressive heart failure or if the death was sudden and 
unwitnessed with an absence of symptoms or signs of other diseases, or 
(b) non-cardiac. The aetiology of the heart failure was confirmed by 
echocardiography and coronary angiography. Classification of the 
symptoms was according to the New York Heart Association (NYHA)
(3) and was made by two clinicians.
Results
Sixty four patients were evaluated, eight were female with an age range 
32-71 years. Total mortality was 36%. The percentage of patients 
assigned each of the NYHA gradings is seen in the Table 2, with the 
largest mortality (43%) occurring in the group with NYHA grade IV.
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b) Introduction
The New York Heart Association grading is a subjective 
assessment of patients' symptoms. The degree of left ventricular 
impairment that underlies these symptoms may vary. Left ventricular 
ejection fraction, a measure mainly of systolic performance, is an 
accepted measure of left ventricular function and is known to be 
predictive of subsequent mortality following myocardial infarction.
Methods
Patient Population
Eighty consecutive patients admitted to the Coronary Care Unit of 
Glasgow Royal Infirmary were subsequently shown to have sustained a 
myocardial infarction on the basis of sequential electrocardiographic 
changes and enzymes. A clinical grading, using the conventional NYHA 
grading system, was made at 7-10 days by two clinicians.
Left Ventricular Function
Left ventricular function was measured using radionuclide angiography
(see Appendix). In brief, following in vivo labelling of red blood cells 
with technetiun^m  pyrophosphate scans were obtained gated to the
electrocardiogram using a Gamma camera fitted with a high sensitivity 
parallel collimator. Data was obtained in listmode using a Link MAPS 
computer and reformatted into a 24 frame representative cardiac cycle. 
Left ventricular ejection fraction (LVEF) was calculated (see Appendix). 
Normal left ventricular ejection fraction >40%.
Results
The correlation of New York Heart Association grading and left 
ventricular ejection fraction are seen in Figure 1 opposite. LVEF
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obtained on the third day following myocardial infarction is used, as this 
has previously been shown to be the most stable (see Appendix). 
Although those patients with the lowest ejection fractions tended to have 
been graded NYHA IV, there is considerable overlap. Indeed, many 
patients graded NYHA I have substantial left ventricular dysfunction 
(LVEF <30%).
c) Introduction
Conventionally, the diagnosis of heart failure (as with any disease 
process) is based on patients' signs and symptoms. The predictive value 
of individual signs and symptoms for the identification of heart failure 
has been calculated. To do this, an entirely arbitrary measure of 
pulmonary capillary wedge pressure £ 15 mm.Hg. has been employed to 
indicate significant left ventricular decompensation, and thus 'heart 
failure'.
Methods
Patient Population
Sixty four patients were judged to have congestive cardiac failure, 
secondary to coronary artery disease (proven either by coronary 
arteriography or consequent upon myocardial infarction). A detailed 
clinical history and examination were obtained by two experienced 
cardiologists. NYHA grading was assigned to each patient.
Non-Invasive Measurements
Chest x-rays were performed on full inspiration in a standard manner. 
Cardiothoracic ratio was obtained by drawing the largest diameter of the 
heart and dividing by the largest diameter of the expanded chest,
Table 3
PREDICTION OF HEART FAILURE
SENSITIVITY SPECIFICITY PRED VALUE
NYHA 86% 45% 75%
Angina 33% 27% 67%
Palpitations 27% 71% 33%
Ankle oedema 48% 100% 100%
Orthopnoea 62% 67% 72%
PND 67% 55% 74%
Cyanosis 24% 100% 100%
HR >  100/minute 29% 100% 100%
SBP < 90 mm.Hg. 10% 100% 100%
JVP 48% 82% 83%
Apex displaced 43% 82% 82%
S3 10% 91% 66%
MR/TR 21% 91% 83%
Crepitations 57% 73% 80%
Effusion 5% 100% 100%
Ascites 5% 100% 100%
CTR > 48% 91% 64% 83%
Cardiac output 50% 64% 71%
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Fig. 2 Cardiothoracic Ratio vs PCWP
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corrected for height and weight, as is described in Radiological Anatomy 
of the Heart (4).
Invasive Data
A Swan-Ganz thermodilution catheter was inserted percutaneously for the 
measurement of pulmonary artery pressure, pulmonary capillary wedge 
pressure (PCWP) and cardiac output. A pulmonary capillary wedge 
pressure > 15 mm.Hg. was taken as indicative of heart failure. Cardiac 
output was obtained in triplicate and cardiac index and stroke volume 
index calculated (see Appendix).
Statistical Methods
Sensitivity, specificity and predictive accuracy were calculated, using 
Stepwise multidiscriminant analysis, based on diagnosis of heart failure 
with a PCWP of 2 15 mm.Hg.
Results
NYHA, grade III and IV, have a predictive value of 75% for heart 
failure, based on a diagnosis by increased PCWP. Not surprisingly, 
symptoms and signs associated with high venous pressure (ankle oedema, 
ascites, pleural effusion) have a high specificity, with a lower sensitivity 
(Table 3). Increased cardiothoracic ratio, reflecting increased left 
ventricular volume as an adaptive response was sensitive, but not 
specific. Cardiothoracic ratio, plotted against PCWP is shown in Figure
2. 18% of patients with a cardiothoracic ratio >48% had a 'normal' 
PCWP (<14 mm.Hg.).
Table 4
PREDICTION OF DEATH
SENSITIVITY SPECIFICITY PRED VALUE
NYHA 85% 32% 46%
Angina 38% 56% 46%
Palpitations 63% 67% 38%
Ankle oedema 50% 64% 38%
Orthopnoea 61% 86% 55%
PND 58% 85% 85%
Cyanosis 40% 59% 15%
HR > 100/minute 67% 65% 30%
SBP < 90 mm.Hg. 100% 63% 15%
JVP 50% 65% 46%
Apex displaced 36% 57% 31%
S3 67% 62% 15%
MR/TR 67% 65% 31%
Crepitations 64% 78% 69%
Effusion 0% 58% 0%
Ascites 0% 58% 0%
CTR > 48% 52% 80% 85%
Cardiac output 43% 53% 46%
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d) Introduction
The predictive value of individual signs and symptoms, generally 
associated with heart failure, for subsequent cardiac mortality has been 
calculated.
Methods
Patient Population
The patients described in the previous study (c) were followed for a 
mean of 19 ±  4 months, and all deaths recorded. The total mortality 
was 36% with one death due to lung carcinoma.
Classification of signs and symptoms, calculation of cardio-thoracic ratio 
and measurements made from Swan Ganz catheter were identical to those 
in Section c).
Results
The sensitivity, specificity and predictive value of the clinical 
descriptions for mortality is seen opposite (Table 4). In general, clinical 
signs and symptoms are not predictive. However, an increased 
cardiothoracic ratio had a predictive accuracy of 85 %, being specific but 
not sensitive. Measurements such as cardiac output, made by 
thermodilution, were neither sensitive nor specific for subsequent 
mortality.
Discussion
(1) Clinical Classifications
In 1949 when the Framingham Study was initiated, the organisers 
devised a system of major and minor criteria (Table 5), by which the 
diagnosis of heart failure was classified as certain, probable or unlikely,
Table 5
Framingham Study (5)
Major Criteria
Paroxysmal nocturnal dyspnoea or orthopnoea
Neck vein distension
Rales
Cardiomegaly
Acute pulmonary oedema
S3 gallop
Increased venous pressures 16 cm. (of water) 
Circulation time s  25 sec.
Hepatojugular reflux.
Minor Criteria
Ankle oedema 
Night cough 
Dyspnoea on exertion 
Hepatomegaly 
Pleural effusion
Vital capacity one third from maximum 
Tachycardia (rate >  120/minute)
Major or Minor Criteria
Weight loss S 4.5 Kg. in 5 days in response to treatment
Table 6
Harlan et al (6)
Chronic Congestive Heart Failure in Coronary Artery Disease
Clinical Criteria
SEN % SPEC % P VAL
Dyspnoea 66 52 23
Orthopnoea 21 81 2
PND 33 76 26
Oedema history 23 80 22
Inotropic
treatment 47 77 34
HR > 100 7 99 6
Rales 13 91 27
Oedema 10 93 3
S3 31 95 61
Neck vein 
distension 10 97 2
HJR 17 91 -
Cardiomegaly 
by x-ray 62 67 32
PND = paroxysmal nocturnal dyspnoea
HR = heart rate
S3 = third heart sound
HJR = hepatojugular reflux
Sen = sensitivity
Spec = specificity
P Value = predictive value
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and using this inferences have been drawn as to the presence of heart 
failure in the population (5). In a study by WR Harlan et al (6) the 
sensitivity, specificity and predictive accuracy of clinical signs were 
presented. This suggested that when the classical signs of cardiac de­
compensation were present (tachycardia, oedema and neck vein 
distension) these were very specific but their predictive accuracy was low 
(Table 6) which is very similar to the findings in our study, presented 
earlier. The only clinical sign that had an acceptable accuracy in 
Harlan's study was the presence of a third heart sound (predictive 
accuracy 61 %) which was somewhat surprising as the authors made no 
attempt to verify its reproducibility. A more recent study (7) has 
demonstrated low agreement as to the presence or absence of a third 
heart sound in a range of patients using clinical observers of varying 
experience.
The need for a classification system, whereby patients could be graded 
and the effect of drug therapy assessed, was clear. The American Heart 
Association published their four point scale (3) based on the patient's 
perception of his own ability to exercise. This has major faults, in that it 
is based on the patient's perception, life styles can be altered so that the 
patient can underestimate the degree of impairment or overestimate 
impairment if the patient does not indulge in exercise that may precipitate 
the symptoms. The subjective nature of this classification is shown by 
Franciosa et al (8) where, in comparison to measured maximal oxygen 
uptake (VC>2 max), there was little correlation with American Heart
Association grading. In a study by JR Wilson et al (9), comparing the 
ability of the New York Heart Association grading measurements to 
predict subsequent mortality, New York Heart Association grades III and 
IV were the strongest (p 0.05). The New York Heart Association
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(NYHA) grading does not easily discriminate between patients with 
different degrees of left ventricular impairment (10).
In the study presented in this thesis, where left ventricular function was 
assessed by LVEF and correlated with NYHA grading of left ventricular 
function there was considerable overlap of results. Those patients with 
the lowest left ventricular ejection fractions tended to have the highest 
New York Heart Association gradings. However, looking at those 
patients with New York Heart Association grading I and II, 55 % of 
patients had substantial left ventricular impairment (left ventricular 
ejection fraction <30%). Maranz et al (11) have shown that three other 
types of clinical scoring systems provide similar, but not identical, 
results. Mean left ventricular ejection fraction for patients with heart 
failure, according to the Framingham scale, was 45 % compared to 53 % 
in patients who had no failure. For the Duke scale, left ventricular 
ejection fractions were 43% versus 58% and the Boston scale, which 
classified heart failure as definite, possible or unlikely, had a mean left 
ventricular ejection fraction of 41 % versus 51 % versus 55 %. When left 
ventricular ejection fraction was <40%, taken to indicate significant left 
ventricular dysfunction, sensitivity and specificity of clinical diagnosis 
using the Framingham scale was 0.63 and 0.62, for the Duke scale was 
0.73 and 0.54 and 0.50 and 0.78 for the Boston scale. In patients with a 
normal left ventricular ejection fraction, 51% had heart failure diagnosed 
by at least one of the scoring system criteria and in those with low left 
ventricular ejection fractions 20% of patients met none of the clinical 
criteria. Thus, although clinical scoring systems may identify patients 
with ventricular dysfunction, the sensitivities and specificities vary (12).
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(2) Chest X-Ray
Enlargement of the heart is usually assumed to be due to left 
ventricular enlargement. An enlarged right ventricle, or an enlarged 
chest diameter due to, for example, emphysema can make the cardio­
thoracic ratio abnormal. Cardiothoracic ratio (CTR) bears some 
relationship to PCWP (see Figure 2), but in 17% of patients with an 
abnormal CTR (>48% ) PCWP was normal (< 1 4  mm.Hg.). 
Demonstration of cardiac enlargement or cardiac dysfunction is not 
adequate for the diagnosis of overt congestive heart failure which is a 
clinical syndrome. In a series of 66 patients with heart failure Franciosa 
(7) found a cardiothoracic ratio of >50% in 75% of patients. Similarly, 
in the patients in this study, a cardiothoracic ratio of >48% was present 
in 75% of patients. In a study by Harlan et al (6) using 40 x-rays, the 
cardiothoracic ratio was analysed by two observers six weeks apart with 
a mean difference that was significant (p<0.05) and the major difference 
was in the long diameter of the heart. However, also in this study, a 
cardiothoracic ratio of >48% was the most valid descriptor of
subsequent heart failure whether measured by left ventricular end 
diastolic pressure, AVO2 (arterio-venous oxygen) differences or ejection
fraction.
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Heart volume can also be calculated (13).
where v =  L x B x D x k x M  
A
where v =  volume of the heart in ml per sq m of body surface
area
L = long diameter
B = broad diameter
D = greatest horizontal depth
A = body surface area m2
k = constant 0.63 (14)
M = magnification factor
However this is time consuming and the measurements are very variable. 
Heart volume (left ventricular volume from contrast ventriculogram) 
was the most accurate (n = 329, p <  0.001) in patients in whom heart 
failure had been defined as left ventricular end diastolic pressure >15 
mm.Hg. (6). Heart size was the most important predictor of death over 
the subsequent three year period (6). In the Coronary Artery Surgery 
Study, of 24,959 subjects, 339 patients were found to have severe 
impairment as a result of heart failure (NYHA Class IV); 39.8% had 
normal heart size on chest x-ray.
(3) Haemodvnamic Measurements
Left ventricular filling pressure:- Pulmonary capillary wedge 
pressure (PCWP) and pulmonary diastolic pressure have been shown to 
correlate well with left ventricular end diastolic pressure (LVEDP) (r = 
0.8) (16,17,18) in the absence of mitral valve disease. The upper limit 
of normal for left ventricular end diastolic pressure is usually regarded as 
12 mm.Hg. but Harlan et al (6) arbitrarily defined 15 mm.Hg. to be 
associated with heart failure. In their population of 273 patients with 
clinical heart failure and 1033 without, 53% of patients with heart failure
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(cardiomegaly or S3) had a left ventricular end diastolic pressure >  15 
mm.Hg. and 20% of those with clinical heart failure had an end diastolic 
pressure of <15 mm.Hg. Thus, an enlarged heart on chest x-ray is 
specific but not sensitive. In our study, 61% had a pulmonary capillary 
wedge pressure > 15 mm.Hg. Wedge pressure did not correlate with the 
left ventricular ejection fraction (r = 0.08). This was not really 
surprising as pressure measurements are very subject to influence, eg 
changing preload with diuretic therapy. The change of filling pressure 
with changes of pre-load are well known and were demonstrated by 
Samoff et al (19,20). As seen in Figure 3, increasing ventricular filling 
pressure is a compensatory mechanism whereby output can be 
maintained. Thus, where a large volume of myocardium is lost (such as 
following myocardial infarction) and contractility is decreased, an 
isolated measurement of LVEDP or PCWP may not on its own be 
helpful in defining the patient with heart failure.
Patients with capillary wedge pressures >20 mm.Hg. tend to have 
poorer ventricular function. Patients with higher wedge pressures tend to 
have a higher death rate (21).
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Cardiac Output
Haemodynamic measurements have been the main tool by which our 
understanding has advanced of the pathophysiology of acute cardiac 
events, such as acute infarction and cardiogenic shock. Haemodynamic 
measurements have also been the main therapeutic end points of studies 
of interventions.
Resting haemdodynamic measurements, in the acute situation, may be 
predictive of subsequent events. Swan and Ganz (22) suggested that 
patients with a cardiac index that exceeded 2.2 1/min/m2 have a 
favourable prognosis, a cardiac index of 1.8 - 2.2 1/min/m2 represents a 
cardiac output that is barely adequate to meet ordinary needs and a 
cardiac index of less than 1.7 1/min/m2 is associated with an extremely 
poor prognosis (unless there is an instantly reversible cause such as 
hypovolaemia).
In chronic cardiac failure, resting haemodynamic measurements such as 
cardiac index or stroke volume index, tend to be lower than normal 
values. Franciosa et al (21) found the cardiac index significantly reduced 
in patients with most reduced exercise capacity compared to normals 
(1.81 ±  0.12 versus 2.53 ±  0.18, p<0.01), but there was no significant 
difference between groups differentiated by degrees of limitation of 
physical work capacity. This is in keeping with our findings.
Earlier studies suggested that patients with the most abnormal 
haemodynamic measurements were most likely to die during long term 
follow-up (23-26). Patients with markedly elevated values of pulmonary 
capillary wedge pressure, left ventricular end diastolic pressure, and 
systemic vascular resistance and markedly reduced cardiac output, had
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the highest mortality, e.g. Franciosa (27). In 182 patients it was found 
that the highest mortality was associated when the left ventricular filling 
pressure was greater than 27 mm.Hg., systemic vascular resistance 
greater than 23 Wood units, and survival longer when cardiac index was 
greater than 2.25 1/min/m2.
In general, most investigators have noted a poorer long term prognosis in 
patients with high left ventricular filling pressures in association with low 
cardiac output (or measures incorporating cardiac output such as stroke 
work) (26,28,29,30), although not all (9,31) suggesting that high risk of 
death in these patients may be related to other factors than abnormal 
haemodynamic measurements. Many of these studies use univariate 
analysis which does not take into account potential inter-relations 
between haemodynamic variables. The patient populations in these 
studies were often skewed as abnormal haemodynamics were required as 
an entry criteria to the study. Thus, the population represents only those 
with abnormal haemodynamics and not all patients with symptomatic 
heart failure. Only left ventricular filling pressure has a weak correlation 
(r =  -0.31) with duration of survival in non-survivors. Higher values 
for systemic vascular resistance may reflect neurohumoral abnormalities, 
particularly of the sympathetic system (32,33). High values for right 
atrial pressure have also been related to poor prognosis but this may 
reflect pulmonary artery pressure elevation and right ventricular 
dysfunction (29,30,34).
Thus, in chronic heart failure, resting haemodynamic measurements do 
not correlate with symptoms or the functional capacity of patients and 
they are of little value in predicting the long term clinical responses to 
treatment (27).
78
Summary
There is a clear need for a classification system whereby patients can be 
graded and the effects of drug therapy assessed. The New York Heart 
Association's four point system is based on the patient's perception of his 
own ability to exercise and as such has major limitations. The subjective 
nature of this classification has been shown by Franciosa et al (8) to have 
little relation to measured physical work capacity. From our own work 
(predictive value 46%) and that of JR Wilson et al (9) New York Heart 
Association classification does not predict subsequent death. Mortality 
was more strongly associated with New York Heart Associations grades 
III and IV (p =  0.01). Similarly, New York Heart Association grading 
cannot discriminate between patients with differing degrees of left 
ventricular impairment although patients with grade III and IV 
classifications tend to have the lowest left ventricular ejection fraction. 
Similar findings are observed using the Framingham data, Duke and 
Boston scales.
The chest x-ray is readily available and simple and cheap to perform. A
cardiothoracic ratio of >50% is relatively sensitive and specific but has
a relatively low predictive value for the diagnosis of heart failure. In our
study, an increased cardiothoracic ratio was not predictive of death. This
was in contrast to Harlan et al (6) who found that using a cardiothoracic
ratio of >48% this was the most valid descriptor of death in the
subsequent three years (compared to left ventricular end diastolic 
pressure, AVO2 differences and ejection fraction).
Haemodynamic measurements, particularly pulmonary capillary wedge 
pressure, left ventricular end diastolic pressure >  15 mm.Hg., are often 
used as a requirement for the diagnosis of heart failure. There are two
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major disadvantages in using this as a criteria for the identification of 
patients with heart failure. Firstly, it requires a catheter measurement 
(either right heart catheter to measure pulmonary capillary wedge 
pressure or left heart catheter for left ventricular end diastolic pressure) 
which is invasive. Secondly, measurement of left ventricular filling 
pressure is sensitive to changes in preload, thus as a single measurement 
can well be misleading. Although not surprisingly patients with more 
extensive left ventricular dysfunction and damage tend to have higher 
filling pressures, as this classically is a ventricular compensatory 
mechanism to maintain cardiac output. Although haemodynamic 
responses do not relate closely to exercise capacity, they are predictive of 
survival, reflecting more extensive ventricular dysfunction (7).
Similarly, with other haemodynamic measurements, at rest, these 
parameters do not correlate with either symptoms or functional capacity 
in patients with chronic heart failure; nor are they of value in predicting 
the long term clinical response to treatment. In general, abnormal 
haemodynamic variables are associated with poorer long term prognosis, 
again reflecting the extent of ventricular dysfunction.
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EXERCISE TESTING 
Introduction
Control of the heart rate, cardiac output and blood pressure is mediated 
by regions of the mid brain, hypothalamus and cerebral cortex, resulting 
in activation of the sympathetic nervous system and the arterial 
baroreceptors some of which have been described by Hilton as organising 
the "defence reaction" (35). This physiological response comprises an 
increased arterial pressure with an increased cardiac output together with 
vasoconstriction in the gut, skin and kidney and vasodilatation in the 
skeletal muscle. During exercise, afferents from the exercising limbs 
and messages from higher centres of the brain reset the medullary 
cardiovascular control system to permit an increased heart rate and blood 
pressure. In the patient with heart failure the damaged ventricle is 
progressively unable to increase its output normally in response to 
sympathetic drive and thus increase arterial pressure (36).
Patients with cardiovascular failure are usually more symptomatic during 
exertion, being limited by dyspnoea or fatigue. Exercise testing can 
objectively assess the degree of "exercise intolerance" and quantify the 
degree of impairment when the patient is symptomatic. Exercise 
capacity can also be used to evaluate effective therapeutic intervention.
Which Test and Which Measurement
(a) Subjective Testing
All muscle activity demands extra energy and will test to a greater 
or lesser extent the oxygen carrying capacity of the body. Undoubtedly 
the simplest way of assessing exercise capacity is to ask the patient. The 
New York Heart Association classification, discussed earlier, is an
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attempt to quantify this. Breathlessness, a symptom common in 
cardiovascular failure, is also difficult to measure as it depends on the 
patient's perception and assessment as a symptom is usually judged by 
clinical interview using questions such as "How far can you walk?" but 
this depends on how fast the patient walks and his judgement of distance, 
for which there is enormous inter-observer variation (37). To provide an 
indirect measure of symptoms, the 12 and 6 minute walk tests have 
become popular (38,39). This involves asking the patient to set his own 
walking rate and to measure how far he walks within the specified time, 
usually six minutes, and is thought to be more typical of "normal 
activity".
Methods
In order to assess the amount of work carried out in such a test, we 
studied nine male patients, very similarly matched both for left 
ventricular dysfunction and for symptoms, who all had New York Heart 
Association grade III and IV heart failure, and who had been stabilised 
on an optimal treatment with diuretic and vasodilators. They were asked 
to walk on a treadmill at a rate and incline which they chose as being 
comfortable and could be instantly increased or decreased by request by a 
pre-determined set of hand signals for six minutes. During the test, no 
vocal instructions or encouragement were given. Electrocardiogram was 
required continuously and blood pressure measured intermittently by cuff 
sphygmomanometer. Respiratory gas exchange was measured with the 
patient breathing from the low dead space and low resistance valve box, 
with which the patient was familiar. The valve box incorporates a 
turbine ventilometer on the inspired limb, for measurement of 
ventilation. The expired limb is fed through a mixing chamber from 
which samples of air are analysed for carbon dioxide by an infra-red
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spectrometer and oxygen by a paramagnetic analyser. Throughout each 
test minute ventilation (VE), oxygen consumption (V02) and carbon 
dioxide production (VC02) were measured by online ventilation and 
expired gas analysis (PK Morgan, Rainham, Kent) using standard 
equations, further details of which are given in the Appendix. Arterial 
blood gas values were monitored during the test with a transcutaneous 
system (TCM3 Radiometer Limited, Copenhagen) which continuously 
monitors transcutaneous oxygen and carbon dioxide tension. Indices of 
gas exchange could thus be calculated. The non-invasive anaerobic 
threshold on exertion was calculated using a plot of oxygen consumption 
against carbon dioxide production (see Appendix). Comparisons were 
made with similar measurements made on symptom limited maximal 
exercise on two occasions - once when treated only with diuretics 
(maximal exercise 1) and secondly with the addition of vasodilator 
therapy (maximal exercise 2).
Results
Heart rate initially increased as one would expect and remained fairly
stable as did systolic and diastolic blood pressure. Oxygen consumption
initially tended to increase in patients but the variation was large with no
patients walking at a level which was close to their predetermined
maximal oxygen consumption. The large individual variation in minute
ventilation and oxygen consumption can be seen in Figures 4a and 3b.
There was no difference in resting minute ventilation or oxygen
consumption at rest with any of the three tests (Figures 4c,4e). On 
exercise, walking tests in all cases had a lower V 02 than maximal
exercise although as a percentage of maximum this was very variable 
(Figures 4d,4f).
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Discussion
These results suggested to us that the six minute walk test reflected the 
patient's motivation rather than as a test of his ability to exercise. 
Although the methodology used to replicate that described by the original 
authors (40) the distance walked during the six minute walk test has been 
reported to discriminate better than measurement of maximal oxygen 
consumption between patients with severe chronic heart failure, where 
differences in distance walked are small compared to differences in 
maximal oxygen consumption in contrast to patients with "mild heart 
failure" (41). In our small number of patients who were similar from the 
point of view of left ventricular dysfunction, symptom severity, drug 
therapy and maximal oxygen consumption, measured oxygen 
consumption during walking and the percentage of maximal oxygen 
consumption varied enormously. In addition, on maximal exercise 
testing the response to vasodilator therapy was variable. More recently 
Parameshwar et al (42) have reported that in patients with mild heart 
failure, the distance travelled in 12 minutes on the self powered treadmill 
correlated significantly with maximal oxygen consumption. It remains to 
be seen whether this approach gives the better method of assessing the 
patient with "heart failure".
(b) Maximal Exercise Testing
Symptom limited maximal exercise testing is used extensively to 
evaluate the patient's ability to perform work. It is arguable whether this 
provides true objective evidence of maximal exercise without actual 
measurements of gas exchange or lactate accumulation (43,44).
However, in the hands of experienced operators the maximal exercise 
time was highly reproducible (0.9 ± 5 %  standard error of mean) in six 
patients exercised two weeks apart to obviate any training effect (see
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Appendix). Either a bicycle ergometer or treadmill can be used. A 
treadmill has the advantage that the highest V02 max can be achieved 
with healthy subjects (95-98% maximum running horizontally with 100% 
running uphill) (45). The disadvantages include that at peak workloads 
whether the subject is running or walking greatly affects the maximal 
oxygen consumption (46,47) and that in subjects with heart failure 
walking technique is important and inefficient gait may also affect 
maximal oxygen consumption (48). If maximal oxygen consumption is 
estimated rather than measured, practical details such as the patient's 
weight and whether they are holding on to the handrails (49) can greatly 
affect the values obtained. Upright bicycle ergometry produces oxygen 
uptake of 93-95 % of maximum with 60 revolutions/minute as the 
optimum for most normal subjects (43) and if prediction of maximal 
oxygen consumption is used rather than measured oxygen consumption, 
the coefficient of variation is lower than with the treadmill (50). The 
disadvantage that is usually quoted is premature leg fatigue (51) but 
many Scots have had bicycles as children and are familiar with this form 
of exercise.
Methods
Thirty six male patients with clinical evidence of heart failure were 
studied. In all patients left ventricular dysfunction was secondary to 
coronary heart disease, 34 of those 36 patients having suffered a previous 
myocardial infarction and the remaining two patients having blocked 
coronary artery vein bypass grafts. All patients complained of 
breathlessness on exertion and were graded II-IV by the New York Heart 
Association. Ages ranged from 38 to 63 years. All patients were 
receiving optimal doses of diuretics and all other concomitant therapy 
was withdrawn (including Digoxin) except for potassium supplements.
Table 7
HAEMODYNAMIC
Heart Rate beats/minute
Systolic BP mm.Hg.
Diastolic BP mm.Hg.
Mean BP mm.Hg.
PCWP mm.Hg.
Cardiac Index 1/min/m2
Stroke Volume Index ml/beat/m2
SVR dyne-s-cm"5
LVEF %
MEASUREMENTS
(mean ±  SEM)
Rest Exercise
79 + 9 124 +  8
120 ±  6 152 ±  7
79 ±  5 85 ±  3
93 ±  5 106 ±  4
21.6 ±  4 36.2 ±  4
2.16 ±  0.2 3.88 ±  0.3
28.3 ±  3 31.2 +  3
1956 ±  163 1274 ±  77
14 +  2 16 +  3
BP Blood pressure
PCWP Pulmonary capillary wedge pressure
Stroke Vol Index Stroke volume index
SVR Systemic vascular resistance
LVEF Left ventricular ejection fraction
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Heart rate was obtained from the electrocardiogram, monitored 
continuously, and blood pressure by cuff sphygmomanometer. A Swan- 
Ganz thermodilution catheter was inserted percutaneously via the internal 
jugular vein for the measurement of pulmonary capillary wedge pressure 
and pulmonary artery pressure. Cardiac output was obtained in triplicate 
by the automatic technique (IL 702) using 10 ml of cooled dextrose 
injected via an automatic injector (OMP thermodilution injector 3700) 
(see Appendix). All measurements were made between the hours of 8 
a.m. and 12 p.m. at rest and during upright dynamic exercise on a 
bicycle ergometer. Exercise was initially against no load, then 
increments of 25 watts every three minutes to a symptom limited 
maximum.
Results
Detailed results are seen in Table 7 opposite. Heart rate increases on 
exercise as does blood pressure although both are substantially lower at 
maximum than normal volunteers or age matched normals (heart rate 124 
±  8 beats/minute in patients, 149 ± 1 1  beats/minute in normal age 
matched; blood pressure 152/87 mm.Hg. and in normal age matched 
180/78 mm.Hg.) (52,53). Pulmonary capillary wedge pressure is 
elevated at rest and increases substantially with exercise although the 
range was very wide (15-53 mm.Hg.). Cardiac index increased on 
exercise but again not as much as any normals (3.88 versus 8.8 
litres/min/m2). Similarly stroke volume index does not increase 
normally (31.2 ±  3 in patients versus 59 ±  5 ml/m2 in normals). 
Exercise time does not correlate with exercise heart rate, blood pressure, 
pulmonary capillary wedge pressure, cardiac index or stroke volume 
index. Exercise time did not differentiate patients with differing New 
York Heart Association gradings.
Table 8 mean ±  SD
Rest Exercise
HR beats/minute 92.3 ±  11.7 128.2 ±  19.0
SBP mm.Hg. 115.5 ±  16.7 145.6 ±  20.3
DBP mm.Hg. 79.2 ± 8.8 85.0 ±  10.8
SMPA mm.Hg. 32.3 ±  13.8 60.6 ±  27.0
DMPA mm.Hg. 21.3 ± 8.1 37.4 ±  18.9
Cl 1/min/m2 2.21 ± 0.45 4.29 ± 1.07
SVI ml/beat/m2 25.5 ± 5.2 33.8 ± 8.0
DP HR x SBP 10286 ±  2577 18809 ±  4523
SVR dyne-s-cm-5 1864 ± 429 1139 ± 330
PVR dyne-s-cm-5 467 ± 226 436 ± 319
LVEF % 11 ± 5 13 ± 5
HR = heart rate
SBP = systolic blood pressure
DBP = diastolic blood pressure
SMPA = systolic mean pulmonary artery pressure
DMPA = diastolic mean pulmonary artery pressure
Cl = cardiac index
SVI = stroke volume index
DP = double product
SVR = systemic vascular resistance
PVC = pulmonary vascular resistance
LVEF = left ventricular ejection fraction
Respiratory Gas Analysis
Rest Exercise
VO2 oxygen consumption 285.1 ±  33.5 881.4 ±  200.5
VE minute ventilation 11.4 ± 2 . 6  33.9 ±  9.3
PAO2 arterial oxygen 87.7 ±  8.3 91.1 ±  11.5
A-a(>2 arterial-alveolar
oxygen gradient 16.26 ±  8.10 18.13 ±  6.72
Vd/vt dead space/tidal
volume ratio 47.8 ±  8.2 42.3 ±  17.3
Exercise time (mins) - 7.8 ±  2.89
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(c) Measurements of Gas Exchange on Exercise
In 10 of the above patients, maximal oxygen consumption was 
measured simultaneously with haemodynamic variables. In a further 10 
similar patients with coronary artery disease and heart failure, respiratory 
gas exchange was measured during exercise using a similar exercise 
protocol. The patients breathed through low dead space in a resistance 
valve box and this incorporated a turbine ventilometer on the inspired 
limb for measurement of ventilation and the expired limb was fed 
through a mixing chamber to allow analysis of carbon dioxide and 
oxygen partial pressures. Throughout the test minute ventilation (VE), 
oxygen consumption (V02) and carbon dioxide production (VC02) were 
measured by online ventilation expired gas analysis (PK Morgan, 
Rainham, Kent) using standard equations (further details are given in the 
Appendix). Arterial blood gas values were monitored throughout using 
trans-cutaneous system (TCM3 Radiometer Limited, Copenhagen) which 
continuously monitors transcutaneous oxygen and carbon dioxide 
tensions. Indices of gas exchange could then be calculated and the non- 
invasive anaerobic threshold on exertion were calculated using a plot of 
oxygen consumption against carbon dioxide production (see Appendix).
Results
Mean exercise time, heart rate and blood pressure were similar to the
previous group and are shown in Table 8. Details of maximal oxygen
consumption and anaerobic threshold are shown in Tables opposite. In
the 10 patients in whom haemodynamic variables were measured 
simultaneously, there was no correlation between VO2 max and heart
rate, blood pressure, pulmonary capillary wedge pressure, stroke volume 
index or cardiac index. VO2 max does correlate to a degree with
exercise time.
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Discussion
The exact mechanisms that underlie the exertional fatigue and dyspnoea 
experienced by patients with heart failure remain unclear. Originally, 
simplistically, the fatigue was thought to be a direct consequence of the 
inability of the heart to act efficiently as the pump and the breathlessness 
resulted from increased reflected left atrial pressure and "stiff" lungs. 
More recently it has been suggested that there is a complex interplay 
between the central and peripheral mechanisms that are activated in 
response to pump dysfunction that become more significant in the 
presence of peripheral oedema. In the presence of reduced oxygen 
delivery to working muscle (43,54) there is evidence of impaired 
vasodilation (55,56), altered skeletal muscle metabolism (57-59) and 
possibly also loss of muscle bulk.
The mechanisms underlying the sensation of breathlessness are 
undoubtedly more complex. Recent data suggests that ventilation/ 
perfusion mismatch (60) with an increase in physiological dead space 
necessitates an increased minute ventilation to maintain normal arterial 
carbon dioxide partial pressure. In addition, in chronic heart failure, 
even moderate workloads are associated with increased carbon dioxide 
production and these two abnormalities are additive, resulting in an 
increased ventilatory requirement even for moderate workloads. This 
together with decreased lung compliance, which increases the intrinsic 
work of breathing, results in increased central respiratory drive to 
maintain eucapnia and appreciation of this at a conscious level could 
result in the sensation of breathlessness (61-63).
The ventilation/perfusion mismatch does not appear to correlate with 
pulmonary capillary wedge pressure (60). However pulmonary
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microvascular permeability is significantly reduced in heart failure, 
possibly as an adaptive process to protect against pulmonary oedema (48) 
and it may well be that this is a further adaptive process in the lungs 
which determine the level at which patients develop both pulmonary 
oedema and the sensation of breathlessness. This would be in keeping 
with the very wide range of pulmonary capillary wedge pressures 
experienced by our patients during exercise who were all limited with the 
symptom of breathlessness.
The assessment of functional capacity by means of exercise testing has 
received increasing attention from investigators with the perceived need 
for objective measures to allow criteria to be established to institute 
therapy and to monitor the effects of these interventions. Clinical 
classifications of symptomatic status are too subjective and do not 
correlate well with measured exercise ability (see Figures 5,6) (8,64,65). 
Table 8 shows that resting haemodynamic variables do not correlate with 
measured functional capacity in patients with chronic left ventricular 
failure as has been demonstrated by numerous other investigators 
(8,10,65,66) as resting haemodynamic measurements cannot be used to 
assess the severity of symptoms or clinical efficacy of treatment.
Exercise haemodyamic measurements correlate more closely with 
symptoms but there is considerable overlap although other workers with 
a wider range of patients have shown a closer correlation (67).
Exercise testing protocols for patients with heart failure are usually 
modified to accommodate a reduced exercise capacity, to allow the 
patient to exercise long enough to attempt to discriminate different grades 
of severity of exercise limitation (8,64). In patients with chronic heart 
failure, the design of the test can influence the limiting symptom -
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breathlessness limiting exercise tests with rapid increases in workload 
while if the work load is increased slowly the exercise is usually 
terminated by fatigue (68). Thus it is preferable to measure the amount 
of exercise in terms of metabolic cost to the body - that is, as total 
oxygen consumption. Symptom limited maximum oxygen consumption 
(V02 max) is reproducible and correlates well with exercise time (Figure 
6). The reduction in V02 max, associated with increasing severity of 
heart failure, correlates well with reduced exercise, cardiac index and 
stroke volume index (69).
Oxygen consumption increases linearly with increasing workload and 
tends to plateau at maximal exercise (70) which approximates maximal 
aerobic capacity. If carbon dioxide production is measured 
simultaneously this can be used as the ratio to oxygen consumption 
(ventilatory exchange ratio) to more accurately indicate the achievement 
of the anaerobic threshold, which correlates well with the onset of 
systemic lactate production (69,71) (see Appendix). Measurements of 
V02 max and anaerobic threshold are less subjective than reliance on 
symptoms at peak exercise. Anaerobic threshold relates to exercise 
duration and in patients with chronic heart failure occurs at a lower heart 
rate than normals (112 + 17 versus 124 +  7 beats/minute) (Figure 7) 
(69) and is less subject to variability with different exercise protocols 
(72).
An important advantage of using measurements of respiratory gas 
analysis is that it allows patients to be classified on the basis of their 
"functional exercise capacity". Franciosa (8) using a four class system 
based on V02 max (1: V02 greater than 20 ml/min/kg; 2: 15-19 
ml/min/kg; 3: 10-14 ml/min/kg; 4: below 10 ml/min/kg) showed that
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patients could be differentiated in a manner that was not possible by 
either exercise capacity or New York Heart Association grading. 
However, maximum oxygen uptake is equally reduced in patients with 
cardiac failure who survive and non-survivors (7).
There is fairly extensive literature on the value of anaerobic threshold, 
but there is little correlative or prognostic information on some of the 
other measurements such as change in V02 relative to the change in 
work rate (8 V02/S WR 73) and the slope of the VC02/V02 ratio above 
the anaerobic threshold (which reflects the rate of lactic acid buffering by 
HC03) (74). Sietsema et al (75) in patients with cyanotic congenital 
heart disease and Nery et al (76) in patients with chronic obstructive 
airways disease have shown that V02 is markedly attenuated during the 
first 20 seconds of exercise, which depends critically on cardiovascular 
function. There is as yet insufficient literature to judge whether these 
measurements will be of value in the assessment of the patient with heart 
failure.
In summary, exercise testing appears to be a useful tool for assessing the 
severity of chronic heart failure and following progress. Functional 
capacity in metabolic terms, can provide an objective measurement 
which is useful to assess responses to pharmacological and other 
interventions.
VENTRICULAR FUNCTION 
Introduction
The ultimate importance of coronary disease is the impact of ischaemia 
upon the ventricle with ultimately the loss of muscle tissue. By assessing
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symptoms of the oxygen carrying capacity of the body or exercise 
tolerance one is, in effect, looking at the end result or the efficiency of 
compensatory mechanisms rather than the organ that is damaged. It 
would therefore be logical to assess the function of the ventricle, or 
rather the degree of dysfunction when attempting to classify patients.
Left Ventricular Function Measurements
The common, and most widely known, are those measurements made 
during angiography. This allows determination of chamber dimensions, 
volume, wall thickness and mass. Combined with the intraventricular 
measurements and cardiac output, angiography can provide a very 
detailed assessment of ventricular function at any one instance in time 
(77,81). With the use of specially adapted catheters specific 
measurements may be made, such as the Miller catheter providing dp/dt, 
but as with any invasive technique these measurements may be made 
only at one, or at most, a few points during the course of the cardiac 
catheterisation and are therefore not ideal for the assessment of out­
patients or long term pharmacological intervention.
Other methods are available to assess many of the measurements that are 
made during cardiac catheterisation. Ventricular end diastolic pressure 
can be estimated either from pulmonary capillary wedge pressure or 
pulmonary diastolic pressure, as discussed earlier. Ventricular volume, 
wall thickness, ejection fraction and regional function can be obtained 
either by echocardiography or radionuclide techniques. Echocardio­
graphy is non-invasive but requires considerable operator skill. 
Radionuclide techniques require intravenous injections of radio-active 
tracers but have the advantage of being less operator dependent, 
particularly during stress and when assessing right ventricular function.
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Studies on Ventricular Function
(a) Left Ventricular End Diastolic Pressure
Normally left ventricular end diastolic pressure is defined as less 
than 12 mm.Hg. (see Appendix) and as the ventricle dilates so the left 
ventricular end diastolic pressure tends to rise although this is not 
inevitable. The Frank-Starling mechanism, described in the intact 
isolated dog heart, demonstrates the ability of increasing pre-load (filling 
pressure) in maintaining cardiac output (Figure 8a). In 1954 Samoff and 
Berglund combined stroke volume in a reflection of "flow work" by the 
heart and systemic pressure, cardiac "pressure work", to describe 
ventricular function curves (Figure 8b) (82). Samoff then went on to 
describe a "family of ventricular function curves" relating stroke work to 
filling pressure depending on the level of contractility of the heart.
In the last 30 years there has been conflicting literature as to the 
importance of left ventricular end diastolic pressure in the limitation of 
exercise tolerance in the patient with heart failure (83,84).
Methods
Thirty patients New York Heart Association graded II-IV heart failure, 
aged 36-66 years, underwent routine cardiac catheterisation. Left 
ventricular end diastolic pressure (LVEDP) was measured prior to the 
ventriculogram using a fluid filled catheter. Recordings were made at a 
range of 50 cm equals to 50 mm.Hg. at a speed of 50 mm/second and 
diastole was taken concurrently with the R wave of lead II of the 
electrocardiogram recorded simultaneously, after the a wave of atrial 
contraction. Ejection fraction was measured from the contrast 
ventriculogram (as determined in the Appendix) (LVEF).
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Results
The lack of correlation of end diastolic pressure and systolic function, 
measured as left ventricular ejection fraction is seen in Figure 9.
Discussion
As an isolated measurement, left ventricular end diastolic pressure may 
not be on its own helpful in defining the patient with heart failure and 
does not predict the measurement of systolic left ventricular performance 
(LVEF), although where LVEF was lowest left ventricular end diastolic 
pressure tended to be highest.
It has been suggested that left ventricular filling pressure is the primary 
haemodynamic abnormality during exercise in patients with heart failure 
(85). Evidence cited to support this includes
(a) that exercise capacity is more closely related to left ventricular filling 
pressure than cardiac output or limb blood flow, as many patients have 
normal increases in skeletal muscle blood flow on exercise (86,87) and 
that pulmonary wedge correlates with the maximal exercise capacity 
(84,88). However this is not our experience (see data on PCWP in this 
thesis), although the number of patients studied was small.
(b) changes in exercise capacity are more closely related to changes in 
LVEDP than to cardiac output.
(c) exercise capacity is more closely related to right ventricular ejection 
fraction than to left ventricular ejection fraction. It was presumed that 
this occurred because only right ventricular systolic function is correlated 
with the levels of pulmonary wedge pressure (89). In a group of patients
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with chronic obstructive airways disease we found only a weak 
correlation with right ventricular function and pulmonary pressure but a 
good correlation with pulmonary vascular resistance (90).
Another explanation that might be considered is that ventricular filling 
pressure may be altered if there is a change in ventricular volume or if 
the pressure-volume relationship is altered by, for example, increasing 
muscle stiffness, as may occur with ischaemia (85).
Ventricular Volumes and Function
Following myocardial infarction, the most important determinant of 
survival is reported to be left ventricular ejection fraction (LVEF, see 
Appendix) (5,91-94) although end systolic volume and end diastolic 
volume may also be important (96). Where heart failure is present 
nearly all the patients have abnormal ventricular function and the 
prognostic value of measurements of ventricular function are less clear as 
are the relationships between other measurements used for assessment of 
heart failure.
Methods
Thirty six patients with documented chronic heart failure New York 
Heart Association grade II-IV were studied. In all patients active drug 
therapy, apart from stable dosages of diuretics and potassium 
supplements, were withdrawn for at least 14 days.
Heart rate was obtained from the electrocardiogram and blood pressure 
by cuff sphygmomanometer. Pulmonary capillary wedge pressure was 
obtained by Swan-Ganz catheter. Cardiac output was obtained in
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triplicate by thermodilution. Cardiac index and stroke volume index 
were calculated (see Appendix). Maximal symptom limited exercise 
testing was performed on a bicycle ergometer using an adjusted protocol 
(see Appendix). Respiratory gas analysis was carried out online in 10 
patients as previously described. Ventricular function was assessed by 
technetium-99m radionuclide angiography. Left ventricular volume and 
left ventricular ejection fraction were calculated.
Results
The results are seen in the Figures opposite. There was no correlation 
between LVEF and wedge pressure, stroke volume index or cardiac 
index, although there was a tendency for the lowest LVEF to occur with 
the highest resting wedge pressure and lowest stroke volume index and 
cardiac index (Figure 10).
End diastolic and end systolic volume as shown in Figures opposite. 
Similarly, there was no correlation with haemodynamic parameters 
(Figure 11). LVEF % is shown, plotted against exercise parameters 
(Figure 12). There was no correlation with exercise heart rate, blood 
pressure, double product, exercise time or work load achieved.
Similarly, there was no correlation between LVEF and exercise 
haemodynamic parameters - pulmonary capillary wedge pressure, cardiac 
index and stroke volume index (Figures 9,12).
Discussion
These results are not entirely surprising since the haemodynamic 
measurements are made at one instance in time and may be affected by 
other factors than ventricular performance. Conversely, ejection fraction 
is affected by changes in loading conditions, independent of changes in
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muscle function. This confirms early reports by Dougherty et al (96) 
and Franciosa et al (10) on the little correlation between haemodynamic 
assessment and measurements of left ventricular function.
Although left ventricular dysfunction may alter exercise capacity, many 
compensatory mechanisms could preserve exercise tolerance despite 
severe left ventricular dysfunction. Exercise capacity has been reported 
to be preserved in patients with severe left ventricular dysfunction (96) 
and in this study there was no correlation between left ventricular 
ejection fraction and maximal symptom limited exercise capacity. In 10 
patients exercise V02 showed little correlation with left ventricular 
ejection fraction. There was a trend for the lower exercise anaerobic 
threshold to correlate with lower left ventricular ejection fraction and 
these are the patients who are symptomatically most impaired. Exercise 
capacity has previously been shown to correlate poorly with LVEF and 
has no correlation with V02 max (8, 84).
Maranz et al (11) compared clinical criteria with left ventricular ejection 
fraction in 407 patients. The clinical criteria were those used by the 
Framingham Study (93), a study performed at Duke University (6) and 
those of a third group in Boston (98). Of 133 patients with low 
ventricular ejection fractions (greater or equal to 40%) 20% met the 
criteria for chronic heart failure, and conversely of 204 patients with 
normal left ventricular ejection fractions (greater equal to 50%) 51 met at 
least one of the criteria for heart failure. These results suggest that a 
combination of clinical assessment and objective measure of left 
ventricular performance may be essential in the definition of patients 
with heart failure (97).
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Global measures of left ventricular function appear to be of prognostic 
value in some patients with heart failure (12,21,30,98) but neither left 
ventricular systolic or diastolic dimensions or volumes discriminate 
between survivors and non-survivors in patients with ischaemic 
''cardiomyopathy" (27).
(c) Regional Function
Measurements of global ventricular function may remain normal 
even when large portions of the ventricle are damaged due to 
hypertrophy and hyperfunction of the "normal segment". As coronary 
artery disease tends to produce regional ischaemia assessment of regional 
wall motion abnormalities may be a more accurate reflection of the 
degree of damage within the ventricle. It is true, however, where there 
is extensive coronary artery disease there is extensive ventricular 
involvement, thus producing a low ejection fraction which is presumably 
why this is a good predictor of subsequent death following myocardial 
infarction.
Regional function can be assessed in several ways. The commonest, and 
probably the most reliable, is the visual detection of regional wall motion 
abnormalities by an experienced observer. Sector analysis of regional 
ejection fraction (99), functional or phase/amplitude images provide little 
advantage in the accuracy of detection of abnormalities (100) but may 
provide a more accurate measure of extent (101,102). Similarly with 
regional ejection fraction images (103) or the stroke volume image which 
we have found to be most useful (104) (see Appendix).
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Methods
In 40 patients with New York Heart Association grade II-IV heart failure 
resting technetium99m radionuclide ventriculo-graphy was performed. 
Regional function was assessed visually by two experienced observers 
using a five point scoring system (l=normal; 5=  aneurysmal) applied to 
the left ventricle, divided into five regions of interest, and by standard 
functional images (stroke volume image and paradox image) and by 
phase analysis (see Appendix). Using this scoring system a score of 5 
was normal, to a maximum of 25 with all regions aneurysmal.
Results
There was no correlation between regional dysfunction, as measured by 
total score, exercise heart rate, systolic blood pressure double product 
(HR x SBP), exercise time or work load achieved (Figure 13).
(d) Ventricular Function on Exercise
Radionuclide scans during exercise have been shown to be an 
accurate and reproducible method of detecting ischaemia and coronary 
artery disease (109-111) and provide prognostic information following 
acute myocardial infarction (112). Exercise tests are usually performed 
supine to minimise the effect of chest wall motion, but exercise tests 
performed upright provide very similar information (113).
Methods
Ten patients with chronic heart failure secondary to coronary artery 
disease were studied. All drug therapy including Digoxin and 
vasodilators had been withdrawn for at least 14 days and patients were
99
receiving a stable dose of diuretic with potassium supplements. Patients 
were symptomatically New York Heart Association grade III or IV.
Heart rate was obtained from a 12 lead electrocardiogram, monitored at 
rest and continuously throughout exercise. Blood pressure was obtained 
intermittently every two minutes and at peak exercise using a cuff 
sphygmomanometer. A Swan-Ganz thermodilution catheter was inserted 
percutaneously through the internal jugular vein and measurements of 
right atrial pressure, pulmonary artery pressure and pulmonary capillary 
wedge pressure were obtained at rest. Pulmonary artery pressure was 
monitored continuously throughout exercise. Cardiac output was 
obtained by a thermodilution technique using an automatic injector (OMP 
thermodilution injector). Measurements were obtained at rest in 
triplicate continuously throughout exercise and for five minutes following 
exercise. Exercise was performed on an upright bicycle ergometer using 
a standard protocol previously described. Respiratory gas analysis was 
performed online to ensure that the patient achieved their anaerobic 
threshold. Ventricular function was measured at rest and continuously 
during exercise and for five minutes post exercise using technetium-99m 
radionuclide ventriculography. Scans were obtained with the patient 
seated comfortably on the bicycle with his left arm positioned on top of 
the camera. The camera was positioned in a 40° left anterior oblique 
projection to provide optimal separation between the right and left 
ventricles. Careful positioning of the bicycle, the Gamma camera and 
the patient ensures that there is little motion of the patient's chest during 
exercise. Scans obtained by this method show acceptable reproducibility 
(see Appendix).
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Figure 15: a) Rest and peak exercise end diastolic images, with stroke volume
images, showing increasing anterior wall motion abnormality
b) Abnormal, dilated left ventricle; phase image showing totally 
inco-ordinate contraction (LV outlined in blue)
100
Results
The 10 patients had similar degrees of severe left ventricular dysfunction 
with resting left ventricular ejection fractions between 6 and 21 % and all 
patients had sustained a previous myocardial infarction. Exercise time 
and maximal oxygen consumption (V02 max) were reduced in all 
patients. Heart rate, blood pressure, cardiac index and stroke volume 
index all increased on exercise as would be expected. Calculated 
systemic vascular resistance and pulmonary vascular resistance fell. 
Ejection fraction was essentially unchanged (11.1 ±  4.73 to 12.8 ±  
4.5%). End diastolic volume increased significantly from 389 ±  72 to 
475 ±  81 (p<0.01). Diastolic pulmonary artery pressure increased 
from 21.3 ±  8.1 to 37.4 ±  18.9 but this change was not significant 
(Figure 14).
Left ventricular contraction became less coordinate with exercise (Figure 
15) with more extensive regional wall motion abnormalities. At peak 
exercise contraction becomes totally incoordinate.
Discussion
Many mechanisms have been proposed for the limitation of exercise in 
patients with chronic heart failure. In general the perceived wisdom is 
that left ventricular end diastolic pressure is the primary determinant of 
exercise intolerance in heart failure (85). This seems unlikely in these 
patients, since although diastolic pulmonary artery pressure increases, 
this was not significant. Systolic function as reflected by left ventricular 
ejection fraction was unchanged. Cardiac index appeared to be sustained 
by a combination of increased heart rate and increasing volume.
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It is generally reported that left ventricular function is abnormal if left 
ventricular ejection fraction fails to increase by 5 % or declines during 
stress (114,115) but other reports suggest that for the detection of 
coronary artery disease, the exercise radionuclide angiogram may have 
limited specificity (114). It is our experience that with upright exercise 
that a normal left ventricular ejection fraction tends to increase and wall 
motion score does not alter. In these patients with severe left ventricular 
dysfunction LVEF was either unchanged or fell, in agreement with 
published work (116). Immediately post exercise left ventricular ejection 
fraction can increase, presumably secondary to catecholamine stimulation 
(115) which is maximal in the 30 seconds after exercise.
As exercise progressed in each patient, left ventricular contraction 
became increasingly discoordinate until at peak exercise there was no 
coordinate left ventricular function. Various factors should be 
considered that might underlie these changes. Ventricular filling 
pressure may alter as a consequence of changing ventricular volume with 
impairment of diastolic function (117). Certainly diastolic function is 
altered as can be seen by the changing shape of the ventricular time 
activity curves (118). Increased left ventricular volume increases left 
ventricular wall tension in accordance with the Laplace equation (119)
wall tension =
left ventricular systolic pressure x diastolic volume 
2 times wall thickness
Left ventricular wall tension is closely related to myocardial energy 
utilisation. In addition, increasing sympathetic drive during exercise will 
stimulate myocardial contractility which further increases myocardial
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oxygen consumption (120). Heart rate, another determinant of 
myocardial oxygen consumption, usually plays a relatively unimportant 
role. Tachycardia is usually associated with a decrease in intracardiac 
volume and myocardial shortening which results in a substantial decline 
in chamber wall stress (121). However, in this group of patients clearly 
intracardiac volume increases and heart rate on exercise must therefore 
be a determinant of myocardial oxygen consumption (122). Another 
factor which may be contributory is the reactive myocardial hypertrophy 
which occurs following myocardial infarction (123,124) as patients in 
this study had sustained substantial previous myocardial infarctions 
presumably with normal compensatory mechanisms. Ventricular 
hypertrophy can result in compromised blood flow during stress with a 
reduced vasodilatory reserve.
These increased demands in myocardial oxygen consumption would 
usually be met by increased coronary flow. In patients with coronary 
artery disease, as in this group of patients, increased demands cannot be 
met resulting in myocardial ischaemia (125,126,127,128). Myocardial 
ischaemia induces reduced performance of the local myocardium 
(125,129). If the extent of the myocardial involvement is sufficient the 
uninvolved myocardium cannot cope with the increased demands.
In these patients with extensive coronary artery disease and extensive 
previous myocardial damage, it is difficult to convincingly demonstrate 
further myocardial ischaemia. Exercise induced regional wall motion 
abnormalities have previously been demonstrated to be associated with 
ischaemia, reversible on revascularisation (123,130,131). New regional 
wall motion abnormalities on exercise have been demonstrated in these 
patients with chronic heart failure without accompanying angina (130).
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This does not exclude myocardial ischaemia, as wall motion 
abnormalities usually precede symptoms and ischaemia may be "silent" 
(131).
What is most striking is loss of coordinate contraction at peak exercise 
and it is difficult to imagine how the heart can fulfil its function as a 
pump if the heart cannot eject efficiently. Stroke volume must be limited 
and blood pressure cannot be further increased.
In summary, in patients with severe left ventricular dysfunction 
secondary to coronary artery disease myocardial stress, such as exercise, 
can induce incoordinate ventricular function, which may reflect 
underlying myocardial ischaemia induced by the stress which limits the 
heart's ability to eject.
RIGHT VENTRICULAR FUNCTION 
(a) Introduction
In 1910 Bemheim (132) suggested that left ventricular dilatation 
could embarrass right ventricular function, producing systemic venous 
congestion and congestive heart failure and in 1914 Henderson and 
Prince (133) demonstrated inter-dependence between the two ventricles 
in an ejecting heart. The interplay between the function of the two 
ventricles has been reviewed in detail by Bove and Santamore in the 
American Journal of Physiology (134) and Sibald and Driedger in 
Critical Care Medicine (135). In essence, experimental data suggests 
that ventricular interdependence is important in systolic function of the 
ventricles, but that responses to changes in volume and compliance are 
more complex and not completely understood.
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In patients with coronary artery disease, the right ventricle is commonly 
involved. A prospective study of 107 autopsies from a Coronary Care 
Unit demonstrated right ventricular infarction in 80% and a 3% 
incidence of isolated right ventricular infarction (136). This is in 
keeping with our own findings that of 100 patients with coronary artery 
disease right ventricular perfusion defects were seen in 67% and 90% of 
the patients with right ventricular perfusion defects had significant right 
coronary artery disease (137). The role of right ventricular dysfunction 
in patients with "ischaemic cardiomyopathy" is less well documented.
Contrast right ventricular angiography is difficult to quantitate due to the 
geometry. The advantages of using radionuclide techniques are that they 
are count dependent and less critically dependent on the geometry. 
Technetium-99m scanning allows assessment of the right ventricle but 
when the right ventricle is dilated it can be difficult to obtain optimum 
septal separation, especially at the apex. We have developed a method 
of assessing right ventricular function using a short (20 seconds intra­
venously) infusion of Xenon-133 (132). Ninety per cent of the Xenon is 
excreted by the lungs allowing the right ventricle to be assessed in 
isolation. The method is simple, reproducible and repeatable and can be 
performed on exercise (see Appendix).
Methods
Of 120 consecutive patients admitted to the Coronary Care Unit, 81 were 
subsequently demonstrated to have sustained a myocardial infarction, 
based on serial electrocardiographic and enzyme criteria. Fifty nine 
(73%) were male and the mean age was 56 years (range 24-74 years). 
Thirty nine (48%) had had previous angina and 15 (18.5%) had sustained 
a previous myocardial infarction. Radionuclide scans were obtained
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acutely (within 24 hours), at 3 days and at 18 months at follow-up. Data 
is presented from the 3 day scans as this time point was found to be most 
predictive of future events. Right ventricular function was assessed 
using Xenon-133 and left ventricular function obtained from gated 
technetium scans (see Appendix). Data was acquired from all patients at 
18 months. In those that were dead, information as to the mode of death 
was obtained from the hospital notes, the general practitioner and the 
family as was appropriate. Deaths were either Hinkle Class I (abrupt 
loss of consciousness without prior circulatory collapse) or Hinkle Class 
II (gradual circulatory failure and collapsed circulation) and were 
therefore considered to be cardiac in origin (139). Normal values for 
ventricular function were obtained from volunteers. The mean normal 
value for left ventricular ejection fraction (LVEF) is 50 ±  4.6% and a 
LVEF of greater than 40% was considered to be normal with a LVEF of 
less than 30% considered to be significant left ventricular dysfunction. 
The mean normal value for right ventricular ejection fraction (RVEF) is 
47.3 ±  4.4% with a RVEF greater than 35% being considered normal 
and below this value right ventricular dysfunction.
Results
At three days following myocardial infarction left ventricular impairment 
was seen in 45/81 patients (56%) and right ventricular impairment in 44 
(54%). Impairment of both ventricles was seen in 25 patients (31%). In 
the 18 months following myocardial infarction there were 18 deaths: ten 
(40%) occurred in Group 1 (see Figure 16), where there was both right 
and left ventricular impairment (n =  25); five (20%) in Group 2, with 
impaired left ventricular function and a normal right ventricle (n =  20); 
and two (12%) in Group 3 with preserved left and right ventricular 
function (n =  17); and one patient died in Group 4, with normal left
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ventricular but impaired right ventricular function (n =  19). There were 
significantly more deaths in Group 1 where both right and left ventricular 
function were impaired (p<0.01) (140).
Discussion
Right ventricular dysfunction following myocardial infarction is common 
but may be transient (due possibly to the fast recovery of the right 
ventricle following acute ischaemia). Right ventricular function assessed 
at three days was the least subject to variation, compared to 
measurements made at 24 hours and seven days. This is presumably 
because the right ventricle is sensitive to alterations in preload which 
acutely can change rapidly and at seven days is subject to alterations due 
to the patient's activity and the introduction of beta blockers etc. (140).
In a group of 34 patients with depressed left ventricular function and 
heart failure secondary to coronary artery disease, concomitant right 
ventricular dysfunction was found to have similar prognostic value in 16 
patients (survivors of 19.9 month period) with a mean left ventricular 
ejection fraction of 18.7 ±  6.8% and right ventricular ejection fraction 
of 41.4 +  23%. Eighteen non-survivors at 6.7 months, the mean left 
ventricular ejection fraction was similar (18.1 ±  10.3%) but right 
ventricular function was reduced (23.9 ±  10.2%, p<0.01) (140,141). 
Actuarial survival curves confirmed this reduced survival in patients with 
right ventricular dysfunction (at 12 months 37% versus 84%, p<0.05).
Right ventricular function appears to be an important determinant of 
survival in the patient with left ventricular dysfunction, secondary to 
coronary artery disease (141,142). Function of the right ventricle is
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probably most accurately and most conveniently assessed by radionuclide 
techniques.
Right Ventricular Function and Haemodvnamic Parameters 
In patients with left ventricular dysfunction, of a significant degree to 
cause the clinical signs of heart failure; often have associated right 
ventricular dysfunction. It is likely that in many cases this is as a 
consequence of right coronary artery disease and thus inferior infarction. 
Malfunction of the right ventricle may embarrass the pulmonary 
circulation and thus contribute to the patient's symptoms.
In 36 patients, known to have heart failure secondary to coronary artery 
disease, right ventricular function was obtained from Tcqqm radionuclide
angiography. Haemodynamic parameters, cardiac index and stroke 
volume index were calculated from cardiac output measurements made in 
triplicate, using a thermodilution catheter (see Appendix).
Exercise was performed to a symptom limited maximum, using an 
upright bicycle ergometer, with incremental loads of 25 watts, 
commending with no load, at 120 second intervals. Heart rate was 
obtained from the electrocardiogram which was recorded continuously 
and blood pressure by cuff sphygmomanometer.
Results
Detailed results are seen in Figure 17. There is little correlation of 
RVEF with exercise tolerance, expressed either as time of exercise or the 
work load achieved. Although exercise heart rate does not correlated 
with RVEF, there is some relationship with systolic blood pressure.
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There was no correlation between right ventricular function and double 
product, which is an indirect measure of myocardial oxygen 
consumption. Similarly there was no correlation between the extent of 
wall motion abnormalities of the right ventricle as measure by right 
ventricular score (3 being normal to a maximum of 15 with all segments 
aneurysmal) with any of the measured parameters. These results are 
discussed in detail with the next section.
(b) Right Ventricular Function on Exercise
Left ventricular function can alter right ventricular function 
(143,144). The factors that limit exercise in patients with left ventricular 
dysfunction are complex, and in patients with coronary artery disease, 
may well involve ischaemia of the ventricle. To assess the exercise 
response of the "failing" right ventricle, we therefore studied patients 
with chronic obstructive airways disease, although clearly pulmonary 
factors play a large part in the limitation of these patients.
Methods
Twenty five patients (seven female) aged 52 to 70 years, with severe
irreversible airways limitation due to chronic bronchitis and emphysema,
were studied. All patients were stable, as indicated by stable body 
weight, FEV \ , arterial gas tensions and the absence of respiratory
infection in the previous three weeks. All were receiving diuretics and 
Beta2 agonists, but none had been treated with digoxin or vasodilators.
Left ventricular function was previously shown to be normal and no 
patient complained of angina.
Heart rate was obtained from the electrocardiogram and blood pressure 
by cuff sphygmomanometer. In 10 patients, simultaneous haemo-
Table 9 Chronic Obstructive Airways Disease (COAD)
Haemodynamic changes (n = 20) ±  SEM
Rest Exercise
HR beats/minute 88 ±  4 105 ±  5
SBP mm.Hg. 143 ±  3 173 ±  9
DBP mm.Hg. 8 1 + 4 95 ±  5
Mean mm.Hg. 103 ±  2 118 +  5
Cl 1/min/m2 3.08 ±  0.19 4.05 ±  0.2
SI ml/beat/m2 35.1 ±  2 39.5 +  3
SMPA mm.Hg. 47 +  6 71 ±  7
DMPA mm.Hg. 23 +  3 40 +  2
Mean mm.Hg. 32 +  4 50 ±  4
PVR dyne-s-cnr5 524 ±  83 609 ±  72
HR = heart rate
SBP = systolic blood pressure
DBP = diastolic blood pressure
Cl = cardiac index
SI = stroke index
SMPA = systolic mean pulmonary artery pressure
DMPA = diastolic mean pulmonary artery pressure
PVR — pulmonary vascular resistance
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dynamic measurements were obtained. Pulmonary artery pressure and 
pulmonary capillary wedge pressure were obtained from a Swan-Ganz 
catheter inserted percutaneously via a vein in the right antecubital fossa. 
Cardiac output was measured by the thermodilution technique in 
triplicate at rest and throughout exercise. Exercise was performed on an 
electronically braked supine ergometer using 25 watt increments in 
workload every three minutes.
Right ventricular function was assessed by the Xenon technique. Data 
were acquired with a mobile Gamma camera in the 5-10° left anterior 
oblique projection with a 6° caudal tilt to allow optimal separation of the 
heart from the lung fields. 400 MBq of Xenon-133 in 20 ml. of saline 
were injected intravenously and data were acquired from the time of first 
visualisation of activity within the right heart until activity was seen to 
leave it (average deposition time 25 seconds).
Cardiac index, stroke index and pulmonary vascular resistance were 
calculated and ejection fraction was obtained from the Xenon scans (see 
Appendix) (138).
Results
Heart rate and blood pressure increased with exercise as did cardiac 
index and stroke index (see Table 9). Pulmonary artery pressure 
increased, with diastolic pulmonary artery pressure increasing from 23 ±  
3 mm.Hg. to 40 ±  2 mm.Hg. Calculated pulmonary vascular resistance 
also increased with exercise.
Right ventricular ejection fraction at rest ranged from 15 to 46% with a 
mean of 32% and on exercise mean RVEF was 30% (range 11-53%). In
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ten normal volunteers RVEF at rest was 40-55% rising by 5-15% during 
exercise (see Appendix). If an RVEF of below 30% was taken to 
represent impaired right ventricular function nine patients fell into this 
group. In patients with preserved right ventricular function (mean rest 
RVEF 39 ±  3%) with exercise RVEF increased (mean 43 ±  2%). 
However in patients with impaired right ventricular function (mean 
RVEF 26 ±  3%) mean RVEF fell with exercise (21 ±  2%).
Correlation of haemodynamic parameters with RVEF demonstrated a 
close relationship between RVEF and pulmonary vascular resistance (see 
Figure 18). However on exercise there was no definite correlation 
between any haemodynamic parameters and exercise RVEF response (see 
Figure 18).
Discussion
Although there is very extensive data regarding right ventricular function 
at rest in a variety of clinical conditions [for review see Ferlinz (142)] 
there is a paucity of data regarding the response of dysfunction in the 
right ventricle to stress. Possibly this is partly due to the early notion 
that the right ventricle was of little importance (143,144,145) but in the 
experiments of Rose et al (146) animals were unable to survive exclusion 
of the right ventricle from the circulation, and elevation of systemic 
pressure alone was unable to support pulmonary circulation, which also 
pertains to humans (147). Problems and complications that occur 
following right ventricular damage are listed by Sade and Casteneda 
(148) and indeed even relatively minor injury to the right ventricle may 
compromise haemodynamic stability (149).
Figure 19: a) Rest end diastolic and end systolic images, normal right
ventricular Xenon scan, with peak exercise images below
b) Rest and peak exercise images from a patient with COAD 
showing end systolic dilatation of the RV and RA
Ill
Studying right ventricular function is hampered by the shape of the right 
ventricle, which defies simple geometric analysis. In the normal right 
ventricle the shape is probably best approximated by an inverted 
pyramid, but with increasing dys-function this changes as the right 
ventricle dilates. Haemo-dynamic measurements do not reflect volume 
changes (150). Echocardiography can provide useful information as to 
both right ventricular function and volume (151,152) but it can be very 
difficult to clearly identify the endocardial surface of the right ventricular 
free wall, especially on exercise. Radionuclides offer a method of 
assessing right ventricular function, which is less dependent on 
geometry, have been shown to be reproducible, and to correlate with 
angiography (153) and can easily be performed on exercise (see 
Appendix).
A previously reported study using technetium scanning demonstrated 
increased right ventricular ejection fraction in normal subjects and a right 
ventricular ejection fraction that was unchanged or decreased in 77% of 
patients with lung disease (including the 27% of patients with abnormal 
resting right ventricular function) (154). Using technetium can result in 
difficulties in identifying the apex of the right ventricle especially if 
either chamber is dilated and the heart rotates with super-impostion of 
the left and right ventricles. The use of Xenon obviates many of these 
problems which is perhaps why we have been able to differentiate the 
response of the normal and dysfunctional right ventricle on exercise.
In patients with chronic obstructive airways disease exercise induces an 
increase in right ventricular afterload as reflected in the increased 
pulmonary vascular resistance (155). The response of the right ventricle 
to increased pulmonary vascular resistance is initially dilatation with
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consequent increase in stroke volume by the Frank Starling mechanism 
(156). However the right ventricle is thin walled in comparison to the 
left ventricle and although initially contractile force increases for any 
given end diastolic volume the adaptive response is not as efficient as in 
the left ventricle, possibly limited by the availability of a compensatory 
increase in coronary blood flow (157). Thus the increase in afterload is 
accompanied by depression of the right ventricular ejection fraction as is 
shown in this study (135).
On exercise, in patients with right ventricular dysfunction end diastolic 
volume increased at peak exercise as did right atrial volume (see Figure 
19). Changes in volume and dynamics within the right ventricle may 
induce tricuspid incompetence. Trivial amounts of tricuspid 
incompetence do not affect radionuclide measurements of right 
ventricular function, but where this becomes significant RVEF may be 
overestimated (155). This, together with the small number of patients, 
may underlie the lack of correlation between haemodynamic 
measurements of afterload and right ventricular performance in these 
patients.
In summary, right ventricular dysfunction is exacerbated by exercise. 
The extent of right ventricular dysfunction appears to be related to after­
load, which is in effect impedance within the pulmonary circulation.
MYOCARDIAL PERFUSION AND FLOW
(a) Introduction
Perfusion imaging has an established place in the identification 
and management of patients with coronary artery disease (158). In 
patients with chronic heart failure the role is less well defined. If large
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areas of myocardium are shown to have reversible ischaemia (e.g. on 
stress and then redistribution on a thallium scan) even patients with 
severe left ventricular dysfunction have been shown to benefit from 
revascularisation (159). The ability of thallium imaging to identify 
viable myocardium has been called into question by some of the newer 
imaging modalities such as positron emission tomography but these are 
not widely available (160.).
Using thallium, defects in regions remote from the site of myocardial 
infarction have been shown to be predictive of future events (161). By 
using re-injection techniques thallium reperfusion in areas of infarct can 
demonstrate myocardial viability, within infarct areas. These areas are 
important in the clinical management of patients as they represent 
myocardial substrate for future ischaemic events (162).
Thallium image defects on scans obtained acutely have been shown to 
correlate well with the site of infarction (161) and in animal models with 
size of infarction (163). Other than for the assessment of the efficacy of 
thrombolysis, the prognostic value of imaging during the acute phase of 
infarction is not well documented.
Methods
One hundred and twenty consecutive patients with chest pain of cardiac 
origin were studied on admission to the Coronary Care Unit. Eighty two 
patients were subsequently shown to have sustained a myocardial 
infarction on the basis of electrocardiographic and enzyme changes 
(WHO criteria). Fifty five were male. No patient had received 
thrombolytic therapy.
Table 10
ALL INFARCTS
mean SD COEFF V
Norris 6.47 2.8 0.42
I/M 25.89 10.7 0.41
P/M 33.87 14.6 0.43
EF 24.18 11.7 0.48
Vol 302.18 106.1 0.35
PCK 2242.28 1607.4 0.71
IGE 80.87 94.9 1.17
Norris =  Norris Index; I/M = infarct perfusion defect; P/M = total 
perfusion defect in left ventricle; EF = left ventricular ejection fraction; 
Vol = left ventricular end diastolic volume; PCK = peak creatine 
kinase; IGE = infarct gram equivalents; SD = standard deviation; 
Coeff. var =  coefficient of variation
DEAD INFARCTS n = 24 ALIVE n = 58
SITE ANT 14 22
INF 6 32
POST 1 1
S/E 1 3
MEAN NORRIS 8.37 5.51
PREVIOUS MI 9 6
DEAD WITHIN 2 WEEKS > 2 WEEKS
n = 11 13
NORRIS MEAN 8.76 ±  3.4 8.04 ±  2.17
KILLIP A O  2
B 3 5
C O  4
D 8 2
ALL INFARCTS n = 82 DEAD INFARCTS n =  24
R. P. R.
Norris vs IGE -0.09 -0.23
Norris vs P/M 0.34 p<0.001 0.60
I/M vs PCK 0.24 -0.13
P/M vs PCK 0.18 0.01
PCK vs EF -0.04 0.02
I/M vs IGE 0.24 p<0.02 -0.16
Vol vs P/M 0.35 0.27
EF vs IGE -0.04 0.02
EF vs P/M -0.46 p<0.001 -0.49
p <  0.001
p<0.01
DYING LESS THAN 14 DAYS n = 11
Norris vs P/M 0.8
I/M 0.5
IGE -0.29
EF IGE 0.29
P/M IGE -0.12
PCK -0.14
P/M IGE 0.007
Norris =  Norris Index; I/M = infarct perfusion defect; P/M = total 
perfusion defect in left ventricle; EF = left ventricular ejection fraction; 
Vol =  left ventricular end diastolic volume; PCK = peak creatine 
kinase; IGE = infarct gram equivalents; SD = standard deviation; 
Coeff. var =  coefficient of variation
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Scans were obtained following 60 MBq of intravenous thallium-201 
using a mobile Gamma camera, fitted with a high sensitivity collimator, 
taken to the bedside. Scans were obtained in three projections (anterior, 
40° left anterior oblique and 70° left anterior oblique). Acquisition was 
in listmode gated to the electrocardiogram and scans were obtained in all 
patients following relief of chest pain on admission to the Coronary Care 
Unit at a mean time of 86 minutes from arrival at the hospital.
Infarct severity was assessed using the Norris Index (164) and Killip 
Class (165). Serial blood samples were taken for the estimation of 
creatine kinase and creatine kinase MB and infarct gram equivalents 
calculated (166). All deaths were recorded and patients were re-assessed 
at one year. Cardiac failure was diagnosed on the basis of clinical 
criteria (dyspnoea on exertion, clinical signs and the use of diuretics ±  
admissions to hospital with heart failure or left ventricular failure).
Scans were analysed in duplicate by drawing a region of interest around 
the defect in the infarct site and expressing this as a percentage of the 
total left ventricle, infarct perfusion defect was obtained. Total perfusion 
defect was all areas of reduced perfusion expressed as a percentage of the 
total left ventricle. Ejection fraction was calculated from the gated 
thallium scan by the area length method (see Appendix).
Results
Of the 82 patients with myocardial infarction, in 36 the site was anterior, 
39 inferior, 2 posterior and 2 subendocardial and in one patient the site 
was unidentified. In 65 patients this was their first documented infarct, 
15 had a history of previous infarction and two possible previous
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Figure 21(a) Sensitivity and specificity of Norris Index
for prediction of acute and all deaths
NORRIS INDEX > 7
Acute deaths 
Sensitivity 82%
Specificity 69%
Predictive accuracy 71 %
NORRIS INDEX > 7
All deaths 
Sensitivity 71%
Specificity 76%
Predictive accuracy 74%
Figure 21(b) Sensitivity and specificity of infarct
perfusion defect for prediction of acute
and all deaths
INFARCT PERFUSION DEFECT > 3 0 %
Acute deaths 
Sensitivity 73 %
Specificity 72%
Predictive accuracy 73 %
INFARCT PERFUSION DEFECT >  30%
All deaths 
Sensitivity 54%
Specificity 72%
Predictive accuracy 67%
Figure 21(c) Sensitivity and specificity of infarct
perfusion defect and Norris Index
for prediction of acute and all deaths
NORRIS INDEX & INFARCT PERFUSION DEFECT
Acute deaths 
Sensitivity 91%
Specificity 56%
Predictive accuracy 5 6 %
NORRIS INDEX & INFARCT PERFUSION DEFECT
All deaths 
Sensitivity 91%
Specificity 56%
Predictive accuracy 56%
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infarction. The mean values for Norris, volume of infarct, ejection 
fraction, are seen in Table 10 opposite.
Twenty four of the patients with myocardial infarction were dead at one 
year and 11 had died within 14 days of the index infarction. Details are 
seen in Table 10a. Deaths were all Hinkle Class I or Hinkle Class II 
(139) and were considered to be cardiac in origin.
Correlations between clinical indices (Norris Index), measurements of 
myocardial damage (CK MB infarct gram equivalents) (166,167), infarct 
perfusion defect and total perfusion defect in the measurement of left 
ventricular function (LVEF) are seen in Table 10b. Ejection fraction 
was inversely correlated with total perfusion defect (p<  0.001) (Figure 
20a). Similar correlations are shown for the 24 patients who died.
Norris Index correlated with total perfusion defect. This finding is 
similar to that in the patients (n = 11) who died in less than 14 days 
from onset of infarction (Figure 20b).
From the data available as the patent was admitted to Coronary Care 
neither site of infarct nor a history of previous infarct were helpful in 
predicting subsequent deaths. Similarly peak creatine kinase, although 
not immediately available, was not predictive of subsequent deaths.
For all deaths where the Norris Index was greater than 7 this was 
predictive of subsequent mortality (predictive accuracy 74%). An infarct 
perfusion defect of greater than 30% of the left ventricle had a predictive 
accuracy of 67 %. Both indices together gave an improved sensitivity 
(83%), but poorer specificity with an overall predictive accuracy of 63% 
(Figures 21a-c).
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Looking at late deaths, Norris Index of greater than 7, was less sensitive 
but still specific. Overall predictive accuracy 73%. Infarct perfusion 
defects were less sensitive than specific. For acute deaths (those within 
14 days) Norris Index greater than 7 and a perfusion defect of greater 
than 30% were both sensitive and specific but together were highly 
sensitive (91 %) but less specific.
At one year, patients were considered to have developed heart failure on 
clinical criteria. Nine patients had been admitted to hospital with heart 
failure. Other events include two patients with infarct extension while in 
hospital, one reinfarction, 14 with post infarction angina, six who 
underwent coronary artery surgery, one who sustained ventricular 
tachycardia, one a cerebrovascular accident, one a brachial embolus and 
one renal carcinoma. Although Norris Index was helpful, total perfusion 
defect was the most sensitive and specific measure made acutely on 
admission to Coronary Care that was predictive of subsequent heart 
failure.
Discussion
Left ventricular ejection fraction and clinical indices such as Norris Index 
have been established as predictive of mortality following myocardial 
infarction. What is less well documented is the place of perfusion 
imaging. Perfusion imaging has been used to establish the efficacy of 
acute intervention such as thrombolytic therapy (158) and to establish 
myocardium at risk following myocardial infarction (159.160,162). 
Myocyte necrosis imaging with technetium pyrophosphate and more 
recently with anti-myosin antibody scintigraphy suggests that uptake in at 
least 50% of the myocardium was predictive of sudden death following 
infarct and was predictive of the severity of wall motion abnormality
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(168,169). The disadvantage of necrosis imaging is the time required for 
optimal uptake of the tracer (48 hours). Gated thallium imaging was 
performed as the patient was admitted to Coronary Care. Our previous 
work in an animal model confirmed that in vivo perfusion imaging of 
infarct size correlated well with infarct extent using conventional staining 
techniques (163). The extent of perfusion defect in patients (greater than 
30%) was predictive especially of acute death (within 14 days). 
Presumably late deaths are less dependent on the extent of acute 
ischaemia. The choice of a total perfusion defect of greater than 30% of 
the left ventricle was based on the fact that this was the best 
discriminator of subsequent events. In the right model of heart failure 
Pfeffer et al noted an abrupt increase in left ventricular end diastolic 
pressure in 13 of 14 rats when the infarct size was greater than 46% and 
when the infarct size was greater than 30%, few rats could generate or 
develop pressure within two standard deviations of normal (170,171).
Total perfusion defect, on admission to Coronary Care, was also 
predictive of the patients that would subsequently develop heart failure. 
Presumably myocardial infarction and its effective stress of the 
myocardium so that perfusion defects reflect the total myocardium at risk 
from ischaemia and it is this that provides the substrate of the 
myocardium that "fails".
(b) Perfusion Imaging in Heart Failure
Most perfusion imaging studies have concentrated on identifying 
viable myocardium within sites of myocardial infarction amenable to 
revascularisation (172,173). There is little information as to perfusion 
patterns in patients with heart failure secondary to coronary artery 
disease. If exercise induced myocardial ischaemia is a significant
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determinant of the limitation of patients, the extent of myocardial 
involvement may relate to exercise capacity.
Methods
Forty patients were studied with established heart failure secondary to 
angiographically documented coronary artery disease, and on optimal 
treatment with diuretics and vasodilators referred for consideration for 
transplantation. Patients performed upright symptom limited exercise on 
a bicycle ergometer, using a standard protocol already described (starting 
with no load, 25 watt increments every 2 minutes). Heart rate was 
obtained from the electrocardiogram and blood pressure by cuff 
sphygmomanometer. 60-80 MBq of thallous chloride were injected 
intravenously 20-30 seconds prior to the termination of exercise. Scans 
were obtained using a mobile Gamma camera for five minutes in each of 
three projections (anterior, 40° left anterior oblique and 70° left anterior 
oblique). Scintigraphic data was collected in listmode, gated to the 
electrocardiogram. Data was retrospectively constructed into eight 
images. Image analysis was reported from a cine group display of eight 
frame representations of the cardiac cycle using a 9 point spatial and 121 
temporal smooth. Perfusion abnormalities were expressed as a 
percentage of the total left ventricle. Left ventricular ejection fraction 
was obtained from the technetium99m scan as previously described.
Results
Substantial perfusion defects were seen in most patients (range 13-82% 
of the left ventricle). Detailed results are seen in Figure 22. There is 
some relationship between exercise heart rate and blood pressure, but the 
closest, inverse relationship is with double product. Double product - 
the product of heart rate and systolic blood pressure is generally
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recognised as an indirect measure of myocardial oxygen consumption. 
Interestingly, there was no relationship between total perfusion defect 
and either left or right ventricular ejection fraction.
Discussion
Total myocardial perfusion defects on exercise did not correlate with 
exercise capacity in our patients with heart failure but there was an 
inverse relationship with double product, which is an indirect measure of 
myocardial oxygen consumption. All these patients had previous angio- 
graphically documented coronary disease or myocardial infarctions and 
had various degrees of left ventricular dysfunction. Left ventricular 
systolic function has previously been shown not to correlate with exercise 
capacity (175). Thus exercise induced ischaemia may play a part in 
exercise limitation.
Using radiotracers such as thallium-201 which reflect relative uptake 
rather than absolute flow in patients with previous myocardial infarction, 
regions of reduced uptake in areas remote from the infarction may not be 
identified. By using a gating technique blurring of the image due to 
cardiac motion is less obvious and the end diastolic image can be 
identified. In an animal model we have shown that the perfusion defect 
in the end diastolic image correlated best with conventional measures of 
myocardial damage and microsphere images (163). Other imaging 
modalities such as positron emission tomography using F I8 FDG, N13 
ammonia or oxygen-15 or FDG/ammonia mismatch may provide a more 
accurate assessment of ischaemic myocardium but this technique is not 
widely available (180). In summary, myocardial perfusion defects seen 
in patients with heart failure suggest that this may play a part in exercise 
limitation.
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MYOCARDIAL FLOW
Myocardial flow in patients with chronic heart failure 
With the declining incidence of rheumatic heart disease, the commonest 
cause of chronic heart failure is now coronary artery disease. There is 
evidence to suggest that this can be associated with different patterns of 
coronary arterial stenosis ranging from triple vessel disease to 
involvement of the microcirculation and "ischaemic cardiomyopathy" 
(184). Rodgers et al investigated the patterns of coronary artery stenosis 
in 145 patients of whom 106 had chronic congestive heart failure (185). 
Just over half (54%) had single vessel disease while the rest had double 
or triple vessel disease. In current cardiological practice, the vast 
majority of patients with heart failure have multiple vessel disease (often 
with previous coronary surgery) (unpublished observations).
In patients with cardiomyopathy myocardial perfusion may be decreased 
(186). In the presence of normal epicardial vessels various explanations 
offered include the presence of myocardial fibrosis, the reduction of 
myocardial oxygen demand related to decreased contractility and possible 
changes in the microcirculation.
The measurement of myocardial flow and oxygen consumption in 
patients who have heart failure have been conflicting.
Methods
Eighteen patients (2 females) aged 37-61 years with a mean of 52 years 
with ischaemic left ventricular dysfunction (left ventricular ejection 
fraction <30%) were studied. All patients had New York Heart 
Association Class III heart failure and had been stable on therapy with
Table 11
XENON n = 18
Mean ±  SD
HR beats/min 75 ± 12.7
SBP mm.Hg. 120 ± 24
DBP mm.Hg. 77 ± 10
Mean mm.Hg. 94 + 15
DMPA mm.Hg. 14 ± 5.5
Cl 1/min/m2 2.63 ± 0.39
SVI ml/beats/m2 35.8 ± 6.7
SVR dyne-s-cm-5 1576 ± 503
CSF 125 ±  34 ml/min 
A-V 11.45 +  1.71 vol% 
M V02 1428.9 ±  429.5
MYOCARDIAL FLOW Normal
RCA 50.0 ±  16.8 ml/100 g/min 67.5 ±  19.1
LAD 60.2 ±  21.7 76.1 ±  9.1
Cx 64.7 ±  16.3 76.1 ±  11.7
LV 63.6 ±  16.9 75.5 ±  8.8
HR = heart rate; SBP = systolic blood pressure; DBP =  diastolic 
blood pressure; DMPA = diastolic mean pulmonary artery pressure; Cl 
=  cardiac index; SVI = stroke volume index; SVR = systemic 
vascular resistance; CSF = coronary sinus flow; A-V = arteriovenous 
oxygen difference; MV02 = myocardial oxygen consumption
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diuretics and vasodilators. Therapy was omitted for 24 hours prior to 
study. Patients were undergoing routine angiography for diagnostic 
purposes.
Heart rate was obtained from the electrocardiogram and blood pressure 
from an intra-arterial line in the ascending aorta. Pulmonary artery and 
pulmonary capillary wedge pressures were measured via a Swan-Ganz 
catheter inserted percutaneously via the femoral vein. Cardiac output 
was obtained by the thermodilution technique. Coronary sinus flow was 
also measured by thermodilution using a Wilton Webster catheter placed 
in the coronary sinus. This catheter has a sampling port and together 
with simultaneous arterial samples obtained via the femoral catheter 
myocardial oxygen consumption can be measured.
Myocardial flow was obtained by the Xenon-133 clearance technique. 
200 MBq of Xenon-133 was injected intracoronary and images were 
acquired using a mobile Gamma camera fitted with a biplane collimator. 
Data were acquited in listmode and analysed retrospectively as outlined 
in the Appendix. In brief, a region of interest is described around the 
left ventricle and each of the territories supplied by the major coronary 
vessels. Washout curves are constructed and after suitable background 
subtraction a monoexponential is fitted from peak activity to 30 seconds. 
Curves can then be calculated using the Kety Schmidt formula (190).
Results
Haemodynamic variables are shown Table 11, and as would be expected 
in this group of patients pulmonary artery end diastolic pressure is 
elevated and cardiac index is reduced. Resting coronary sinus flow, 
arteriovenous oxygen difference are also normal and mean left
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ventricular flows from Xenon washout are also within normal (Figure 
23). Myocardial flow is plotted against wedge pressure and, as can be 
seen, there is little correlation (Figure 24).
Discussion
In this group of patients resting myocardial flow was similar to normal 
values. Since a large proportion of coronary blood flow to the left 
ventricle occurs during diastole and raised end diastolic pressure could 
induce increased wall tension and thus reduce coronary flow, this was 
plotted against pulmonary capillary wedge pressure. However there was 
no correlation.
Henry et al (191) using helium found a decreased coronary flow in 
patients with ventricular dysfunction and with an associated decrease in 
myocardial oxygen consumption, but in contrast Porinn et al (192) 
demonstrated that coronary sinus flow was similar in patients with 
congestive cardiomyopathy to that found in patients with angina.
It is not altogether surprising that resting myocardial flow is normal as 
various compensatory mechanisms maintained cardiac flow. Even in 
areas of myocardial infarction, collateral flow will be induced and indeed 
can replace the native vessel (see Figure).
In summary, resting flow to the myocardium in patients with left 
ventricular dysfunction appears to be maintained presumably by a variety 
of compensatory mechanisms.
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PART 3
TREATMENT OF PATIENTS WITH HEART FAILURE
The literature on this subject is encyclopaedic. Small studies cannot 
attempt to answer questions about efficacy, morbidity or effect on 
mortality. Indeed there has been a profusion of large multicentre studies 
published with acronyms such as CONSENSUS, SOLVD and V-HeFT. 
Although much is known as to the effects of these drugs and overall 
mortality and morbidity, it is not always clear which is the optimal 
treatment for an individual patient. In the following section, using small 
numbers of patients but detailed measurements, I have attempted to 
address some of these uncertainties.
Diuretics
By far the commonest treatment for any patient with heart failure is 
diuretics. In plant form, these were well known to the Greeks, Romans, 
Arabians and Egyptians before them. A combination of emetics, 
purging, diuretics and bleeding were common practice among mediaeval 
physicians. Galega ossicinalias (goats rue), scrophularia nodosa 
(figwort) and Scutellaria lateriflora (skullcap), all known for their diuretic 
action, can still be found in the Chelsea Physic Garden.
In modem cardiology practice, the introduction of diuretics was 
undoubtedly one of the major advances in the treatment of heart failure. 
They remain the commonest initial treatment. There is not a great deal 
of literature on the haemodynamic effects of diuretics. The majority of 
information is derived from haemodynamic studies in patients with acute 
myocardial infarction. Loop diuretics rapidly reduce left heart filling
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pressures usually with a concomitant fall in cardiac output (1,2). In 
patients with chronic heart failure the data is very sparse.
Methods
Eight male patients with severe left ventricular dysfunction (LVEF 
<30%) secondary to coronary artery disease were studied. All were 
clinically classified as New York Heart Association Grade III and had 
received no drugs for 24 hours. Patients had been stable on a 
combination of diuretics and vasodilators and no patients was receiving 
digoxin.
Heart rate was obtained from the electrocardiogram which was monitored 
continuously. Intra-arterial pressure was obtained from a catheter placed 
in the ascending aorta. Pulmonary artery pressure and capillary wedge 
pressure were obtained from a Swan-Ganz catheter inserted 
percutaneously via the femoral vein. Cardiac output was obtained by the 
thermodilution technique in triplicate (see Appendix). Coronary sinus 
flow was also obtained by the thermodilution technique from a Wilton 
Webster catheter inserted in the coronary sinus. This catheter allows 
blood sampling from the coronary sinus for measurement of oxygen 
saturation and this, together with an arterial sample, allows myocardial 
oxygen usage to be calculated. Myocardial flow was measured using the 
Xenon washout technique by direct injection of Xenon-133 intracoronary 
and scans obtained by a mobile Gamma camera. Myocardial flow to the 
total left ventricle and in each of the major coronary artery distributions 
was calculated. Frusemide was given intravenously in a dose of 0.5 mg/ 
kg. All measurements were taken for a control period of 10-15 minutes 
prior to administration of frusemide and for 30 minutes thereafter.
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Results
Heart rate increased by 5 minutes and remained elevated. Similarly there 
was a small but significant increase in systolic, diastolic and mean 
arterial pressure. Cardiac output and stroke volume were essentially 
unchanged. Pulmonary artery pressure and in particular pulmonary 
artery diastolic pressure, as a reflection of pulmonary capillary wedge 
pressure or left ventricular filling pressure, was unaltered.
With the increased blood pressure and unaltered cardiac output, 
calculated systemic vascular resistance was increased although this did 
not achieve statistical significance until 30 minutes after administration of 
the frusemide.
Coronary sinus flow measured by the thermodilution technique had 
increased significantly by 5-10 minutes and remained elevated at 20-30 
minutes. There was a similar directional change in myocardial nutrient 
flow as measured by the Xenon clearance technique. This increase was 
mainly in the territory of the left coronary artery. This was achieved 
only with a widening of the arteriovenous oxygen difference and hence a 
small increase in calculated myocardial oxygen consumption.
Discussion
These haemodynamic changes are in keeping with those previously 
reported by Verma et al (3) but not with several studies reporting 
reduced cardiac output when diuretics are given in acute heart failure 
complicating acute myocardial infarction (4-9). Given in acute heart 
failure left heart filling pressure is also universally lowered and this 
reduction in preload is thought to be its mode of action (10) with a 
reduced venous compliance due possibly to the release of prostacyclin or
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kallikrein (8,11 >12). In acute situations, the acute elevation of systemic 
arterial pressure is thought to be mediated by activation of the renin- 
angiotensin system (13,14).
In patients with chronic heart failure, diuretics undoubtedly produce 
symptomatic improvement, with increased exercise capacity, but with 
stimulation of the renin-angiotensin system (15) and probably also the 
sympathetic nervous system (16). A study by Francis et al (17) 
demonstrated that, following the intravenous administration of frusemide 
to chronically diuresed patients with heart failure, systemic vascular 
resistance increased together with stimulation of the sympathetic nervous 
system, the renin-angiotensin system and anti-diuretic hormone, which is 
consistent with our findings. Similar findings were reported following 
an oral dose of frusemide with no change in cardiac output pulmonary 
pressure (measured by doppler) or blood pressure (18).
Presumably, in our study, the resulting small increase in heart rate 
together with the increased blood pressure was sufficient to increase 
myocardial flow measured by the Xenon technique and also by comary 
sinus flow. The unchanged arteriovenous oxygen difference with 
unchanged oxygen extraction results in an increased calculated 
myocardial oxygen consumption. Increased myocardial flow balanced by 
the increased myocardial oxygen consumption may well contribute to 
unchanging exercise tolerance with chronic diuretic therapy.
In summary, acute diuretic therapy in chronically diuresed patients 
appears to increase heart rate, blood pressure, and thus systemic vascular 
resistance but with no change in cardiac output or stroke volume. This 
results in an increased myocardial blood flow.
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Nitrates
Oral nitrates, particularly isosorbide dinitrate, were the first oral 
vasodilators used in the management of patients with severe heart failure 
(19). Nitrates act primarily by lowering right and left heart filling 
pressures by direct action on venous capacitance vessels (20-22) usually 
with a small increase in cardiac output, particularly in patients with a low 
cardiac index prior to treatment (23,24). They have been found to be 
effective in alleviating dyspnoea and fatigue and to improve exercise 
tolerance (25-28).
Theoretically, the potential efficacy of reducing preload is less certain.
In isolated muscle preparations, when preload reserve is fully utilised, 
after-load mismatch can exist in steady state with heart function 
operating on an apparent descending limb. As long as venous return to 
the heart is not reduced, adaptive changes in preload probably have little 
effect (29, 30). This may not be the case in patients with chronic heart 
failure, when small changes in left ventricular volume may be critical in 
determining the output from the failing heart (31). However, nitrates 
also reduce left ventricular filling pressure, and thus left ventricular wall 
stress with subsequent improvement in myocardial subendocardial flow 
(32,33).
Methods
Ten male patients with New York Heart Association Grade III heart 
failure (left ventricular ejection fraction <30%) were studied at the time 
of routine coronary arteriography. All drug therapy was discontinued for 
24 hours and no patient was receiving long acting vasodilators, ACE 
inhibitors or digoxin.
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Heart rate was obtained from the electrocardiogram and blood pressure 
from an intra-arterial line placed in the ascending aorta. Pulmonary 
artery pressure and pulmonary capillary wedge pressure were obtained by 
Swan-Ganz catheter inserted percutaneously into the femoral vein. 
Cardiac output was obtained by the thermodilution technique in 
triplicate. Coronary sinus flow was also measured by the thermodilution 
technique via a Wilton Webster catheter placed in the coronary sinus. 
Simultaneous sampling from the coronary sinus and aorta allowed 
myocardial oxygen consumption to be calculated. Myocardial flow was 
obtained from the Xenon clearance technique as previously described 
(see Appendix).
Isosorbide mononitrate 15 mg. was given intravenously into the right 
atrium over two minutes. Venous samples were obtained every minute 
for five minutes, at 10 minutes, 20 minutes and 30 minutes for drug 
levels.
Results
There was an initial small insignificant drop in blood pressure and reflex 
tachycardia though blood pressure returned to control values but the 
slight tachycardia persisted. Diastolic pulmonary artery pressure was 
reduced significantly but returned to control by 30 minutes. Cardiac 
output showed a small progressive decrease. Stroke volume was reduced 
and calculated systemic vascular resistance increased.
Myocardial flow by both the Xenon technique and coronary sinus flow 
were unchanged but arteriovenous oxygen difference was significantly 
narrowed reflecting decreased oxygen usage. However the combination 
of the slight reduction in myocardial flow (especially from the left
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coronary artery) resulted in a small, non-significant drop in calculated 
myocardial oxygen consumption.
Blood levels of isosorbide mononitrate are shown with the peak 
occurring at two minutes following the end of the two minute infusion 
with adequate levels at 30 minutes.
In one patient systolic blood pressure dropped from 137 to 132 mm.Hg. 
with diastolic blood pressure dropping from 93 to 88 mm.Hg. and mean 
blood pressure 112 to 104 mm.Hg. with a small reflex tachycardia. At 
this point the patient developed chest pain, typical of his angina but 
without electrocardio-graphic change. Blood pressure was restored with 
intravenous fluid administration.
Discussion
Previous work would suggest that with the administration of intravenous 
nitrate one would expect a reduction in blood pressure with a reflex 
tachycardia. In this study there was an initial small decrease in systolic 
blood pressure which very quickly returned to control values although 
the minor tachy-cardia persisted. With the decrease in pulmonary artery 
diastolic pressure (left ventricular filling pressure) one might have 
expected the cardiac output and stroke volume to increase. This may 
have been a reflection partly of the dose chosen, which was fixed rather 
than titrated for each individual, and this has been shown to be required 
for isosorbide dinitrate (34) and partly that these were chronically treated 
patients, who had received no drugs for 24 hours, and no oral fluid for 
12-15 hours and hence the initial the pulmonary artery diastolic pressure 
was not high. These patients undoubtedly had heart failure on the basis 
of clinical findings and the associated left ventricular dysfunction. The
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action of nitrate is dependent on the prevailing haemodynamic findings 
(35).
The increase in calculated systemic vascular resistance is interesting. 
Myocardial flow was unchanged, but myocardial arteriovenous oxygen 
difference narrows, suggesting decreased oxygen usage. In one patient 
chest pain developed, without electrocardiographic change, due 
presumably to subendocardial ischaemia which would be impossible to 
detect either with coronary sinus flow measurements or Xenon clearance.
In summary, it is possible therefore that the maintenance of cardiac 
output is more beneficial in patients with chronic heart failure, to 
maintain myocardial flow, and that agents that are predominantly 
venodilators should be reserved for situations where filling pressure has 
increased.
Calcium Channel Blockers
The only vasodilators employed in the treatment of patients with heart 
failure tended to be predominantly effective in reducing venous 
capacitance, or preload, with drugs such as nitrates or reducing systemic 
vascular resistance (afterload) using for example hydralazine. In animal 
models of the ischaemic myocardium, increased preload improved 
cardiac output but at the expense of aggravated ischaemia while increased 
afterload reduced cardiac output but tended to improve perfusion and 
lactate uptake of the ischaemic myocardium (36).
Calcium antagonists are widely used for the treatment of angina and are 
known to reduce smooth muscle tone in the coronary and peripheral 
resistance vessels (37,40). Nifedipine has also been shown to increase
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coronary blood flow to ischaemic regions (41-43). Felodipine is a di- 
hydropiridine which inhibits the activation of intracellular calmodulin by 
calcium ions and in high concentrations acts as a slow calcium channel 
blocker (44). It is a potent systemic vasodilator with no direct effect on 
left ventricular function (45).
Methods
We studied 22 patients with left ventricular dysfunction secondary to 
arteriographically demonstrated coronary artery disease. Nineteen were 
male and the mean age was 46 years with a range of 29-66 years. Anti- 
anginal therapy was withdrawn for 72 hours prior to this study and the 
patients were premedicated with 10 mg. of oral diazepam.
Heart rate was obtained from the electrocardiogram and blood pressure 
from an intra-aortic line placed in the descending aorta. A Swan-Ganz 
catheter was inserted percutaneously via a femoral artery for 
measurement of pulmonary artery pressure and pulmonary capillary 
wedge pressure. Cardiac output was obtained in triplicate using the 
thermodilution technique. Coronary sinus flow was also measured by 
thermodilution using a Wilton Webster catheter placed in the coronary 
sinus. Simultaneous aortic and coronary sinus samples were withdrawn 
for measurement of blood oxygen content (Instrumentation Laboratories 
802). In eight patients heart rate was held constant by atrial pacing via 
the Wilton Webster catheter.
After the catheterisation procedure the patients were allowed to rest for 
30 minutes when control measurements were obtained. They were then 
given a 10 mg. oral solution of felodipine and measurements repeated at 
15, 30, 45 and 60 minutes.
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Results
The results are shown in Table 14. There was a small decrease in blood 
pressure of 16% and a 38% decrease in systemic vascular resistance 
resulting in a reflex tachycardia. Stroke volume increased as did the 
cardiac index by 35 %. Filling pressures were unchanged. Coronary 
sinus flow increased with a concomitant reduction in coronary vascular 
resistance and arteriovenous oxygen differences narrowed suggesting 
reduced myocardial oxygen consumption. In the eight patients in whom 
heart rate was held constant by atrial pacing, there was a similar 
reduction in blood pressure and systemic vascular resistance with a 
concomitant increase in cardiac index. Coronary haemodynamics 
showed similar changes in coronary sinus flow, coronary vascular 
resistance and again a narrowed arteriovenous oxygen difference.
Discussion
In these patients systemic blood pressure and the vascular resistance fell 
and when heart rate was held constant by atrial pacing the changes were 
maintained. Therefore it seems likely that afterload reduction (or 
impedance) was the major contributing factor. No effect on preload was 
seen as filling pressures remained unchanged. The oral felodipine gave 
rise to increases in both cardiac index and stroke volume index.
There was also dilatation in the coronary vasculature reflected as an 
increase in coronary sinus flow and a decrease in coronary vascular 
resistance. Myocardial arteriovenous oxygen differences narrowed on 
the combination of the increased coronary blood flow together with the 
fall in calculated left ventricular stroke work index would suggest this 
was due to less myocardial demand or work.
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These haemodynamic changes resemble those found with hydralazine, 
but without the side effects (47). It has been suggested that felodipine 
exerts its main vasodilating effect via calmodulin which has high 
concentrations in vascular smooth muscle with relatively low 
concentrations in the myocardium (44) providing an explanation for its 
predominantly peripheral action. In summary, the reduced impedance 
allows an increase in cardiac output and despite reduced blood pressure 
and reflex tachycardia coronary sinus flow increases with reduced 
myocardial oxygen usage.
Calcium Channel Blocker. Oral Administration
The advantageous effects of felodipine in reducing systemic vascular 
resistance and favourable coronary haemodynamic findings were tested 
with chronic administation in patients with chronic heart failure 
secondary to coronary artery disease.
Methods
Ten patients (nine males) Grade III-IV New York Heart Association 
heart failure with a mean age of 55 years (range 42-63 years) were 
studied. Coronary artery arterial disease was confirmed at angiography 
and eight of the ten patients had sustained a previous myocardial 
infarction. The patients were maintained on a stable dose of diuretics 
and none had received vasodilators or digoxin.
Heart rate was obtained from the electrocardiogram and blood pressure 
by cuff sphygmomanometry. A Swan-Ganz catheter was inserted 
percutaneously via the neck for measurement of pulmonary artery 
pressure and pulmonary capillary wedge pressure. Cardiac output was
Control Acute 4 weeks
Heart rate 
(beats min-1) 124 ± 8 122 ± 7 121 ± 8
Systolic blood pressure 
(mm Hg) 154 ± 7 145 ± 6 147 ± 7
Diastolic blood pressure 
(mm Hg) 86 ± 3 83 ±3* 81 ±3*
Mean arterial pressure 
(mm Hg) 107 ± 4 103 ± 4 103 ± 4
Pulmonary capillary 
wedge pressure (mm Hg) 35 ± 4 27 ± 4** 31 ± 5
Cardiac index 
(1 min-1 m-2) 4.4 ±0.3 5.3 ±0.3* 4.9 ±0 .2
Stroke index 
(ml beat-1 m-2) 36 ± 3 43 ± 4** 42 ±4*
Systemic vascular 
resistance (dyn s cm-5) 1113 ± 77 903 ± 65* 953 ± 57
Left ventricular 
ejection fraction (%) 15 ± 3 + 4*** 20 + 3***
* P  <  0.05 ** P <  0.01 *** p  <  0.02
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obtained by the thermodilution technique in triplicate. Ejection fraction 
was calculated from the radionuclide angiogram.
All haemodynamic measurements and radionuclide angiography were 
performed at rest and during upright dynamic exercise on a bicycle 
ergometer. The workload was predetermined for each individual as 
being near maximal and able to be sustained for two minutes. Two 
hours following the administration of placebo control data were obtained. 
The patient was then rested and depending on the haemodynamic 
response either 5 mg. or 10 mg. of felodipine were given six hourly.
Rest and exercise measurements were repeated two hours after the fourth 
dose of felodipine, i.e. 24 hours after the initial control data. The 
patients were then given what appeared to be the optimal dose for four 
weeks and measurements were repeated at rest and during dynamic 
exercise two hours after the initial morning dose. In eight patients the 
dose was 10 mg. three times daily, in one 5 mg. three times daily and in 
one 5 mg. twice daily.
Results
The results are shown in Table 15. At rest there was no change in heart 
rate and very little change in blood pressure or pulmonary capillary 
wedge pressure. There was an initial increase in cardiac index but no 
change in stroke volume. Calculated systemic vascular resistance fell but 
left ventricular function measured by right and left ventricular ejection 
fractions was unchanged. During exercise heart rates were similar with 
felodipine treatment to control measurements as was systolic blood 
pressure. However diastolic blood pressure was significantly lower. 
Pulmonary capillary wedge pressure was lowered acutely but had 
returned to control values by four weeks. Exercise cardiac output and
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stroke volume were both increased by felodipine with a reduction in 
calculated systemic vascular resistance. Exercise left ventricular ejection 
fraction improved and this improvement was maintained at four weeks.
Discussion
These results are in keeping with those of Timmis et al (48). In patients 
with congestive cardiomyopathy and ischaemic heart disease felodipine 
would appear to be an effective arteriolar vasodilator with maintenance 
of the effect at four weeks. Systemic vascular resistance is reduced with 
subsequent changes in cardiac index, stroke volume index and ejection 
fraction. The fall in pulmonary capillary wedge pressure on exercise 
may well be secondary to the increase in stroke volume but an effect on 
capacitance vessels could not be excluded.
In patients with chronic heart failure increased cardiac output does not 
necessarily imply improved tissue perfusion. Skeletal blood flow may be 
normal at rest but fails to increase normally on exercise due partly to the 
inability of peripheral conductance vessels to dilate to appropriate stimuli 
and partly to the phenomenon of deconditioning which may result in 
structural changes in the muscles (49,50). In a pig model of ischaemic 
heart failure nisoldipine ( a calcium antagonist which 4-10 times the 
vasodilatory effect of nifedipine but with less cardiac depressant action) 
produces similar haemodynamic changes to felodipine. Blood flow to 
kidney, brain, liver and skin were unaffected but skeletal muscle flow 
increased by just over 350%. Blood flow also increased to normal 
myocardium by 60% and by nearly 50% to infarcted myocardium (51).
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Summary
Felodipine treatment for four weeks in patients with chronic heart failure 
produced maintenance of effect with reductions in systemic vascular 
resistance and cardiac index and increased left ventricular systolic 
function. Myocardial oxygen consumption was not increased, indeed 
myocardial flow may well improve and underlie the increased ventricular 
function.
Balanced Vasodilators
With the demonstrated advantageous effects of reduction impedance and 
the putative benefits of reduction in elevated filling pressure, a balanced 
vasodilator which acts on both arterial and venous sites should, 
theoretically, be the ideal therapeutic solution. Flosequinan (7-fluro-l- 
methyl-3-methyl-sulphinyl-4-quinolone, Boots) is a vasodilator which 
acts directly both on arterial and venous sites (53) and has previously 
been shown to be effective in prolonging exercise capacity, improving 
peak oxygen consumption and improving New York Heart Association 
grading (54). Ten patients with exertional dyspnoea (New York Heart 
Association Grade III-IV) were studied. Heart failure was secondary to 
documented coronary artery disease and left ventricular function was 
severely impaired with resting left ventricular ejection fraction ranging 
between 6 and 22%. All patients were stabilised on optimal diuretic 
therapy for at least four weeks prior to the study.
Heart rate was obtained by the electrocardiogram and blood pressure by 
cuff sphygmomanometer. A Swan-Ganz thermodilution catheter was 
inserted percutaneously via the neck to give accurate measurements of 
pulmonary capillary wedge pressure and pulmonary artery pressure. 
Cardiac output measurements were by the thermodilution technique and
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were in triplicate at rest, throughout exercise and post exercise for five 
minutes.
Symptom limited exercise tests were obtained using an electronically
braked bicycle ergometer with the patient breathing a low dead space and
low resistance valve box. The valve box incorporates a turbine
ventilometer on the inspired limb for the measurement of ventilation.
The expired limb is fed through a mixing chamber from which samples
of air are analysed for carbon dioxide and oxygen by a infra-red
spectrometer and paramagnetic analysis respectively. Ventilation and
expired gas analysis were measured online throughout exercise and
oxygen consumption and carbon dioxide production were calculated
using standard equations. Arterial blood gas values were monitored
using a transcutaneous system (TCM3 Radiometer Limited, Copenhagen) 
to measure transcutaneous oxygen (tcpC>2) and carbon dioxide (tcpCC>2)
tensions. Indices of gas exchange, the alveolar oxygen gradient and dead 
space to tidal volume ratios were calculated. The patient exercised using 
a standard protocol already described. The non-invasive anaerobic 
threshold on exertion was calculated by the curve fitting method of 
Beever et al (see Appendix). Left and right ventricular function were 
obtained simultaneously from the technetium-99m radionuclide 
angiogram. Scans were obtained at rest and continuously throughout 
exercise and for five minutes post exercise by placing the Gamma camera 
close to the patient's chest in the left anterior oblique projection, with the 
left arm supported from the camera and the camera angled to give the 
best septal separation.
Ta
bl
e 
16
(a)
 
Re
sti
ng
 
ha
em
od
yn
am
ic
s 
ac
ut
ely
 
an
d 
af
ter
 
6 
w
ee
ks
' 
tr
ea
tm
en
t 
wi
th 
Fl
os
eq
ui
na
n 
the
n 
O
ua
ba
in
CN CNo  o  
d  d’O V W ’O ' O ’O ’O ’O
</3 v  v  C/3 C/3 C/3 C/3 C/3G Q h Pu G G G G G
”0  T3 -O
c/3 c/3 e/3G G G
T 3 *0
C/3 C/3
C G
G
•c3
■§
O
+
© 1—H CN VO
O n
wo ON ©
r"H © CO ON o C-’ wo
i H CN r-H f1 ^
+ 1 + 1 + 1 + 1 + 1 + 1 +1 + 1
CO CN v o v o ON
ON O n CN ON ON wo ON r t
00
▼-H
OO CN ▼■H CN CN
CN
oo wo t-»
on  co  *—iH «  m
+1 +1 +1
■*frON CO 
COVOo  U VO3fr3j-
O n 
tJ- ®
c n  r -  
+1 +1
OO 
• VO O n
OO ON 
CN 00
o♦
6cdG
>,T3
O
£
<Dc3as
OJ
C•C/5
&
CN
O
A
£
vo
ns
d V
o< ns
d
ns
d psu ns
d
ns
d
ns
d
ns
d
CO co ON ON ON CO 00 o o
T-H vd O n T tT-H
ON © r t ON*-H
+ 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1
o
8 8
ot " ; oCN CN oON OCN 8
CO
O n vd o or - WOCN vd1-H CN WOCN CO COr -o o
*o -o
C/3 C/3G G
CN OO Tf *-H
 +1 +1
o  
00
r-~ co
T3 "O
C/3 C/3G G
CO 
CN »0
©
CN
+1 +1 
o  o
OO Tfr
CN VO 
oo oo 
CN
3
G
o
<
c/3
o
x :
CN
vo CN CN
wo
ON
WO VO ON
vd CN O n T-H 00 o 00 CN
+ 1 + 1 + 1 + 1 + 1 + 1 +1
WO
+ 1
o
CN
O
00
o
00 8
o
3fr t " 8
o
wo
wo vd ON vd CN vd
CNO n o VO CN Nt-H
& a
+ i  + i
8 8 5
N 3  ^§s§
wo
ON VO
r-’ •>
CN 
+1 +1 
O  o
t "
^  vd 
oo 00
CN
WO
3}-
G
O
U
r-> oo oo r-H o CN
CO
r--
r-H
r-H
vd
r-H
oo cd
*"H
00
+1
WO woCN
+ 1 + 1 + 1 + 1 + 1 ^ H + 1 + 1 + 1
o o o o o CN o o 8CO wo CN CO CO CN wo
CN wo ON CN r H wo r-H vd
ON H
i-H
r - CO CN CN r-H oo
CN
ON VO 
CN CN 
N - CN
 +1 +1
o  o
VO VO
ONm cn
CO oo 
CO
+1 +1 
o  ot-H t'"~
W0 l>  
00 00 
CN
. CLP4 S  pqas S q
<Oh
2
00
<
O h
2
Q
o
~  >
U  oo
Oh
W
5 ft >  >Q 00 0h S 9>  0h
Ta
bl
e 
16
(b)
 
Ex
er
cis
e 
ha
em
od
yn
am
ic
s 
ac
ut
ely
 
an
d 
af
ter
 
6 
w
ee
ks
' 
tr
ea
tm
en
t 
wi
th 
Fl
os
eq
ui
na
n 
the
n 
O
ua
ba
in
-O ^  73
X/X V )  C/3 C/3 C/3
c  c  d  c  c
vo
o
o
vV C/3
O h C  C
T 3 T 3 
C C
e
*a
•8Po
+
h-h 00
CN v d( N  l-H
cn  
cn  ^  
o  i>
O  O  vo
CN Tfr r+"
CN CN r-H
+1 +1 +1 +1 +1 +| +1 +1 
O  O  oCN 00 c o
O ^ h-Hh—i O i/^OOtJ' m v o o v r t c n  cO’—i
O  o  o  
t *  o  CN VO
OO
ON
on cn  oo Os 
CN ’-H
+1 +l -H
00 3  
55
CN
tJ-
o
’O ’a ’O ' O ' o  v / ’O ’O00 00 00 00 OO v  00 00
d d d d d & d d
CN r j-
o  o
O O
v V 2ft
C/3
O
scd
g.
■8
6
s
K
<Dc/3
§
CN q CN vq ON
ON
T f 00 O n oON
in
VO
CN
C/1
M
0)
OO id
CN
T f id
CN
cnr*H o »d
cn
+ 1 + 1  + 1  + 1  + 1  + 1  +1 + 1 + 1 + 1
1 8
O
CN
o o<n q oO n oq vooo
CN00
VO vdcn
vdm vd00 vdm cn T t
Ti­
en
T t oo
CN
o
*
VO r - CN o oo © CN i—H
oo
m
cd
CN
ON d1—HT fCN dCN
d O n vd T f t—H
<D + 1 + 1  + 1  + 1  + 1  + 1  + 1 +1 +i + 1+-*
P
o
O
Ov
o
CN 8 oCN oq voCN Oq o i>r- cn
< l>
cn
idin s oin Tf"cn id*
00
cn
cn in
CN
O n
s•H-»co
U
O
O n
cn
o
oo
d
o
r^’
q
oo'
r-
o o in
cn
CN
in 3
30
CN wH CN i—H v-H 00* T f T f
+1 + 1  + 1  + 1  + 1  + 1  + 1 + 1 + 1 + 1
o
CN
Ovq 8 oVO oT f ONCN o00 oOO ONo
ON
cn
00 id id d T f cn CN 00
CN T f
t-H
00 VO cn cn 1—H oo
h-H
T—H
Os
+1
VOmTj-
cd
S
00
s
JO
6
ob ob ob ob ^  *2  EC 33 EC SC s S
S B S H g §
e g s e I I ®
Oh
PQ00
X
&
ffi
6 60  o1 I(/} oo i i<L> <D 
dd cd
T3 T3
Us<J <
W o o Q c o Q U o o J >  >  Q on ftn
Ta
bl
e 
16
(c)
 
Ve
nt
ila
tio
n 
an
d 
re
sp
ira
to
ry
 
ga
s 
an
al
ys
is 
ac
ut
ely
 
an
d 
af
ter
 
6 
w
ee
ks
' 
tr
ea
tm
en
t 
wi
th 
Fl
os
eq
ui
na
n 
th
en
 
O
ua
ba
in
 
on 
ex
er
ci
se
T3 TD • o
o
d
V T3C/i C/3 C/3 C/2
P P P a P
P |
p -
©
p"
vq i n
O
CN OO CO
CN r«H ON vd
+ 1 +1
i-H
+ 1  +1 +1
v-H O n P p
ON O O in co
P CN vd ON vd
00 00 CO
T3c/i
p
vo
ONP
’OC/i
p
O nCO
co
+1
CO
CO
oo
CO
o
T3cn
P
T3c/ia
00 00
in m
8 8
<N CN
+1 +1
t—H
oo oo
OO 0 0
C/i 
pH P
T3c/2
P
cq
VO
p CN vo
O n r-H o CN
vd O
+ 1  + 1 +1 +1
O n t-H
CO o
CN
CO o n oo o
CO ON p
T3C/3
P
oo
dm
CN
O n
00
CN
CN O n
S
ON
VO
vq
vd
Pin
CO 2
.7
4
+1 +1 + 1  + 1 + 1 + 1 + 1
cq 00 cq in pCN CO 00
CN
O n
vd
in00
00
co
CO
ON
o ’
P
oo
OO
CN00
CN
CO
O n 6
.7
96*11 10
.5
2
9
.2
7
2
.5
3
+ 1 +1 + 1  +1 + 1 + 1 +1
O cq o o
o
cq ON o
CN
CN
p *i—H vdCO
d
O n
00
h-H idp
00
ON
00
CN
+1
OO
o
C/i
&
<DC/2 • ^
£
<D
8
£
Poo
C/ip
*3o
5o
£
0)
6 p
p
p po o 
•J3 -P  P  a  ft o
pepC/3 C/3
P  Po
o
p
<D
e «  00 »-!
<D
p
S>
£60 60 p 
Px x *SO O P
p p
<L> <D
^  S  pD  CD P
x  w> §
<D P  
-  X  O
§ o > c -a •a 
8 >'S 3  
I* I  U
°  Uh «
73 5  &Hi
O O 
>  >
O O >  
W <J ?  T3 
>  Oh < >
(D
£
CDC/3 
♦ ^
(D
XW
(D
epC/3
o  o  w <  . _>  >  >  Cu <  >
160
Results
Detailed results are seen in the Tables opposite. There was a small 
change in the resting heart rate with flosequinan given acutely and a 
small drop in systolic blood pressure, consistent with vasodilatation. As 
might be expected in this group of patients with severely impaired left 
ventricular function, cardiac index and stroke volume index were 
reduced. During exercise, flosequinan given acutely produced an 
increase in exercise cardiac index but this was attenuated by six weeks as 
was a small and insignificant increase in stroke volume. Left ventricular 
ejection fraction and pulmonary artery diastolic pressure (pulmonary 
capillary wedge pressure) were unaltered. With intravenous ouabain 
exercise heart rate was similar to control but exercise systolic blood 
pressure was increased, producing a significant increase in double 
product with a small insignificant increase in left ventricular ejection 
fraction.
On exercise 9/10 patients achieved their anaerobic threshold. Oxygen 
consumption was unaltered by flosequinan therapy either at peak exercise 
or at the same watt load as the initial exercise test. Similarly, arterial 
blood gas values and indices of gas exchange were unaltered by 
treatment. Exercise was performed to a symptom limited maximum as 
indicated by the patient raising his hands and there was no difference in 
exercise times with treatment.
Discussion
Flosequinan is thought to modify the phosphoinositide pathway and have 
a weak non-selective inhibitory activity against phospho-diesterase. 
Previous work has suggested that the drug is effective long term in 
patients with chronic heart failure in both reducing filling pressure and
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impedance and thus producing symptomatic improvement (54-57).
Results from the V-HeFT study, of the combination of prazosin and 
hydrallazine, showed significantly lower mortality compared to placebo 
which with the high incidence of side effects requiring withdrawal from 
the trial (58). Conceptually a drug with venodilating action and effects 
on arteriolar resistance vessels is attractive.
In our patients at best, there were minor reductions in pulmonary artery 
diastolic pressure and small falls in blood pressure and systemic vascular 
resistance (and also pulmonary vascular resistance) with small increases 
in cardiac index and left ventricular ejection fraction. On exercise higher 
heart rate and systolic blood pressures were achieved with higher double 
product which is a reflection of myocardial oxygen consumption.
Exercise systemic vascular resistance was reduced and cardiac index 
increased but there was no change in maximal oxygen consumption, 
exercise time or anaerobic threshold or indeed in ventricular function.
Ouabain given intravenously produced a further small increase in the 
exercise systolic blood pressure and increased cardiac output but with no 
change in ventricular function. These patients were undoubtedly 
substantially impaired and although exercise haemodynamics improved a 
little, there was no change in exercise capacity.
Summary
Although theoretically a balanced vasodilator would appear to be 
advantageous, in this group of patients with severely compromised left 
ventricular function, flosequinan had little effect.
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Right Ventricular Function
Vasodilators can be effective in patients with chronic cardiac failure, but 
the benefits achieved in an individual patient vary considerably. It has 
been suggested that the response may depend on the extent of the reflex's 
constrictory action (59) or on the initial size of the left ventricle (60). 
Clinical observations suggested that the response to afterload reduction 
was smaller in patients when right ventricular function was impaired.
Methods
Fifteen male patients with New York Heart Association Grade III-IV 
heart failure secondary to coronary artery disease were studied. The 
mean age was 53 years with an age range of 46-62 years. All were on 
stable diuretic therapy and none had received vasodilators or digoxin.
Heart rate was obtained from the electrocardiogram and blood pressure 
by cuff sphygmomanometer. A Swan-Ganz catheter was inserted 
percutaneously for the measurement of pulmonary artery pressure, 
pulmonary capillary wedge pressure and cardiac output. Right and left 
ventricular function were obtained from radionuclide scans using a 
mobile Gamma camera. Measurements were made at rest and 20-30 
minutes following 10 mg. of oral felodipine when maximum 
haemodynamic changes are known to occur.
Results
Fifteen patients were arbitrarily divided on the basis of their right 
ventricular function (RVEF 25%). In 10 patients the right ventricular 
function was considered to be preserved with a mean RVEF of 33 
1 %. Five patients were considered to have right ventricular dysfunction 
with a right ventricular ejection fraction of 20 i  3 %. Left ventricular
Table 17(a) Haemodynamic variables in patients with
preserved right ventricular function and right 
ventricular dysfunction
Resting Measurements
RVEF <25% RVEF >25%
HR beats/minute 8 5 + 6 7 1 + 5 nsd
SBP mm.Hg. 114 ±  2 129 ±  6 nsd
DBP mm.Hg. 69 ±  8 83 ±  4 nsd
Mean mm.Hg. 83 ±  5 100.5 +  4 nsd
DPA mm.Hg. 2 7 + 7 17 +  2 nsd
Cl 1/min/m2 2.25 +  0.4 2.48 ±  0.08 nsd
SI ml/beat/m2 24.7 ±  3 37.2 +  3 nsd
LVEF % 12 ±  3 18 ±  2 nsd
RVEF % 20 ±  3 33 +  1
Exercise time (seconds) 146 ±  15.5 168 +  22 nsd
HR =  heart rate; SBP = systolic blood pressure; DBP = diastolic 
blood pressure; DPA = diastolic pulmonary artery pressure; Cl = 
cardiac index; SI = stroke volume index; LVEF = left ventricular 
ejection fraction; RVEF = right ventricular ejection fraction.
Iab lel7 (b )
Treatment with Arteriolar Dilator
RVEF <25% RVEF >25%
HR beats/minute 79 ± 6 79 ± 5 nsd
SBP mm.Hg. 108 ± 3 112 ± 7 nsd
DBP mm.Hg. 67 ± 5 71 ± 4 p < 0.02
Mean mm.Hg. 78 ± 5 87 ± 3 p <  0.005
DPA mm.Hg. 18 + 3 15 ± 2 nsd
Cl 1/min/m2 2.58 ± 0.4 3.29 ± 0.21 p < 0.02
SI ml/beat/m2 30.7 ± 3 41.9 ± 2 nsd
LVEF % 13 ± 4 20 ± 3 nsd
HR = heart rate; SBP = systolic blood pressure; DBP =  diastolic 
blood pressure; DPA = diastolic pulmonary artery pressure; Cl =  
cardiac index; SI = stroke volume index; LVEF = left ventricular 
ejection fraction; RVEF = right ventricular ejection fraction.
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ejection fraction in both groups was similar. In the 10 patients with 
preserved right ventricular function the range for left ventricular ejection 
fraction was 7-29% with a mean of 19 i  2%. In those with right 
ventricular dysfunction left ventricular ejection fraction ranged from 7 to 
23% with a mean of 12 i .  3% (nsd). Baseline haemodynamic 
measurements between the two groups were similar. Heart rate, blood 
pressure, diastolic pulmonary artery pressure, cardiac index, stroke 
volume index and systemic vascular resistance (not shown) were not 
statistically significantly different between the two groups. Exercise 
tolerance was similar in both groups. With treatment with felodipine in 
the group with right ventricular dysfunction heart rate fell whereas in 
those patients with preserved right ventricular function blood pressure 
fell and there was a small reflex tachycardia. Cardiac index increased 
significantly in those patients with preserved right ventricular function 
but did not change in those with right ventricular dysfunction.
To determine whether this effect was due to associated left ventricular 
dysfunction, the patients were re-divided on the basis of left ventricular 
ejection fraction. Ten patients had a left ventricular ejection fraction of 
less than 20% (mean 12 - i  2%) and five had a LVEF of greater than 
20% (25 ^  2%). The mean increase in cardiac index induced by 
treatment with arteriolar vasodilators was similar in both groups 2.47 i  
0.2 to 3.14 i  0.4 litres/minute/m2 where left ventricular ejection 
fraction was less than 20% and 2.29 i  0.15 to 2.96 0.25
litres/minute/m2 where the left ventricular ejection fraction was greater 
than 20%.
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Discussion
There is very little information in the literature concerning chronic right 
ventricular dysfunction in patients with coronary artery disease, as 
opposed to those with chronic obstructive airways disease. In chronic 
pulmonary hypertension secondary to obstructive airways disease, 
generally drugs that reduce afterload increase cardiac output with 
minimal changes in pressure, whereas drugs that reduce preload 
markedly reduce right ventricular filling pressure with a minimal change 
in cardiac output with certain similarities to the situation in the left 
ventricle (61). Since the right ventricular ejection fraction is highly 
dependent on afterload (62) effective arteriolar vasodilation would be 
expected to increase right ventricular systolic performance (63). Right 
ventricular systolic function is linearly related to end systolic volume 
(64) above a right ventricular ejection fraction of 20%. Below this value 
there is little relationship.
Changes in right ventricular function are known to affect left ventricular 
pressure generation (65) and indeed there is inter-dependence between 
the damaged left ventricle and right ventricle if septal function is 
abnormal (66).
In this study the patients had substantially impaired right and left 
ventricular function. The right ventricle dilates as it becomes 
increasingly dysfunctional but there must come a point at which it no 
longer acts as the pump but merely as a conduit and haemodynamic data 
would suggest that this may be in the region of a RVEF of 20% (64). A 
dilated, grossly dysfunctional right ventricle may not be capable of 
improvement, whereas the right ventricle that is less damaged is capable
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of improving which, in turn, due to inter-dependence between the 
ventricles would be translated into improved left ventricular ejection.
In a study of 29 patients with severe left ventricular dysfunction given 
nifedipine (67) the patients in whom cardiac index increased acutely, 
long term prognosis was better than in the 16 patients who exhibited 
haemodynamic deterioration with a marked hypotensive response.
Patients were identical with respect to other haemodynamic 
measurements except that plasma renins were higher and serum sodiums 
lower in those whose haemodynamics deteriorated in response to 
nifedipine, and in fact this latter was the most powerful of those three 
variables in predicting the long term prognosis. Unfortunately in that 
study right and left ventricular ejection fractions were not measured. We 
know from previous work in acute myocardial infarction that right 
ventricular dysfunction in association with left ventricular dysfunction 
carries a grave prognosis (see under Right Ventricular Function).
In summary, in patients with left ventricular dysfunction the 
haemodynamic response to vasodilators may be partly dependent on right 
ventricular performance.
Inotropic Agents
The use of inotropic agents is based on the premise that although the 
myocardium is depressed, there is residual contractile reserve which is 
capable of contributing to improvement in myocardial performance. In 
heart failure, catecholamine stimulation is part of the heart's adaptive 
response to reduced output (68,69). In the myocardium, catecholamines 
increase contractility by stimulation of the beta receptors on the 
myocardial cell surface, but also increase heart rate. The
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sympathomimetic amines dopamine and dobutamine are effective 
inotropic agents, with differing degrees of associated vasodilation due to 
dopaminaergic or beta2 effects, but require to be given as an infusion.
Various attempts have been made to synethise agents that act as agonists 
to beta! or beta2 receptors with various degrees of specificity.
Prenalterol was a relatively selective betaj agonist which, in volunteers,
produced an inotropic effect with a small increase in heart rate (70). In 
patients with coronary heart disease it increased left ventricular dp/dt 
with no change in heart rate (71).
Methods A
We studied six patients with left ventricular dysfunction secondary to 
coronary artery disease, all patients having sustained a previous 
myocardial infarction. The mean age was 47 years with a range of 37-59 
years and no patient had taken any drug therapy for 48 hours. Heart rate 
was obtained from the electrocardiogram and blood pressure from an 
intra-arterial line placed in the descending aorta. A Swan-Ganz catheter 
was inserted percutaneously for the measurement of pulmonary capillary 
wedge pressure and pulmonary artery pressure. Cardiac output was 
obtained by thermodilution in triplicate. Coronary sinus flow was also 
obtained by the thermodilution technique via a Wilton Webster catheter 
placed in the coronary sinus. Simultaneous sampling from the arterial 
line and the coronary sinus allowed the measure of oxygen content and 
myocardial oxygen consumption to be assessed. Prenalterol was given in 
a dose of 1.5 mg. in 50 ml. over 30 minutes. Results are seen in the 
Table opposite. There was an increase in cardiac index but this was 
accompanied by a significant (20%) increase in heart rate. There was 
no change in blood pressure or filling pressure. Coronary sinus flow
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increased but this was also accompanied by an increase in myocardial 
oxygen consumption although this was not significant.
Methods B
We studied nine patients with New York Heart Association Grade III 
heart failure with a mean of age of 51 years and an age range of 45 to 65 
years. Heart rate was obtained from the electrocardiogram, blood 
pressure by cuff sphymomanometer and a Swan-Ganz catheter was 
inserted percutaneously via the neck for measurement of pulmonary 
artery pressure and pulmonary capillary wedge pressure. Cardiac output 
was obtained by thermodilution. Left ventricular function was measured 
by radionuclide angiography. Prenalterol was infused at a dose of 1.5 
ug/kg.
Results
Detailed results are tabulated opposite.
At rest there was a small increase in cardiac index from 1.8 to 2.1 
litres/min/m2, which was associated with an increase in heart rate and 
systolic blood pressure and a fall in calculated systemic vascular 
resistance. Filling pressure did not change. On exercise heart rate was 
unchanged as was blood pressure and filling pressure. Calculated 
systemic vascular resistance was lower and this was associated with a 
small (13%) increase in cardiac index.
Methods C
We studied 10 male patients with New York Heart Association grade III- 
IV heart failure secondary to coronary artery disease. The mean age was 
52 years with an age range of 47 to 57 years. The dose of Prenalterol to
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be given was predetermined by that which gave an increase in heart rate 
of 10 beats/minute or a maximum of 100 mg. Placebo or prenalterol 
were given in a randomised cross-over fashion for periods of four weeks. 
At the end of each four week period measurements were obtained at rest 
and throughout exercise using a bicycle ergometer at a predetermined 
near maximal workload which could be sustained for three minutes.
Heart rate was obtained from an electrocardiogram, blood pressure by 
cuff sphygmomanometer. A Swan-Ganz catheter was inserted 
percutaneously for measurement of pulmonary capillary wedge pressure 
and pulmonary artery pressure and cardiac output which was obtained by 
the thermo-dilution technique. Left ventricular ejection fraction was 
obtained by radionuclide angiography.
Results
At rest heart rate was increased compared to placebo and although 
cardiac output measurements were significantly increased, cardiac index 
although higher was not significantly different. With exercise, heart rate 
with prenalterol treatment was lower than with placebo, thus the double 
product of heart rate and systolic blood pressure was 14% lower during 
exercise. However, systemic vascular resistance was elevated but left 
ventricular filling pressure was identical.
Discussion
Prenalterol, the relatively selective betaj agonist, which given as an 
infusion produces an increase in cardiac output but with an increased 
heart rate. Coronary sinus flow is enhanced but with an increased 
myocardial oxygen consumption. The increased cardiac output appears 
to be mainly dependent on a reduced calculated systemic vascular 
resistance presumably due to a vasodilatory action. With oral treatment
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for four weeks resting heart rate effect was maintained and there was a 
small increase in cardiac output but no haemodynamic benefit on 
exercise. This loss of efficacy is thought to be due to "down- 
regulation", or a progressive decrease in the number of active beta- 
receptors, presumably as a protective response by the myocardium to 
over-stimulation from the sympathetic system (72, 73).
Digoxin
Since Withering wrote his treatise on the use of digoxin, there has been 
controversy as to its efficacy where the controversy concerned types of 
patients who should receive digoxin (74), much as today (75). As in 
Withering's day, it is difficult to demonstrate efficacy when the drug is 
given inappropriately, the effects being of greater benefit as the heart 
failure becomes worse (76). It produces a mild inotropic effect by 
inhibiting membrane sodium potassium ATPase activity resulting in 
enhanced calcium entry into the cells (77).
Methods
We studied 10 patients, nine of whom were male, of New York Heart 
Association grade III-IV heart failure with a mean age of 51 years and a 
range of 42 - 65 years. Heart rate was obtained from the electrocardio­
gram and blood pressure by cuff sphygmomanometer. A Swan-Ganz 
catheter was inserted percutaneously for the measurement of pulmonary 
capillary wedge pressure and pulmonary artery pressure and cardiac 
output which was obtained by the thermodilution technique in triplicate. 
Left ventricular function was measured by radionuclide angiography. 
Measurements were made at rest and during dynamic exercise at a fixed 
workload. Twenty four hours later a second set of measurements were 
made following 0.5 mg. of intravenous ouabain, again at rest and during
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exercise. Patients then received oral digoxin for six weeks and the 
measurements were repeated.
Results
The results are shown in the tables opposite. There was no change in 
any of the resting haemodynamic parameters and left ventricular ejection 
fraction was unchanged. Exercise was performed in only eight patients 
as two patients were unable to exercise for three minutes. Heart rate was 
unchanged compared to control with either the ouabain or digoxin 
therapy. Pulmonary capillary wedge pressure was reduced by 13% with 
ouabain and 15% by digoxin. Cardiac index increased by 21 % with 
ouabain and by 15% with digoxin. Systemic vascular resistance was 
unchanged. Left ventricular ejection fraction increased both with 
ouabain and digoxin.
Discussion
These results suggest that there is haemodynamic improvement with 
digoxin manifest only during exercise with no changes at rest. Changes 
with ouabain were sustained at six weeks with digoxin. Since both 
systemic vascular resistance and blood pressure are unchanged it is likely 
that the improvement is related to increased contractility. In addition, 
pulmonary capillary wedge pressure on exercise fell which would reduce 
left ventricular wall tension and thus may reduce myocardial oxygen 
consumption.
The published data suggests that long term therapy with digoxin reduces 
symptoms, prolongs exercise tolerance and decreases the risk of clinical 
progression of heart failure (78-80). In addition to its inotropic effects, 
in contrast to cyclic AMP dependent agents, digitalis reduces activation
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of both the sympathetic nervous system and the renin angiotensin system 
(81,82). This appears to be related to the ability of digoxin to restore the 
inhibitory effect of cardiac baroreceptors on sympathetic outflow from 
the central nervous system (81).
In summary, in the appropriate patient, digitalis is effective in producing 
haemodynamic improvement which is manifest only during exercise. In 
recent studies long term therapy has reduced symptoms, improved 
exercise tolerance and decreased the risk of clinical deterioration due, 
presumably, to the complex interplay between the adaptive responses of 
the failing heart and the central and peripheral effects of the drug.
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PART 4
CONCLUSIONS
"Heart failure" has a long history. Its recognition and management, or 
indeed its very nature, have intrigued physicians for centuries. In this 
thesis I have tried systematically to examine the different ways in which 
a patient with this condition may be identified. Implicit are questions 
about the condition itself, its characteristics and underlying mechanisms.
Peter Harris, St. Cyres Lecture of 1987, provided a penetrating insight 
into the condition and I have drawn heavily on the concepts outlined in 
the lecture to provide a broad framework of reference.
The function of the circulation is to perfuse tissues as appropriate to the 
varying metabolic needs. Although metabolic signals predominate in 
setting local tissue perfusion, overall cardiac output appears to be 
controlled primarily in response to sensors of arterial pressure which is 
maintained. This adaptive response developed during evolution to 
maintain the high cardiac output warm blood animals need to support 
physical activity fuelled by oxygen. Anything which impairs cardiac 
output such as increased systolic load or loss or ischaemia of 
myocardium will reduce arterial pressure. The resultant neurohumoral 
signals are unsurprisingly similar to those induced by exercise. A 
damaged or overloaded heart becomes progressively less able to maintain 
arterial pressue; at first during exercise and ultimately at rest. The body 
responds by a series of acute or chronic adaptive responses, programmed 
by natural selection to maintain the arterial pressure during exercise or 
trauma.
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The neurohumoral signals result in resetting of fluid balance and they 
influence vascular and myocardial behaviour. Direct or secondary 
mechanical effects cause chronic adaptive changes in the vasculature, 
myocardial structure and the cardiac myocyte itself. The myocardium 
hypertophies, increasing its contractile protein and mass and normalises 
ventricular wall stress, with slower maximum velocity of contraction and 
lower energy requirements. Since cell division probably does not occur 
in mammalian myocardium after the neonatal period, this hypertrophy is 
due to increases in the size of individual myocytes. Genetic changes in 
the control of cytosolic calcium and the contractile proteins may be seen 
as improving metabolic efficiency in face of altered mechanical 
workload, as reflected by reducing energy requirements in relation to 
developed tension. At the myocyte level, these compensatory changes 
are appropriately adaptive. However, the cells are abnormally large, cell 
function is abnormal and this, ultimately, is associated with fibrosis 
which affects the mechanical properties of the heart, inevitably leading to 
progressive 'adaptive' hypertrophy and/or dilatation, thus the net benefits 
are over-ridden by functional deterioration.
Biological adaption represents a cascade of modifications to multiple 
physiological conditions and in general the adaption of any system not 
only has limits but potentially detrimental consequences. In 
characterising a patient with heart failure, there are clearly several 
aspects that require consideration. Firstly, the extent of damage that has 
initiated these adaptive processes; secondly, a measure of the results of 
this adaptation to characterise its adjustments and the stage of its 
development between initiation and ultimate "failure''; and thirdly, 
assessment of consequent processes which might contribute to further
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deterioration, possibly through stimulating further the very process 
involved originating the adaptive process.
The commonest cause of heart failure in the West today is ischaemic 
heart disease. This is the group of patients addressed in this thesis. A 
co-existing potential for intercurrent episodic myocardial ischaemia and 
its functional consequences may not be clinically overt, but may 
contribute to the overall condition of heart failure. A further feature of 
heart failure due to coronary artery disease is the potential for 
implication in both the initial and further myocyte damage and 
detrimental consequences of the adaptive changes.
The first aspect to consider - the severity of the initiating cardiac insult 
appears to relate to prognosis. In this thesis I have tried to demonstrate 
that extent of damage can easily and practically by assessed by using a 
non-invasive measure of left ventricular ejection fraction. However in 
the setting of left ventricular dysfunction involvement of the right 
ventricle is also an important consideration. Mechanisms that would 
contribute to further damage - specifically the underlying coronary artery 
disease in the population of patients studied - are an often underestimated 
part of this equation. Secondly, I have approached the problem of 
measuring the degree of adaptation through its overall consequences, 
namely, physical work capacity which overall is testing the efficiency of 
all the adaptive processes to maintain blood pressure and transport 
oxygen during exercise. Other measures of the adaptive process, such as 
activation of the renin-angiotensin systems were not addressed in this 
thesis. Thirdly, processes that lead to further myocardial impairment, in 
what could be regarded as a vicious cycle of events, deserve greater 
recognition than they have generally received. These may act relatively
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acutely with, for example, stress induced myocardial ischaemia resulting 
in further left ventricular dysfunction, as demonstrated in this thesis, 
ischaemia resulting in transient deterioration of cardiac function or more 
prolonged dysfunction as in myocardial stunning. When this occurs, the 
adaptive processes "fail" acutely but presumably are stimulated further 
by the resulting impairment in performance, particularly the inability to 
maintain the blood pressure
As Bernard Swynghendauw has said "heart failure is a disease of 
adaption”, implying that it is a syndrome which results from the ultimate 
failure of the initially beneficial adaptive process.
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APPENDIX
Introduction
Much of the methodology employed in this thesis is standard clinical 
practice. However, as with all measurements, in order to be able to 
judge the significance, the variability of the measurement must be 
determined. This degree of detail, although critically important, was felt 
to be intrusive within the body of this thesis. It is therefore presented in 
the Appendix. Standard measurements are presented with little detail 
other than to describe the precautions taken to produce reproducible 
results. Where methodology is less standard, or innovative, this has 
been compared with more standard measures.
Electrocardiography
Heart rate and ST segment changes were obtained from standard electro­
cardiograms, using a 6 lead Mingograph recorder at 25 mm/second. 
Electrocardiograms (ECGs) were recorded continuously throughout 
exercise at a slow speed (10 mm/second) and the speed increased to 25 
mm/second each minute and at peak exercise. Mingograph recorders 
provide a good quality ECG with an ink jet recorder that has a good 
frequency response (1). All measurements were made with a Mingo­
graph 62 ECG amplifier/recording system which has a frequency 
response of 0.05 Hz to 1200 Hz with no filter selected. Tremor filter 
reduces frequency response to approximately 30 Hz.
Blood Pressure
Blood pressure was usually measured in the right arm, using a cuff 
sphygmomanometer, with a single observer. The reproducibility for
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systolic blood pressure (SBP) was 5 +  3 % (standard error of estimate n 
=  20) and for diastolic blood pressure (DBP) 5 ±  5 % on exercise.
An automatic blood pressure cuff was found to be less reproducible on 
exercise and was difficult to use in patients with chronic heart failure, 
where exercise blood pressure can drop very suddenly, and the cuff takes 
10-15 seconds to inflate. Intra-arterial blood pressure recording could be 
more accurate but was not considered ethical.
As blood pressure is measured moving from central aorta to the 
periphery systolic blood pressure increases, diastolic blood pressure 
decreases and mean arterial pressure remains unchanged (2). The 
relationship between central and peripheral arterial pressure is not 
constant and is critically dependent on peripheral vascular impedance.
Measurement of blood pressure by cuff sphygmomanometer introduces 
an additional variable. Sphygmomanometry underestimates direct 
brachial pressure by approximately 10-25 mm.Hg. (3). Interestingly, 
although cuff blood pressure may still overestimate central aortic 
pressure to an extent, sphygmomanometry at the brachial artery more 
closely approximates central aortic systolic pressure, than does a direct 
arterial recording either from the same site or from the radial artery (4).
It is therefore critical to appreciate why blood pressure is being 
measured. During exercise testing, an important warning sign is exercise 
induced hypotension. This may be a real fall in systolic blood pressure, 
or a failure of the blood pressure to increase with increasing workloads 
(5). In patients with coronary artery disease, this usually indicates multi-
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vessel disease or left main disease (6) and continued exercise may 
precipitate ventricular fibrillation (7).
Blood pressure may also be used to determine the effect of exertion on a 
number of physiological parameters. Indices such as heart rate-blood 
pressure product, designed to estimate myocardial oxygen demand, use 
systolic blood pressure for their calculation and are most accurate if 
central systolic measurements are used (7), hence the use of sphygmo­
manometry. However if calculating systemic vascular resistance, the 
diastolic pressure must be employed to obtain mean arterial pressure, if 
this is not measured directly. As cuff measurement of diastolic blood 
pressure is notoriously less reliable than systolic pressure this inevitably 
will introduce errors.
Exercise Testing
The function of the circulation is to perfuse tissues. This requires 
adequate blood flow and gas transport between the lungs and cells of the 
body. With exertion, these requirements increase enormously and it is 
this inability of the cardiovascular system to sustain an increased demand 
that underlies the limitation in patients with heart failure.
Fick (8) in formulating his method of measuring cardiac output 
appreciated that the heart's output was intimately related to the body's 
oxygen consumption. It was some 70 years later before Harrison and 
Pilcher (9) examined gas exchange in patients with heart failure, showing 
that oxygen uptake was reduced but carbon dioxide output increased 
during exercise. The total oxygen (O2) required to perform work was no
different from normals but oxygen uptake at near maximal work rates 
was reduced and carbon dioxide (C02) output higher in patients with
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heart failure compared to normal controls. They clearly realised that the 
increased CO2 output was derived from bicarbonate (HCO3), formed to
buffer acid produced during exertion. Lactate was shown to increase 
with strenuous exercise by Barr and Himwich (10) and Brock et al (11), 
who demonstrated the 'threshold behaviour1 of acid-base balance. To 
understand the pathophysiological mechanisms in patients with heart 
failure, it is necessary to explain the normal physiological response to 
exercise.
Exercise capability and evaluations of physical work capacity in normals 
At rest, human basal metabolic rate is usually 5500-7000 kilojoules/24 
hours and muscular activity can increase this by as much as a factor of 
50 with a concomitant increase in oxygen consumption, removal of heat, 
carbon dioxide, water and waste products (12). At rest, and with 
moderate exertion, the necessary energy is provided by aerobic 
metabolism (oxygen converted to carbon dioxide) by mitochondrial 
oxidation of free fatty acids, carbohydrate and protein. With more 
vigorous exercise oxygen supplied to the working muscle is delayed, 
with a subsequent oxygen deficit, and at this point, part of the energy is 
supplied from anaerobic metabolism (produced predominantly from 
metabolic lactic acid, producing H + plus HCO3 - producing H2CO3 
producing H2+CO2) but also from the breakdown of ATP, CK and 
glycogen to pyruvic acid. This mechanism usually plays a relatively 
unimportant part of the energy supplied muscles and can be maintained 
only for a short period of time.
For many activities the individual energy cost is similar and this is true 
for exercise performed on a bicycle ergometer, whereas with the 
treadmill body weight is crucial for any given speed or slope, and the
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energy costs differ for walking and jogging at a simialr incline (13). By 
knowing the individual's potential ability to transport oxygen one can 
predict his potential to perform vigorous exercise (e.g. cross country ski­
ing requires a maximal oxygen uptake of approximately 80 ml/kg/ 
minute).
Normal limitations of oxygen transport during exercise
The Fick formula (8) for oxygen transport states that 
V 02 =  heart rate x stroke volume x Ca02-Cv02
CO (cardiac output) x arterial and venous oxygen content = 
a-v0 2 difference
The increased oxygen demand during exercise is met by increased 
cardiac output and a wider a-v02 difference (10,12,14). Pulmonary
function does not limit oxygen uptake in normal individuals. Increasing 
cardiac output is reflected in an increased arterial-venous oxygen 
difference which provides an indirect evaluation, as during maximal 
exercise there is a linear relationship between maximum cardiac output 
and maximum oxygen uptake (13) irrespective of whether the subject is 
trained or untrained (14) and the form of exercise (12,15,16).
With upright exercise, stroke volume increases by approximately 50% to 
a maximum at roughly 40% of the individual's maximal oxygen 
consumption (although stroke volume increases with training).
Thereafter the main factor in providing the increased cardiac output is 
the linear increase in heart rate. Heart rate does tend to be somewhat 
higher for any given load of oxygen uptake or cardiac output when using 
small muscle groups (arm exercise) with isometric exercise than with 
dynamic exercise. If normal heart rate is altered by drug administration, 
e.g. beta blockers, normal maximum oxygen uptake is achieved but with
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a shortened performance time and reduced blood pressure (17).
Normally during dynamic exercise, despite the reduced peripheral 
vascular resistance, intra-arterial blood pressure increases with aortic 
systolic levels approaching 175 mm.Hg. although it may be higher with 
isometric or arm exercise.
During strenuous exercise maximum oxygen consumption (V 02) can
attain maximal values varying from 22 to 50 ml/kg/minute, depending on 
age and fitness. V 02 max declines with age by roughly 30% from the
age of 40 to 65+ years (18) (40.5 ±  4.7 ml/kg/minute to 27.7 +  4.2 
ml/kg/minute in a 65 +  year old) with a corresponding decrease in 
exercise time (10.3 ± 1 .1  minutes to 7.5 +  3.0 minutes at 65+ years of 
age). This represents a 3-8% decline per decade throughout adult life.
% average normal V 02 max =  observed VP2 max x 100
predicted V 02 max for age
Fitness
This age related decline in V 02 max correlates inversely with the peak
decreases in heart rate and decreases in peak cardiac index but not with 
a-v02 oxygen difference or stroke volume index. Thus, from the Fick
equation, the only parameter affected by age is heart rate. The 
mechanisms for this decline with age are less clear, although it should be 
remembered that the changes are small when compared with overall 
variations in groups which are determined by other factors such as 
physical training. The cardiac output may be maintained by 
compensatory mechanisms, such as increased diastolic volume, calling 
into play the Frank-Starling mechanism. Left ventricular hypertrophy is 
a common ECG finding in elderly populations (19) and this may be
Table 22
Volunteers
(submaximal testing/HR 130-150) n = 8 ±  SEM 
fixed workload
HR Variations Rest Exercise
0 67.0 +  4.1 142.0 ±  3.5
90 minutes 73.0 ±  3.5 138.0 ±  3.5
3 hours 70.0 ±  5.4 133.0 ±  2.4
5 hours 83.0 ±  5.0 145.0 ±  2.3
7 hours 74.0 ±  3.9 139.0 ±  2.1
24 hours 80.0 ±  2.8 145.0 ±  3.5
SBP
0 125.8 ±  3.2 175.0 ±  4.6
90 minutes 129.3 ±  4.4 184.3 ±  6.7
3 hours 125.3 ±  3.0 183.3 ±  5.6
5 hours 130.0 ±  3.5 187.8 ±  7.8
7 hours 128.0 ±  4.1 183.0 ±  5.1
24 hours 125.0 ±  3.4 187.0 ±  8.8
DBP
0 82.0 ±  2.4 75.0 ±  5.7
90 minutes 85.0 ±  2.2 81.3 ±  3.5
3 hours 85.5 ±  2.5 76.5 ±  3.7
5 hours 83.0 ±  3.0 75.0 ±  3.8
7 hours 84.0 ±  2.9 77.3 ±  4.2
24 hours 81.9 ±  3.5 79.8 ±  3.7
VOLUNTEERS n = 8
2 0 0 i
HEART RATE
3  100
□  TIMEO 
B  90 MINS
□  3 HOURS 
0  5 HOURS
□  7 HOURS 
■  24 HOURS
Rest
VOLUNTEERS n = 8
2 0 0 i
Exercise
SYSTOLIC BLOOD PRESSURE
CD
X
I  100
0
I/ /
Rest
□  TIMEO 
B  90 MINS 
El 3 HOURS 
B  5 HOURS
□  7 HOURS 
B  24 HOURS
Exercise
VOLUNTEERS n = 8 
100
80-
CD 60" 
x
DIASTOLIC BLOOD PRESSURE
40-
2 0 -
0
□  TIMEO 
B  90 MINS
□  3 HOURS 
0  5 HOURS
□  7 HOURS 
B  24 HOURS
Exercise
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another compensatory mechanism reflecting increased systemic vascular 
resistance.
Methodology used
Exercise testing was performed using a bicycle ergometer. Ergometers 
are calibrated regularly against a Kg weight so that work loads exerted 
are within 5 % of measured and differences between ergometers are 
reduced as far as possible.
Exercise Protocol
Exercise testing protocols have to be modified in patients with heart 
failure to accommodate a reduced exercise capacity (20,21). Multistage 
tests have to have stages that are long enough to accummulate data, but 
not so long that the end points change. There is some doubt as to 
whether metabolic and haemodynamic stability can be achieved (22,23).
To Test Variation in Haemodynamic Variables
To test the variation in haemodynamic variables at rest and with exercise, 
eight volunteers were tested over a 24 hour period starting at 9 in the 
morning.
Heart rate was taken from the electrocardiogram, measured continuously, 
and blood pressure obtained by cuff sphygmomanometer by a single 
operator. Exercise was performed upright on a bicycle ergometer to an 
individual fixed work load* producing an exercise heart rate of 130-150 
beats/minute. An incremental protocol was used, with 50 watt steps, to 
this fixed maximum. Volunteers performed at least two tests to 
familiarise them with the protocols and to obviate training effects.
193
Heart rates and blood pressures are shown in Table 1 and Figure 1.
Heart rate both at rest and during exercise tends to be lower in the 
morning, whereas there is little difference with blood pressure. Because 
of this effect, exercise tests used for serial testing should be performed at 
roughly the same time of day.
It has been suggested that higher levels of physical work, heart rate and 
oxygen consumption, can be achieved using a treadmill rather than a 
bicycle (24). We, and others (21), have found no significant differences 
in peak performance and bicycle exercise, with simultaneous expired gas 
analysis, provides more reproducible results in our laboratory 
(unpublished data). Exercise testing was evaluated once patients had 
performed at least one previous test (greater than one week previously) in 
order to familiarise them with the equipment and this has been shown to 
provide more reproducible results (25).
The protocol used in all testing was as follows:
2 minutes rest, sitting on bike, to allow collection of stable resting 
data. If respiratory gas analysis was being performed this was with a 
nose clip and mouthpiece attached to a low deadspace and low 
resistance valve box.
2 or 3 minutes at no load.
2 or 3 minute increments of 25 watts to a symptom limited 
maximum.
If expired gas analysis was being performed, the patient lifted his 
hand and thereafter was encouraged to continue to exercise for 20-30
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seconds. If routine exercise testing was being performed, the patient 
had previously been given instructions to give warning when he felt 
he had to stop and again was encouraged to continue for 20-30 
seconds.
Expired gas analysis and haemodynamic monitoring was continued 
for at least 1 minute post exercise, or until the patient was haemo- 
dynamically stable.
Measurement of Ventilation
Minute ventilation and respiratory rate were measured using a vane 
turbine placed on the inspiratory side of a non-rebreathing respiratory 
valve circuit and a ventilometer (PK Morgan). The rotating vane 
interrupts a beam of light and the number of pulses generated are 
integrated to measure inspired volume which can be converted to expired 
volume (VE) using the Haldane correction (26).
Measurement of VQ2 and VC02
Expired gas was fed through a mixing chamber from which samples were 
analysed for carbon dioxide using an infra-red spectrometer and oxygen 
using a paramagnetic analyser. Oxygen consumption (VO2) and carbon 
dioxide production (VCO2) were measured on line (PK Morgan Ltd, 
Rainham, Kent) using standard equations (7,27)
Arterial Gas Analysis
Arterial blood gas values were monitored throughout exercise testing
using a transcutaneous system (TCM3 Radiometer Ltd, Copenhagen) 
which continuously monitors transcutaneous oxygen (tcp02) and C 0 2 
(tcpC02) tensions. This has been shown in our laboratory to be
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reproducible, repeatable and to correlate well with direct brachial arterial 
sampling (28). Indices of gas exchange - the alveolar-arterial oxygen 
gradient (A-a02) and dead space to tidal volume ratio (vd/vt) were
calculated from expired gas analysis and transcutaneous oxygen gas 
tensions using standard formula (27).
Measurements
Gas and flow measurements were corrected for ambient temperature, 
barometric pressure and water vapour. Measurements were made 
continuously, breath-to-breath.
Minute ventilation VE litres/minute
Oxygen uptake V 02 ml/min/kg } compared to normal
Carbon dioxide production VC02 ml/min/kg } values of Jones &
Campbell (29)
A-a02 Alveolar-arterial oxygen gradient
vd/vt Dead space to tidal volume ratio
Anaerobic threshold (AT) was calculated by the curve fitting method of 
Beaver et al (30) using a plot of V 02 against VC02.
Anaerobic threshold has been shown to correlate closely with the onset of 
lactate acid production (31) when the balance of oxygen supply and 
energy requirement is met by increased anaerobic glycolysis. 
Measurements of maximum oxygen consumption and anaerobic threshold 
therefore provide indices of the maximum ability of both aerobic and 
anaerobic mechanisms to supply energy to working skeletal muscle (32). 
Weber and Janicki (33) have proposed a classification of severity of heart 
failure based on levels of oxygen consumption, as has Franciosa (31), the 
classification assuming that maximal oxygen consumption has been
Table 23
Range Normal in Adult Clinical Cardiology JTW  & CA Sanders
Average Range Exercise
Cl 1/min/m2 3.1 2.5 - 4.0 Increase x 2.3
Venous pressure
mm.Hg. 5 3 .0 -8 .0 Increase x 2.3
RA 2 -2 - +5 Increase x 2.3
RV systolic 25 18 -30 Increase
end diastolic 2 -5 - +5 Increase
PA systolic 25 18 -3 0 Increase
diastolic 10 6 - 12 Increase
mean 15 10 -20 10 mm. increase
PCW 6 0 - 12 0-4 mm. increase
LA 6 0 - 12 0-4 mm. increase
LV systolic 120 100 - 140 Increase
LV diastolic 6 0 - 12 Increase
Brachial artery
measurement 45 85 - 105 Decrease
LVEDP 12
CTR less than 50% Clinical Cardiology, page 177
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reached. The relationship between oxygen consumption and work load 
during graded exercise is curvilinear - measurements are most reliable if 
a plateau of oxygen consumption is achieved (34).
In general, the maximal oxygen consumption increases when anaerobic 
threshold increases. The use of anaerobic threshold to assess functional 
capacity is based on the evidence that inadequate blood supply or reduced 
oxidative capacity are the major determinants of limitation of exercise in 
patients with heart failure. Exercise at levels above the anaerobic 
threshold rapidly induces fatigue (32) in these patients and improved 
cardiac output during exercise may delay the anaerobic threshold but 
does not necessarily improve the exercise capacity (35). Thus, anaerobic 
threshold is a marker of the success of the cardiovascular system in 
meeting the oxygen demands of working skeletal muscle (36).
Cardiac Output
Cardiac output is the volume of blood ejected either from the left 
ventricle into the systemic circulation, or the right ventricle into the 
pulmonary circulation. It is usually measured in litres per minute, but 
to permit comparisons between output measurements of individuals of 
different body weight, cardiac index is usually employed.
Cardiac index =  cardiac output 1/min/m2
body surface area (m2)
Stroke volume is the volume of blood ejected per heart beat
Stroke volume = cardiac output 
heart rate
mls/beat
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and stroke index =  stroke volume ml s/beat/m2
body surface area (m^)
The theoretical principle enunciated by Adolph Fick in 1870 (8) states 
that the flow of blood in a given period of time is equal to the amount of 
substance entering the stream of flow in the same period of time divided 
by the difference between the concentrations of the substance in the 
blood upstream and downstream from its point of entry into the 
circulation.
The earliest studies of cardiac output were based on the Fick principle 
(8,37,38,39), but as this requires the direct measurement of 
oxygen consumption and oxygen content of venous and arterial blood, 
this has largely been replaced by indicator dilution methods.
This technique, developed and refined by Stewart and Hamilton (40), 
states that the volume of fluid in a container can be calculated if a known 
quantity of indicator (eg dye, cold saline, or radio-isotope) is added and 
the concentration of indicator measured after it has been uniformly 
dispersed throughout the fluid.
Q (flow ml s -l)=  amount indicator injected
mean concentration of indicator x time
Specialised thermodilution catheters have been developed that allow 
injection of dextrose-saline, cooled to less than body temperature, into 
the right atrium. A thermistor incorporated into the distal end of the 
catheter, positioned in the pulmonary artery, allows measurement of the 
resultant change in blood temperature, which is proportional to blood
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flow. Small dedicated computers allow curve integration and calculation 
of cardiac output, given by the equation
Q = Av (Tb-TB x Dc Sc - B 
STbdt Db Sb
A and B are constants from the thermodilution/Fick regression equation 
of Braithwaite and Bradley (1968) (41)
V is the volume of dextrose-saline injected - the dead space of the 
catheter
T is temperature °C 
D is density 
S is specific heat
subscripts b and c blood and injectate
STbdt is the interval of change in blood temperature with time, t in 
seconds.
This can be simplified (42) to
Cardiac output = Vj x CTB-T{1 x 60 x 1.08 
A (cmnr1)
199
Vj =  volume of injectate in ml; TB = blood temperature; Tj = 
injectate temperature; 1.08 = correction factor for specific gravity and 
specific heat of blood and indicator; A = the area under the dilution 
curve multiplied by time for inscription of the curve.
To accurately assess blood flow requires that (i) the amount of indicator 
injected must be measured accurately and there should be no loss of 
indicator between the sites of injection and detection, (ii) the injection 
should be "instantaneous”, (iii) there must be adequate mixing of the 
injectate with the volume flow and there must be no additional blood 
leaving or entering the circulation beyond the site of mixing and before 
the site of detection, (iv) steady-state conditions must apply.
It is clear that these perfect conditions cannot exist in the circulation in 
man, and therefore all measurements are subjects to error. The most 
signficant source of error is the accurate measurement of injected 
volume. This can be largely overcome by the use of injectors that are 
pre-set to inject exact volume. In this thesis all cardiac output 
measurements were made either with an electrically driven injector (IL 
801 computer) or on exercise with a hand held gas cyclinder powered 
gun (OMP Thermodilution Injector 3700). The injectate (10 ml of 
dextrose) is cooled by storing the dextrose in iced water to reduce the 
variability of readings (43).
Good correlation has been found between thermodilution and Fick 
methods (Fegler, 1954) (44,45) and between dye and thermodilution 
(Goodyear et al, 1959; Ginz et al, 1971) (46,47).
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Results are reproducible over a wide range of measurements, 
reproducibility being ± 2 % ,  and in our laboratory an r value of 0.95 
was obtained against dye dilution.
Pressure measurement
The advantage of using a thermodilution catheter is that it also allows a 
measure of intra-cardiac pressure. Pulmonary "wedge” pressure is taken 
as an accurate reflection of left atrial pressure. Mean atrial pressure is 
thought to correlate well with the end diastolic pressure of the associated 
ventricle (1), thus mean wedge pressure correlates well with left 
ventricular end diastolic pressure in the presence of a normal mitral 
valve. Normal left ventricular end diastolic pressure is less than 12 
mm.Hg. and does not rise with exercise.
Chest X-Rav
As the heart size increases, as an adaptive response in heart failure, this 
may be detected by chest x-ray. Heart size may be assessed by 
subjective grading, measurement of transverse diameter or volume 
measurements.
Subjective grading consists of grading heart size as normal, slight but 
definite, obvious or gross cardiomegaly. The accuracy of this form of 
grading may be increased by using a lateral view to assess whether the 
heart is deep or shallow.
Transverse diameter - This is the ratio between the maximum transverse 
diameter of the heart and the width of the thorax (the maximum width 
above the costophrenic angle measured from the inner ends of the ribs).
In general, 50% is taken as the upper limit of normality. This may be
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exceeded, without cardiac enlargement, if the heart is depressed (eg by 
sternal depression) or if the diaphragm is raised (eg obesity).
Conversely, the cardiothoracic ratio may remain normal where the heart 
expands downwards (eg aortic regurgitation).
An alternative is to use a measurement of transverse cardiac diameter 
>  15 cm. in an adult, or of more value, the transverse diameter predicted 
from height and weight (49) with a measurement of >10% outside of 
this being abnormal.
Heart volume - This is based on the assumption that the heart is 
ellipsoid and requires measurements from the anterior and lateral views 
(50).
Volume mls/m2 =  L x B x D x k x M
A
where (L) is the long diameter, measured from the superior vena caval/ 
right atrial junction to the cardiac apex
B is the broad diameter, from diaphragm/right atrial junction to 
pulmonary trunk/left atrial appendix junction
D is the depth diameter, or the greatest horizontal depth of the heart
k is a constant of 0.63
M is the magnification factor (Jonsell, 1939 (50))
A is the body surface area, derived from height and weight
The upper limit of normal for adult males is 550 ml/m2 and 500 ml/m2 
for females (51)
Left Ventricular Function
Left ventricular function may be assessed by several methods, of which 
the commonest is left ventricular ejection fraction. By injecting contrast
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medium into the left ventricle and recording on cine film, end diastolic 
and end systolic frames may be obtained. Left ventricular volumes and 
ejection fraction (LVEF) can then be calculated (Dodge and Sandler) 
(52,53,54).
Assuming the ventricle to be ellipsoid, the volume can be derived from
D 4A
rcL
where D is the minor axis, A is the area of the ventricle and L is the long 
axis measured from the mid-aortic root to the apex of the ventricle. This 
becomes more accurate where a grid calibration correction for 
magnification is used, together with a correction for the right anterior 
oblique projection (55) or patient size (56,57).
Normal end diastolic volume index is 70 ±  20 (SD) ml/m2 (53).
Left ventricular ejection fraction (LVEF) is given by the formula
LVEF = EDV - ESV
EDV (Dodge and Sandler (54))
where EDV = end diastolic volume
ESV = end systolic volume
Normal LVEF by angiography ranges from 52-64% (57).
Technetium Scanning
Radio-isotopic angiocardiography was developed in 1969 (Mason et al, 
1969; Mullins et al, 1969 (59,60)) and in 1971 a non-invasive 
radionuclide method was described for gated blood pool imaging, using a 
scintillation camera for estimating ejection fraction and segmental 
contraction (Strauss et al, 1971; Zaret et al, 1971 (61,62)).
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In vivo labelling is achieved by injecting intravenously sodium per- 
technetate, followed 5-10 minutes later by 600-800 MBq of technetium 
(Tc99m). Images are obtained in listmode, gated to the 
electrocardiogram, using a mobile gamma camera fitted with a high 
sensitivity parallel collimator. Images may then be reconstructed into 24 
frames. End diastolic and end systolic frames may be identified from the 
40° left anterior oblique projection.
Calculation of Left Ventricular Ejection Fraction 
By drawing a region of interest around the left ventricle in end diastole 
(Figure 35a) to encompass the whole of the left ventricle, taking care not 
to include left atrial activity, a background region of interest was drawn 
3 pixels wide adjacent to the left ventricular region of interest. Using a 
semi-automated technique time activity curves (Figure 34d) were 
generated for both regions of interest, allowing ejection fraction to be 
calculated (63,64,65).
LVEF = EDc - ESc 
EDc - B
where EDc =  end diastolic counts
ESc = end systolic counts
B = background activity from mean counts
throughout background activity curve.
In 10 volunteers LVEF was above 45 % with a mean standard deviation 
of 1.6%. The reproducibility of this measurement is high - both for 
repeatability with one observer, two and three observers. The day to day 
variation has been obtained in 20 subjects and was ±  2.2%. The
Figure 35:
Figure 35: a) Normal end diastolic and end systolic images from a technetium
scan, with stroke volume and paradox images below
b) Abnormal technetium scan, with an apical aneurysm best seen on 
the paradox image
c) Abnormal end diastolic and end systolic images from a biplane 
technetium scan
d) Normal ejection fraction curve
e) Phase image, showing an apical aneursym and curves, of phase 
delay
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reproducibility of the technique with either upright or supine exercise 
was 2.9% (Figure 36c).
Left ventricular ejection fraction obtained by technetium scanning was 
compared with angiography (calculated by the method of Dodge and 
Sandler). In 63 individuals, over wide range of LVEF r =0.9 (Figure 
36c). Errors for calculated and true left ventricular ejection fraction for 
a range of end diastolic volumes are shown in Figure 36f. The inferior 
wall is best assessed using a 70° left anterior oblique or a lateral 
projection. Both a 30° and 70° left anterior oblique projection may be 
acquired simultaneously using a biplane collimator, for which LVEF 
may be calculated as seen in Figure 36d.
Volumes
End diastolic and end systolic volume may be calculated if a reference 
blood sample has been obtained (66,67,68).
Normal ED Vol is 70 ±  20 (SD) ml/m2 
Reproducibility ± 4 %
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Functional images and Regional wall motion
Wall motion can be assessed by viewing the cine images and using a four 
point scoring system, ranging from 1 normal motion, 2 reduced motion,
3 little motion, 4 motion absent, and 5 aneurysmal motion, i.e. moving 
out of phase. With experienced observers, this is simple and very 
reproducible, cf. Figure 37. By simply adding the regional 'scores', 
normal =  5 ranging to a maximum of 25, with all segments aneurysmal.
In an effort to quantify the degree of regional abnormality, various 
methods have been employed (69).
Functional images:-
The stroke volume image, Figure 35a, ED - ES image, gives a simple 
visual estimate of the degree of wall motion abnormality.
Estimation of the degree of abnormality from the stroke volume image 
gives a simple, reproducible measurement (70).
The paradox image ES - ED allows identification of areas moving out of 
phase, or true aneurysm formation (Figure 35b).
The phase image:-
For each pixel, a time activity curve may be generated. If each pixel is 
coded for the time to end systolic counts, a phase image may be 
produced, which allows areas of ventricular motion which are delayed or 
"out of phase" to be identified, Figure 35e.
The degree of ventricular abnormal phase can be used to assess the extent 
of regional abnormality within the ventricle. Normal phase can occur
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where left ventricular ejection fraction is reduced, reflecting global rather 
than regional abnormalities (Figure 38). One of the ways in which the 
extent of phase abnormality may be simply assessed is to use 
measurements of full width half maximum (FWHM) of the phase degree. 
This is reproducible and repeatable and separates patients with normal 
ventricular function (n = 12, with normal coronary arterio-graphy) and 
patients with myocardial infarction (n =  20) (Figures 38 a-d).
Conduction abnormalities may influence this measurement and this was 
excluded by measuring QRS duration on the ECG (Figure 38e).
Technetium Scans on Exercise
Technetium scanning may be performed on exercise, providing 
reproducible and repeatable data to assess ventricular function on 
exercise (69-72). This may be performed using either a) a first pass 
technique which optimally employs a multi-crystal Gamma camera and 
allows a measurement over approximately 20 seconds at 'peak exercise1, 
or b) the gated technique. The accuracy of the latter may be enhanced 
by the use of two modifications 1) a biplane collimator which 
simultaneously acquires a 30° and 70° LAO projection, and allows the 
inferior surface of the ventricle to be assessed, and 2) collecting data 
continuously in list mode, together with careful timing, then 
retrospective reconstruction allows the 30 seconds' data at peak exercise 
to be assessed (Figure 35c).
Exercise is usually performed supine, but where phsyiological parameters 
are to be tested that require normal ventricular filling, this is better 
performed upright (73,74). This necessitates taking care in positioning 
the camera while the subject is seated on the bicycle and restraining the 
chest (best achieved by leaning on the patient's back).
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Global and regional function may then be assessed using various 
techniques already described. Exercise induced regional ventricular wall 
motion abnormalities correlate well with angio-graphic evidence of 
coronary disease (75-79) and electrocardio-graphic evidence of ischaemia 
(80).
Summary
Regional wall motion is most easily assessed from cine images by 
experienced observers. For the quantification of the extent of regional 
wall motion abnormalities, the stroke volume image would appear to 
have advantages as the most reproducible, particularly on exercise.
Right Ventricular Function
The geometry of the right ventricle, with the lack of any approximation 
to known geometrical shape, makes angiographic measurements of right 
ventricular function subject to error. Radionuclides provide a count 
based assessment, which is less influenced by geometrical assumptions. 
Previously described methods include first pass techniques (81,82) and 
gated equilibrium technetium blood pool scanning (83,84,85,86). 
However, as the right ventricle enlarges, or indeed as the left ventricle 
enlarges, it may be difficult to adequately separate the right and left 
ventricle. It is therefore an attractive idea to use a nobel gas, such as 
either Xenon-133 or Krypton-133, of which 90% is excreted by the 
lungs. Previous work using first pass techniques have shown this is 
feasible, but these images tend to be of poor quality due to reduced count 
density (87,88,89,90). We therefore developed a method of assessing 
right ventricular function using gated Xenon 133 imaging (91).
f f
E D  E S
N O R h f t L
a
b
Figure 39: a) Normal right ventricular Xenon, end diastole and end systole
b) Normal stroke volume and paradox images
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Data were acquired using a mobile gamma camera fitted with an ultra- 
high sensitivity parallel collimator. The camera was interfaced with a 
mobile computer system (Link MAPS). All data were acquired in 
listmode, to allow accurate retrospective construction of a 
representative cardiac cycle. The camera was positioned in 5-10° left 
anterior oblique projection with 6° caudal tilt, to allow optimal 
separation of the right atrium from the right ventricle, and isolation of 
right ventricular activity from the lung fields. 400-600 MBq of 
Xenon 133 was injected intravenously over 20 seconds and data were 
acquired from time of first visualisation of activity within the right 
heart, until activity was seen to leave it. Average data acquisition time 
was 25 seconds and in 20 studies the average net end diastolic counts 
were 3620 +  978 in 1/16 of a cardiac cycle.
Data were processed to construct a cycle of 16 frames for analysis, with 
cycles with R-R intervals outwith 20% of the running average being 
discarded. After spatial and temporal smoothing, the end diastolic and 
end systolic frames are used to produce standard stroke volume and 
paradox images, Figure 39b, allowing definition of the tricuspid and 
pulmonary valve planes. The right ventricular region of interest was 
then extended from the valve planes to encompass the whole of the right 
ventricle. The region of interest was confirmed by superimposing the 
cine display and modifying as necessary. A background region of 
interest was drawn 3 pixels wide, adjacent to the right ventricular region 
of interest. Time-activity curves were then generated for both regions of 
interest, allowing right ventricular ejection fraction (RVEF) to be 
calculated.
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RVEF = EDc - ESc 
E D c - B
where EDc =  end diastolic counts
ESc = end systolic counts
B =  background activity determined as mean
counts throughout the time activity curve for 
the background region of interest.
Normal RVEF, in volunteers (n =  16,aged 23-36 years), was 35 - 55% 
with a mean 43 ±  5%. Gated Xenon 133 scans were compared with first 
pass technetium scans performed in the right anterior oblique projection 
in 13 patients with a correlation coefficient of 0.80. In 15 patients, gated 
Xenon 133 scans were compared with right ventricular ejection fraction 
obtained from standard gated technetium scans, with a correlation 
coefficient of 0.91 (Figure 40e).
Reproducibility and repeatability of the technique are also good with 
mean differences of 2.2 and 2.75% (Figures 40c,40d).
Coronary Flow
Coronary Sinus Flow
Coronary flow can be inferred from measurements of coronary sinus 
flow, which can be assessed during cardiac catheterisation by the 
thermodilution technique (92). A catheter is inserted into the coronary 
sinus, most easily through the left antecubital vein and saline is infused 
continuously with the temperature of the injectate measured by a 
thermistor at the tip of the catheter. The temperature of the blood-saline 
mixture downstream in the coronary sinus measured by a thermistor
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mounted on the catheter. The coronary sinus flow may be calculated 
(see below) by using samples of coronary sinus blood and simultaneous 
arterial samples, oxygen content and therefore oxygen usage may be 
calculated. A Wilton-Webster catheter also incorporates a pacing 
electrode that allows overdrive pacing within the right atrium.
Coronary sinus flow (CSF) ml/min -  x k x Qi
Myocardial oxygen consumption (MVO2) =
CSF x AV oxygen difference ml/min
A-VO2 difference =
arteriovenous oxygen difference vols % 
arterial - coronary sinus O2 content
Coronary vascular resistance = mean arterial pressure x 80
dyne-s-cm-5 mean coronary sinus flow
Care must be taken to ensure that the flow of the inejctate is sufficiently 
fast - in this thesis 60 ml/minute, administered by a fast infusion pump 
(Sage Pumps) with a reproducibility of infusion rate ± 2 % .  This 
method allows repeated measurements of coronary flow, which are 
reproducible ( ± 5 % )  and are similar to coronary arterial flow (r =  0.9)
k
Qi
temperature of mixture of blood and injectate, °C 
temperature of injectate, °C 
temperature of blood, °C 
a constant 1.08
rate of infusion of the injectate
(92).
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Myocardial Flow
Myocardial flow can also be assessed by using radioactive substances (a) 
radioactive diffusable substances that actively enter the cell, (b) 
distribution of radio-labelled particles, or (c) disappearance of 
radioactive diffusable gases.
(a) Radioactive isotopes of sodium, potassium and rubidium 
(93,94,95) all actively enter the cell, and clearance of these 
tracers from blood by myocardium measures nutritional (or 
effective capillary) flow. The validity of this technique is 
dependent on the premise that myocardial uptake is a flow 
dependent process, therefore
Coronary blood flow = Myocardial uptake
cardiac output total body uptake
However the extraction ratio of myocardium is not complete and
re-circulation occurs. As the tracer is fixed in the myocardium,
sequential measurements of flow are difficult.
(b) Radiolabelled particles.
This is the standard technique for the measurement of regional 
myocardial flow in animals (96). Microspheres 8-10 X in 
diameter, injected into the left atrium are trapped in the 
myocardium and may be quantitated by serial sectioning of the 
myocardium. Particles in the form of radiolabelled albumin 
macroaggregates may be injected directly intra-coronary in 
patients, but as they embolise the coronary capillary bed and have 
a biological half life of 4-8 hours, repeated measurements are 
difficult. In addition, recently it has been demonstrated that this
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technique suffers from systematic errors due to the particulate 
nature of the microspheres (97).
(c) Radioactive Nobel gases
These agents have distinct advantages (i) as they are fat soluble 
they are capable of rapidly diffusing through the endothelium into 
surrounding tissue and thus can measure higher rates of flow than 
water soluble cations; (ii) approximately 95 % of the gas tracer 
enters the alveolar air during first circulation through the lungs, 
thus there is little recirculation. As the gas is quickly cleared 
from the lungs, repeated measurements can be made. Krypton 85 
has a very short half life (2-4 minutes) and requires to be infused 
continuously. Xenon 133 with a half life of 5.27 days, being 
more stable, is more convenient to use. Xenon 133, 1-200 MBq, 
is injected directly intracoronary and scans are obtained using a 
mobile gamma camera fitted with a biplane collimator, which 
allows the simultaneous acquisition of 30° and 70° left anterior 
oblique projections. Activity is acquired initially in 1 second, 
then 5 second frames, to produce washout curves. As the 
radioactivity reaches the capillary bed of the myocardium, Xenon 
leaves the capillary space and diffuses into the myocardium with 
the relationship.
Solubility of Xenon 133 in myocardial muscle (or fat) =  X 
Solubility of Xenon 133 in blood
where X is the partition coefficient - for myocardium this is 0.72 
but for fat the coefficient is 8.0 .
R E P R O D U C I B I L I T Y  OF R E P E A T  I N J E C T I O N S -
SE GM EN TAL  PERFUSION
Injection
# 2
24 1M4*
r =0*6 2
y =1 0*4 ♦ 0 8  5 x
Injection # 1
1M
Left
Coronary
Xenon
1*41M21 99 « •  m  12*
C o ro n a ry  Sinus Flow ml/min
4 9
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The blood flowing past the myocardium contains less tracer than 
the capillary bed, so the tracer begins to diffuse back into the 
vascular space at a rate proportional to blood flow. Blood flow 
can be calculated from the washout curve using the Kety-Schmidt 
formula (98).
F k /t  100 ml/min/ 100 g mvocardium 
p
where
F blood flow
k rate constant, the slope of the washout curve
X partition coefficient for Xenon in myocardium
0.72 obtained in normal dog by Cohn (99).
P specific gravity of myocardium 1.05
(Volume = mass
specific gravity)
Blood flow is expressed in terms of an arbitrary 100 g of tissue, which is 
converted to volume by dividing by specific gravity.
The rate constant, k, is the slope of the washout curve and is derived 
from a semi-logarithmic data plot. By using only peak to 30 seconds of 
data, a monoexponential curve is obtained and factors which affect the 
latter end of the curve, such as washout of tracer from fat, are avoided as 
far as possible. The method is reproducible ± 2 %  (SD) and repeatable 
± 5 %  (SD) (100-103) (Figure 41).
Direct comparison with other techniques, e.g. microspheres, has proved 
difficult. In a comparison with coronary sinus flow, measurements were 
similar but absolute values were different. Coronary sinus flow
a) Normal intracoronary Xenon, right coronary artery red, left 
coronary artery green
b) Abnormal intracoronary Xenon, patient with triple vessel disease
c) Intracoronary Xenon, showing flow to septum from right 
coronary artery
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measures drainage predominantly from the left coronary artery and the 
correlation between CSF and left coronary artery flow is shown in 
Figure 41.
In addition to flow, by imaging the myocardium, radio-tracer distribution 
can be followed. By knowing the normal variations (Figure 42a), 
distribution outside of these can be attributed to collateral flow (Figure 
42c). The washout curves from a region of interest constructed around 
this distribution provides a measure of collateral flow.
Perfusion Imaging
Direct measurements of coronary flow require invasive procedures and 
since 1973, thallium-201 has been used extensively as a marker of 
myocardial perfusion (104-107).
Myocardial flow is reflected fairly closely by thallium-201.
In a study of 19 pigs, where the left anterior coronary artery was ligated, 
gated thallium scans were obtained in the anterior projection. Infarct 
size was determined from the end diastolic image, by drawing a region 
of interest around the infarct, and expressing this as a percentage of the 
total left ventricle. Infarct perfusion defects ranged from 15-30%. The 
hearts were extracted and stained with tetrazolium and infarct expressed 
in terms of the percentage of the weight of the total left ventricle. This 
correlates well with the end diastolic image in vivo with r =  0.94 (108) 
(Figure 43).
In humans, thallium 201 imaging has various technical and fundamental 
limitations due primarily to the low energy emission of thallium 201 and
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the inhomogeneity of normal myocardium (109). Myocardial motion, 
due to contraction, results in blurring of static images while electro­
cardiographic gating of images can produce motion free images with 
improved resolution of the myocardial wall (110) (Figure 45).
Thallium 201, maximum 60 MBq, is injected intravenously either at rest 
or during the last 15-30 seconds of symptom limited maximal exercise. 
Scans are obtained using a mobile gamma camera, fitted with a high 
sensitivity parallel collimator. A 20% window centred on the thallium 
75 keV photopeak was used. Imaging was obtained in 3 projections, 
anterior, 40° and 75° left anterior oblique, each for five minutes, gated 
to the electrocardiogram. Data are acquired in listmode and 
reconstructed in to 8 frames representative cycle. R-R intervals outwith 
20% of the running average are excluded. Typically between 6 x 105 
and 1.2 x 106 counts were acquired in each projection.
Scans are reported by two experienced observers from static totalised 
images and the cine display in colour, using a 16 point colour scale and 
in black on white. Perfusion is reported as normal or abnormal in each 
of 15 segments as in Figure 46, wall motion is scored using a 4 point 
scoring system, with 1 considered normal, 2 reduced motion, 3 markedly 
reduced motion and 4 no visible or 5 paradoxical motion.
In 100 patients with angiographic data for the detection of coronary 
disease (Figure 45), the specificity was 88% with a sensitivity of 92% 
and an overall predictive accuracy of 91 %. The interobserver variation 
for the reporting of perfusion defects varied from 9-16% and was most 
marked in the apical region. For wall motion, disagreement occurred in 
approximately 10% of segments between observers in comparison to the
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Figure 46: a) Normal end diastolic and end systolic images on a gated thallium
scan
b) Abnormal end diastolic thallium image, 40° LAO showing an 
anterior defect in a patient with an inferior infarction
c) Region o f interest around an infarct area (blue) to be expressed as 
a percentage of total left ventricular perfusion (red)
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technetium-99m scan, in 25 patients, disagreements in regional wall 
motion abnormalities occurred in 4% (110).
Summary
The extent of myocardial ischaemia and the physiological significance of 
coronary artery lesions are best assessed by perfusion imaging, 
performed following stress. Thallium-201 is a convenient, available 
isotope that can be imaged using a standard Gamma camera, providing 
clinically useful data.
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